The	O
palmitoylation	O
state	O
of	O
the	O
beta(2)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
regulates	O
the	O
synergistic	O
action	O
of	O
cyclic	O
AMP-dependent	O
protein	O
kinase	O
and	O
beta-adrenergic	B-DNAMutation
receptor	I-DNAMutation
kinase	O
involved	O
in	O
its	O
phosphorylation	O
and	O
desensitization	O
.	O

Although	I-DNAMutation
palmitoylation	O
of	O
the	O
beta(2)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
beta(2)AR	B-DNAMutation
,	O
as	O
well	O
as	O
its	O
phosphorylation	O
by	O
the	O
cyclic	O
AMP-dependant	O
protein	O
kinase	O
(PKA)	O
and	O
the	O
beta-adrenergic	B-DNAMutation
receptor	I-DNAMutation
kinase	O
(	O
beta	B-DNAMutation
ARK	I-DNAMutation
)	O
,	O
are	O
known	O
to	O
play	O
important	O
roles	O
in	O
agonist-promoted	O
desensitization	O
,	O
their	O
relative	O
contribution	O
and	O
mutual	O
regulatory	O
influences	O
are	O
still	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
that	O
the	O
carboxyl	O
tail	O
PKA	O
site	O
(Ser(345,346))	O
of	O
the	O
beta(2)AR	B-DNAMutation
plays	O
in	O
its	O
rapid	O
agonist-promoted	O
phosphorylation	O
and	O
desensitization	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
site	I-DNAMutation
(Ala(345,346)beta(2)AR)	I-DNAMutation
significantly	O
reduced	O
the	O
rate	O
and	O
extent	O
of	O
the	O
rapid	O
desensitization	O
promoted	O
by	O
sustained	O
treatment	O
with	O
the	O
agonist	O
isoproterenol	O
.	O

The	O
direct	O
contribution	O
of	O
Ser(345,346)	O
in	O
desensitization	O
was	O
then	O
studied	O
by	O
mutating	O
all	O
other	O
putative	O
PKA	O
and	O
beta	B-DNAMutation
ARK	I-DNAMutation
phosphorylation	O
sites	O
(	O
Ala(261,262)beta	B-DNAMutation
ARK(-)beta(2)AR	I-DNAMutation
)	O
.	O

We	O
found	O
this	O
mutant	O
receptor	O
to	O
be	O
phosphorylated	O
upon	O
receptor	O
activation	O
but	O
not	O
following	O
direct	O
activation	O
of	O
PKA	O
,	O
suggesting	O
a	O
role	O
in	O
receptor-specific	O
(homologous)	O
but	O
not	O
heterologous	O
phosphorylation	O
.	O

However	O
,	O
despite	O
its	O
phosphorylated	O
state	O
,	O
Ala(261,262)beta	B-DNAMutation
ARK(-)beta(2)AR	I-DNAMutation
did	O
not	O
undergo	O
rapid	O
desensitization	O
upon	O
agonist	O
treatment	O
,	O
indicating	O
that	O
phosphorylation	O
of	O
Ser(345,346)	O
alone	O
is	O
not	O
sufficient	O
to	O
promote	O
desensitization	O
.	O

Taken	O
with	O
the	O
observation	O
that	O
mutation	B-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
Ser(345,346)	I-DNAMutation
or	O
of	O
the	O
beta	B-DNAMutation
ARK	I-DNAMutation
phosphorylation	O
sites	O
prevented	O
both	O
the	O
hyper-phosphorylation	O
and	O
constitutive	O
desensitization	O
of	O
a	O
palmitoylation-less	B-DNAMutation
mutant	I-DNAMutation
(Gly(341)beta(2)AR)	I-DNAMutation
,	O
our	O
data	O
suggest	O
a	O
concerted/synergistic	O
action	O
of	O
the	O
two	O
kinases	O
that	O
depends	O
on	O
the	O
palmitoylation	O
state	O
of	O
the	O
receptor	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
in	O
vitro	O
phosphorylation	O
of	O
Gly(341)beta(2)AR	B-DNAMutation
by	O
the	O
catalytic	O
subunit	O
of	O
PKA	O
facilitated	O
further	O
phosphorylation	O
of	O
the	O
receptor	O
by	O
purified	O
beta	B-DNAMutation
ARK	I-DNAMutation
.	O

Our	O
study	O
therefore	O
allows	O
us	O
to	O
propose	O
a	O
coordinated	O
mechanism	O
by	O
which	O
sequential	O
depalmitoylation	O
,	O
and	O
phosphorylation	O
by	O
PKA	O
and	O
beta	B-DNAMutation
ARK	I-DNAMutation
lead	O
to	O
the	O
functional	O
uncoupling	O
and	O
desensitization	O
of	O
the	O
ss(2)AR	O
.	O

Molecular	O
screening	O
of	O
ALK1/ACVRL1	B-DNAMutation
and	O
ENG	B-DNAMutation
genes	O
in	O
hereditary	O
hemorrhagic	O
telangiectasia	O
in	O
France	O
.	O

Hereditary	O
hemmorrhagic	O
telangiectasia	O
(	O
HHT	O
,	O
or	O
Osler-Rendu-Weber	O
syndrome	O
)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
characterized	O
by	O
arteriovenous	O
malformations	O
,	O
affecting	O
1	O
out	O
of	O
10,000	O
individuals	O
in	O
France	O
.	O

The	O
disease	O
is	O
caused	O
by	O
mutations	O
of	O
two	O
genes	O
:	O
ENG	B-DNAMutation
and	O
ALK1	B-DNAMutation
ACVRL1	B-DNAMutation
.	O

We	O
screened	O
the	O
coding	O
sequence	O
of	O
ENG	B-DNAMutation
and	O
ALK1	B-DNAMutation
in	O
160	O
unrelated	O
French	O
index	O
cases	O
.	O

A	O
germline	O
mutation	O
was	O
identified	O
in	O
100	O
individuals	O
(62.5%)	O
.	O

A	O
total	O
of	O
36	O
mutations	O
were	O
found	O
in	O
ENG	B-DNAMutation
,	O
including	O
three	O
nonsense	O
mutations	O
,	O
19	O
small	O
insertions/deletions	O
leading	O
to	O
a	O
frameshift	O
,	O
two	O
inframe	O
deletions	O
,	O
seven	O
missense	O
mutations	O
,	O
and	O
five	O
intronic	O
or	O
splice-site	O
mutations	O
.	O

Of	O
the	O
36	O
mutations	O
,	O
33	O
were	O
novel	O
mutations	O
.	O

A	O
total	O
of	O
64	O
mutations	O
were	O
found	O
in	O
ALK1	B-DNAMutation
,	O
including	O
six	O
nonsense	O
mutations	O
,	O
28	O
small	O
insertions/deletions	O
leading	O
to	O
a	O
frameshift	O
,	O
one	O
inframe	O
deletion	O
,	O
27	O
missense	O
mutations	O
,	O
and	O
two	O
intronic	O
or	O
splice-site	O
mutations	O
.	O

Of	O
the	O
64	O
mutations	O
,	O
27	O
were	O
novel	O
mutations	O
.	O

Mutations	O
were	O
found	O
in	O
most	O
parts	O
of	O
the	O
coding	O
sequence	O
for	O
both	O
genes	O
,	O
except	O
ALK1	B-DNAMutation
exon	O
5	O
and	O
ENG	B-DNAMutation
exons	O
12	O
to	O
14	O
.	O

Missense	O
mutations	O
in	O
ALK1	B-DNAMutation
were	O
more	O
frequent	O
in	O
exons	O
7	O
,	O
8	O
,	O
and	O
10	O
.	O

ENG	B-DNAMutation
cDNA	O
was	O
sequenced	O
for	O
three	O
intronic	O
mutations	O
:	O
c.689+2T>C	B-DNAMutation
produced	O
an	O
abnormal	O
transcript	O
excluding	O
exon	O
5	O
,	O
c.1103+3_1103+8del	B-DNAMutation
activated	O
a	O
cryptic	O
splice	O
site	O
22	O
bp	O
upstream	O
,	O
and	O
c.1428G>A	B-DNAMutation
produced	O
two	O
abnormal	O
transcripts	O
,	O
one	O
including	O
intron	O
11	O
and	O
the	O
other	O
excluding	O
exon	O
10	O
.	O

Although	O
most	O
of	O
the	O
mutations	O
were	O
private	O
,	O
some	O
recurrent	O
mutations	O
in	O
ALK1	B-DNAMutation
were	O
of	O
particular	O
interest	O
.	O

Mutation	O
c.1112_1113dupG	B-DNAMutation
p.Gly371fsX391	B-DNAMutation
was	O
found	O
in	O
17	O
unrelated	O
individuals	O
sharing	O
a	O
common	O
haplotype	O
,	O
strongly	O
suggesting	O
a	O
founder	O
effect	O
related	O
to	O
the	O
concentration	O
of	O
patients	O
previously	O
reported	O
in	O
a	O
specific	O
French	O
region	O
(RhÃ´ne-Alpes)	O
.	O

Three	O
missense	O
mutations	O
involved	O
the	O
same	O
codon	O
:	I-DNAMutation
c.1231C>T	I-DNAMutation
(p.Arg411Trp)	I-DNAMutation
,	I-DNAMutation
c.1232G>C	I-DNAMutation
(p.Arg411Pro)	I-DNAMutation
,	O
and	B-DNAMutation
c.1232G>A	I-DNAMutation
(p.Arg411Gln)	I-DNAMutation
were	O
found	O
in	O
seven	O
,	O
two	O
,	O
and	O
one	O
patients	O
,	O
respectively	O
.	O

Haplotype	O
analysis	O
was	O
in	O
favor	O
of	O
both	O
a	O
founder	O
effect	O
and	O
a	O
mutation	O
hot-spot	O
.	O

Molecular	O
characterization	O
of	O
medium-chain	O
acyl-CoA	O
dehydrogenase	O
(MCAD)	O
deficiency	O
:	O
identification	O
of	O
a	O
lys329	B-DNAMutation
to	I-DNAMutation
glu	I-DNAMutation
mutation	I-DNAMutation
in	O
the	O
MCAD	O
gene	O
,	O
and	O
expression	O
of	O
inactive	O
mutant	O
enzyme	O
protein	O
in	O
E	O
.	O

coli	O
.	O

A	O
series	O
of	O
experiments	O
has	O
established	O
the	O
molecular	O
defect	O
in	O
the	O
medium-chain	O
acyl-coenzyme	O
A	O
(CoA)	O
dehydrogenase	O
MCAD	B-DNAMutation
gene	O
in	O
a	O
family	O
with	O
MCAD	B-DNAMutation
deficiency	O
.	O

Demonstration	O
of	O
intra-mitochondrial	O
mature	O
MCAD	B-DNAMutation
indistinguishable	O
in	O
size	O
(42.5-kDa)	O
from	O
control	O
MCAD	B-DNAMutation
,	O
and	O
of	O
mRNA	O
with	O
the	O
correct	O
size	O
of	O
2.4	O
kb	O
,	O
indicated	O
a	O
point-mutation	O
in	O
the	O
coding	O
region	O
of	O
the	O
MCAD	B-DNAMutation
gene	O
to	O
be	O
disease-causing	O
.	O

Consequently	O
,	O
cloning	O
and	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(PCR)	O
amplified	O
complementary	O
DNA	O
(cDNA)	O
from	O
messenger	O
RNA	O
of	O
fibroblasts	O
from	O
the	O
patient	O
and	O
family	O
members	O
were	O
performed	O
.	O

All	O
clones	O
sequenced	O
from	O
the	O
patient	O
exhibited	O
a	O
single	B-DNAMutation
base	I-DNAMutation
substitution	I-DNAMutation
from	I-DNAMutation
adenine	I-DNAMutation
(A)	I-DNAMutation
to	I-DNAMutation
guanine	I-DNAMutation
(G)	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
985	I-DNAMutation
in	O
the	O
MCAD	B-DNAMutation
cDNA	O
as	O
the	O
only	O
consistent	O
base-variation	O
compared	O
with	O
control	O
cDNA	O
.	O

In	O
contrast	O
,	O
the	O
parents	O
contained	O
cDNA	O
with	O
the	O
normal	O
and	O
the	O
mutated	O
sequence	O
,	O
revealing	O
their	O
obligate	O
carrier	O
status	O
.	O

Allelic	O
homozygosity	O
in	O
the	O
patient	O
and	O
heterozygosity	O
for	O
the	O
mutation	O
in	O
the	O
parents	O
were	O
established	O
by	O
a	O
modified	O
PCR	O
reaction	O
,	O
introducing	O
a	O
cleavage	O
site	O
for	O
the	O
restriction	O
endonuclease	O
NcoI	O
into	O
amplified	O
genomic	O
DNA	O
containing	O
G985	B-DNAMutation
.	O

The	O
same	O
assay	O
consistently	O
revealed	O
A985	B-DNAMutation
in	O
genomic	O
DNA	O
from	O
26	O
control	O
individuals	O
.	O

The	O
A	O
to	O
G	O
mutation	O
was	O
introduced	O
into	O
an	O
E	O
.	O

coli	O
expression	O
vector	O
producing	O
mutant	O
MCAD	O
,	O
which	O
was	O
demonstrated	O
to	O
be	O
inactive	O
,	O
probably	O
because	O
of	O
the	O
inability	O
to	O
form	O
active	O
tetrameric	O
MCAD	O
.	O

All	O
the	O
experiments	O
are	O
consistent	O
with	O
the	O
contention	O
that	O
the	O
G985	B-DNAMutation
mutation	I-DNAMutation
,	O
resulting	B-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
lysine	I-DNAMutation
to	I-DNAMutation
glutamate	I-DNAMutation
shift	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
329	I-DNAMutation
in	O
the	O
MCAD	B-DNAMutation
polypeptide	O
chain	O
,	O
is	O
the	O
genetic	O
cause	O
of	O
MCAD	B-DNAMutation
deficiency	O
in	O
this	O
family	O
.	O

We	O
found	O
the	O
same	O
mutation	O
in	O
homozygous	O
form	O
in	O
11	O
out	O
of	O
12	O
other	O
patients	O
with	O
verified	O
MCAD	B-DNAMutation
deficiency	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
membrane	O
protein	O
(	O
y+L	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
transporter-1	I-DNAMutation
)	O
that	O
associates	O
with	O
4F2hc	B-DNAMutation
to	O
encode	O
the	O
amino	O
acid	O
transport	O
activity	O
y+L	O
.	O

A	O
candidate	O
gene	O
for	O
lysinuric	O
protein	O
intolerance	O
.	O

We	O
have	O
identified	O
a	O
new	O
human	O
cDNA	O
(	O
y+L	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
transporter-1	I-DNAMutation
(	O
y+LAT-1	B-DNAMutation
)	O
)	O
that	O
induces	O
system	O
y+L	O
transport	O
activity	O
with	O
4F2hc	B-DNAMutation
(	O
the	O
surface	O
antigen	O
4F2	B-DNAMutation
heavy	I-DNAMutation
chain	I-DNAMutation
)	O
in	O
oocytes	O
.	O

Human	O
y+LAT-1	B-DNAMutation
is	O
a	O
new	O
member	O
of	O
a	O
family	O
of	O
polytopic	O
transmembrane	O
proteins	O
that	O
are	O
homologous	O
to	O
the	O
yeast	O
high	O
affinity	O
methionine	O
permease	O
MUP1	B-DNAMutation
.	O

Other	O
members	O
of	O
this	O
family	O
,	O
the	O
Xenopus	O
laevis	O
IU12	O
and	O
the	O
human	O
KIAA0245	O
cDNAs	O
,	O
also	O
co-express	O
amino	O
acid	O
transport	O
activity	O
with	O
4F2hc	B-DNAMutation
in	O
oocytes	O
,	O
with	O
characteristics	O
that	O
are	O
compatible	O
with	O
those	O
of	O
systems	O
L	O
and	O
y+L	O
,	O
respectively	O
.	O

y+LAT-1	B-DNAMutation
protein	O
forms	O
a	O
approximately	O
135-kDa	O
,	O
disulfide	O
bond-dependent	O
heterodimer	O
with	O
4F2hc	B-DNAMutation
in	O
oocytes	O
,	O
which	O
upon	O
reduction	O
results	O
in	O
two	O
protein	O
bands	O
of	O
approximately	O
85	O
kDa	O
(	O
i.e	O
.	O

4F2hc	B-DNAMutation
)	O
and	O
approximately	O
40	O
kDa	O
y+LAT-1	B-DNAMutation
.	O

Mutation	O
of	O
the	O
human	O
4F2hc	B-DNAMutation
residue	O
cysteine	B-DNAMutation
109	I-DNAMutation
(Cys-109)	I-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
abolishes	O
the	O
formation	O
of	O
this	O
heterodimer	O
and	O
drastically	O
reduces	O
the	O
co-expressed	O
transport	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
y+LAT-1	B-DNAMutation
and	O
other	O
members	O
of	O
this	O
family	O
are	O
different	O
4F2	B-DNAMutation
light	O
chain	O
subunits	O
,	O
which	O
associated	O
with	O
4F2hc	B-DNAMutation
,	O
constitute	O
different	O
amino	O
acid	O
transporters	O
.	O

Human	O
y+LAT-1	B-DNAMutation
mRNA	O
is	O
expressed	O
in	O
kidney	O
>	O
peripheral	O
blood	O
leukocytes	O
>	O
lung	O
>	O
placenta	O
=	O
spleen	O
>	O
small	O
intestine	O
.	O

The	O
human	O
y+LAT-1	B-DNAMutation
gene	O
localizes	O
at	O
chromosome	O
14q11.2	O
(	O
17cR	O
approximately	O
374	O
kb	O
from	O
D14S1350	O
)	O
,	O
within	O
the	O
lysinuric	O
protein	O
intolerance	O
(LPI)	O
locus	O
(	O
Lauteala	O
,	O
T.	O
,	O
Sistonen	O
,	O
P	O
.	O

,	O
Savontaus	O
,	O
M	O
.	O

L.	O
,	O
Mykkanen	O
,	O
J.	O
,	O
Simell	O
,	O
J.	O
,	O
Lukkarinen	O
,	O
M.	O
,	O
Simmell	O
,	O
O.	O
,	O
and	O
Aula	O
,	O
P	O
.	O

(1997)	O
Am	O
.	O

J	O
.	O

Hum	O
.	O

Genet	O
.	O

60	O
,	O
1479-1486	O
)	O
.	O

LPI	O
is	O
an	O
inherited	O
autosomal	O
disease	O
characterized	O
by	O
a	O
defective	O
dibasic	O
amino	O
acid	O
transport	O
in	O
kidney	O
,	O
intestine	O
,	O
and	O
other	O
tissues	O
.	O

The	O
pattern	O
of	O
expression	O
of	O
human	O
y+LAT-1	B-DNAMutation
,	O
its	O
co-expressed	O
transport	O
activity	O
with	O
4F2hc	B-DNAMutation
,	O
and	O
its	O
chromosomal	O
location	O
within	O
the	O
LPI	O
locus	O
,	O
suggest	O
y+LAT-1	B-DNAMutation
as	O
a	O
candidate	O
gene	O
for	O
LPI	O
.	O

Mechanism	O
of	O
human	O
aldehyde	O
reductase	O
:	O
characterization	O
of	O
the	O
active	O
site	O
pocket	O
.	O

Human	O
aldehyde	O
reductase	O
is	O
a	O
NADPH-dependent	O
aldo-keto	O
reductase	O
that	O
is	O
closely	O
related	O
(	O
65%	O
identity	O
)	O
to	O
aldose	B-DNAMutation
reductase	I-DNAMutation
,	O
an	O
enzyme	O
involved	O
in	O
the	O
pathogenesis	O
of	O
some	O
diabetic	O
and	O
galactosemic	O
complications	O
.	O

In	O
aldose	B-DNAMutation
reductase	I-DNAMutation
,	O
the	O
active	O
site	O
residue	O
Tyr48	O
is	O
the	O
proton	O
donor	O
in	O
a	O
hydrogen-bonding	O
network	O
involving	O
residues	O
Asp43/Lys77	O
,	O
while	O
His110	O
directs	O
the	O
orientation	O
of	O
substrates	O
in	O
the	O
active	O
site	O
pocket	O
.	O

Mutation	O
of	O
the	O
homologous	O
Tyr49	B-DNAMutation
to	I-DNAMutation
phenylalamine	I-DNAMutation
or	I-DNAMutation
histidine	I-DNAMutation
(	O
Y49F	B-DNAMutation
or	O
Y49H	B-DNAMutation
)	O
and	O
of	O
Lys79	B-DNAMutation
to	I-DNAMutation
methionine	I-DNAMutation
K79M	B-DNAMutation
in	O
aldehyde	O
reductase	O
yields	O
inactive	O
enzymes	O
,	O
indicating	O
similar	O
roles	O
for	O
these	O
residues	O
in	O
the	O
catalytic	O
mechanism	O
of	O
aldehyde	O
reductase	O
.	O

A	O
H112Q	B-DNAMutation
mutant	O
aldehyde	O
reductase	O
exhibited	O
a	O
substantial	O
decrease	O
in	O
catalytic	O
efficiency	O
(kcat/Km)	O
for	O
hydrophilic	O
(	O
average	O
150-fold	O
)	O
and	O
aromatic	O
substrates	O
(	O
average	O
4200-fold	O
)	O
and	O
50-fold	O
higher	O
IC50	O
values	O
for	O
a	O
variety	O
of	O
inhibitors	O
than	O
that	O
of	O
the	O
wild-type	O
enzyme	O
.	O

The	O
data	O
suggest	O
that	O
His112	O
plays	O
a	O
major	O
role	O
in	O
determining	O
the	O
substrate	O
specificity	O
of	O
aldehyde	O
reductase	O
,	O
similar	O
to	O
that	O
shown	O
earlier	O
for	O
the	O
homologous	O
His110	O
in	O
aldose	B-DNAMutation
reductase	I-DNAMutation
[	O
Bohren	O
,	O
K	O
.	O

M.	O
,	O
et	O
.	O

al	O
.	O

(1994)	O
Biochemistry	O
33	O
,	O
2021-2032	O
]	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
Ile298	I-DNAMutation
or	O
Val299	B-DNAMutation
affected	O
the	O
kinetic	O
parameters	O
to	O
a	O
much	O
lesser	O
degree	O
.	O

Unlike	O
native	O
aldose	O
reductase	O
,	O
which	O
contains	O
a	O
thiol-sensitive	O
Cys298	O
,	O
neither	O
the	O
I298C	B-DNAMutation
or	O
V299C	B-DNAMutation
mutant	O
exhibited	O
any	O
thiol	O
sensitivity	O
,	O
suggesting	O
a	O
geometry	O
of	O
the	O
active	O
site	O
pocket	O
different	O
from	O
that	O
in	O
aldose	B-DNAMutation
reductase	I-DNAMutation
.	O

Also	O
different	O
from	O
aldose	B-DNAMutation
reductase	I-DNAMutation
,	O
the	O
detection	O
of	O
a	O
significant	O
primary	O
deuterium	O
isotope	O
effect	O
on	O
kcat	O
(	O
1.48	O
+/-	O
0.02	O
)	O
shows	O
that	O
nucleotide	O
exchange	O
is	O
only	O
partially	O
rate-limiting	O
.	O

Primary	O
substrate	O
and	O
solvent	O
deuterium	O
isotope	O
effects	O
on	O
the	O
H112Q	B-DNAMutation
mutant	O
suggest	O
that	O
hydride	O
and	O
proton	O
transfers	O
occur	O
in	O
two	O
discrete	O
steps	O
with	O
hydride	O
transfer	O
taking	O
place	O
first	O
.	O

Dissociation	O
constants	O
and	O
spectroscopic	O
and	O
fluorimetric	O
properties	O
of	O
nucleotide	O
complexes	O
with	O
various	O
mutants	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
Tyr49	O
and	O
His112	O
,	O
Lys79	O
plays	O
a	O
hitherto	O
unappreciated	O
role	O
in	O
nucleotide	O
binding	O
.	O

The	O
mode	O
of	O
inhibition	O
of	O
aldehyde	O
reductase	O
by	O
aldose	O
reductase	O
inhibitors	O
(ARIs)	O
is	O
generally	O
similar	O
to	O
that	O
of	O
aldose	B-DNAMutation
reductase	I-DNAMutation
and	O
involves	O
binding	O
to	O
the	O
E:NADP+	O
complex	O
,	O
as	O
shown	O
by	O
kinetic	O
and	O
direct	O
inhibitor-binding	O
experiments	O
.	O

The	O
order	O
of	O
ARI	O
potency	O
was	O
AL1576	O
(	O
Ki	O
=	O
60	O
nM	O
)	O
>	O
tolrestat	O
>	O
ponalrestat	O
>	O
sorbinil	O
>	O
FK366	O
>	O
zopolrestat	O
>	O
alrestatin	O
(	O
Ki	O
=	O
148	O
microM	O
)	O
.	O

Our	O
data	O
on	O
aldehyde	O
reductase	O
suggest	O
that	O
the	O
active	O
site	O
pocket	O
significantly	O
differs	O
from	O
that	O
of	O
aldose	B-DNAMutation
reductase	I-DNAMutation
,	O
possibly	O
due	O
to	O
the	O
participation	O
of	O
the	O
C-terminal	O
loop	O
in	O
its	O
formation	O
.	O

PAT1	B-DNAMutation
,	O
a	O
microtubule-interacting	O
protein	O
,	O
recognizes	O
the	O
basolateral	O
sorting	O
signal	O
of	O
amyloid	O
precursor	O
protein	O
.	O

In	O
epithelial	O
cells	O
,	O
sorting	O
of	O
membrane	O
proteins	O
to	O
the	O
basolateral	O
surface	O
depends	O
on	O
the	O
presence	O
of	O
a	O
basolateral	O
sorting	O
signal	O
(BaSS)	O
in	O
their	O
cytoplasmic	O
domain	O
.	O

Amyloid	O
precursor	O
protein	O
(APP)	O
,	O
a	O
basolateral	O
protein	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer's	O
disease	O
,	O
contains	O
a	O
tyrosine-based	B-DNAMutation
BaSS	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
tyrosine	I-DNAMutation
residue	O
results	O
in	O
nonpolarized	O
transport	O
of	O
APP	O
.	O

Here	O
we	O
report	O
identification	O
of	O
a	O
protein	O
,	O
termed	O
PAT1	B-DNAMutation
(	O
protein	O
interacting	O
with	O
APP	O
tail	O
1	O
)	O
,	O
that	O
interacts	O
with	O
the	O
APP-BaSS	O
but	O
binds	O
poorly	O
when	O
the	O
critical	O
tyrosine	O
is	O
mutated	O
and	O
does	O
not	O
bind	O
the	O
tyrosine-based	O
endocytic	O
signal	O
of	O
APP	O
.	O

PAT1	B-DNAMutation
shows	O
homology	O
to	O
kinesin	O
light	O
chain	O
,	O
which	O
is	O
a	O
component	O
of	O
the	O
plus-end	O
directed	O
microtubule-based	O
motor	O
involved	O
in	O
transporting	O
membrane	O
proteins	O
to	O
the	O
basolateral	O
surface	O
.	O

PAT1	B-DNAMutation
,	O
a	O
cytoplasmic	O
protein	O
,	O
associates	O
with	O
membranes	O
,	O
cofractionates	O
with	O
APP-containing	O
vesicles	O
,	O
and	O
binds	O
microtubules	O
in	O
a	O
nucleotide-sensitive	O
manner	O
.	O

Cotransfection	O
of	O
PAT1	B-DNAMutation
with	O
a	O
reporter	O
protein	O
shows	O
that	O
PAT1	B-DNAMutation
is	O
functionally	O
linked	O
with	O
intracellular	O
transport	O
of	O
APP	O
.	O

We	O
propose	O
that	O
PAT1	B-DNAMutation
is	O
involved	O
in	O
the	O
translocation	O
of	O
APP	O
along	O
microtubules	O
toward	O
the	O
cell	O
surface	O
.	O

Novel	O
splice-site	O
and	O
missense	O
mutations	O
in	O
the	O
ALDH1A3	B-DNAMutation
gene	O
underlying	O
autosomal	O
recessive	O
anophthalmia/microphthalmia	O
.	O

AIM	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
underlying	O
genetic	O
defect	O
responsible	O
for	O
anophthalmia/microphthalmia	O
.	O

METHODS	O
:	O
In	O
total	O
,	O
two	O
Turkish	O
families	O
with	O
a	O
total	O
of	O
nine	O
affected	O
individuals	O
were	O
included	O
in	O
the	O
study	O
.	O

Affymetrix	O
250âK	O
single	O
nucleotide	O
polymorphism	O
genotyping	O
and	O
homozygosity	O
mapping	O
were	O
used	O
to	O
identify	O
the	O
localisation	O
of	O
the	O
genetic	O
defect	O
in	O
question	O
.	O

Coding	O
region	O
of	O
the	B-DNAMutation
ALDH1A3	I-DNAMutation
gene	O
was	O
screened	O
via	O
direct	O
sequencing	O
.	O

cDNA	O
samples	O
were	O
generated	O
from	O
primary	O
fibroblast	O
cell	O
cultures	O
for	O
expression	O
analysis	O
.	O

Reverse	O
transcriptase	O
PCR	O
(RT-PCR)	O
analysis	O
was	O
performed	O
using	O
direct	O
sequencing	O
of	O
the	O
obtained	O
fragments	O
.	O

RESULTS	O
:	O
The	O
causative	O
genetic	O
defect	O
was	O
mapped	O
to	O
chromosome	O
15q26.3	O
.	B-DNAMutation
A	I-DNAMutation
homozygous	I-DNAMutation
G>A	I-DNAMutation
substitution	I-DNAMutation
(c.666G>A)	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
last	I-DNAMutation
nucleotide	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
6	O
in	O
the	B-DNAMutation
ALDH1A3	I-DNAMutation
gene	O
was	O
identified	O
in	O
the	O
first	O
family	O
.	O

Further	O
cDNA	O
sequencing	O
of	B-DNAMutation
ALDH1A3	I-DNAMutation
showed	O
that	O
the	B-DNAMutation
c.666G>A	I-DNAMutation
mutation	O
caused	O
skipping	O
of	O
exon	O
6	O
,	O
which	O
predicted	B-DNAMutation
in-frame	I-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
43	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
(p.Trp180_Glu222del)	I-DNAMutation
.	B-DNAMutation
A	I-DNAMutation
novel	I-DNAMutation
missense	I-DNAMutation
c.1398C>A	I-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
12	O
of	B-DNAMutation
ALDH1A3	I-DNAMutation
that	O
causes	O
the	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
conserved	I-DNAMutation
asparagine	I-DNAMutation
by	I-DNAMutation
lysine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
466	O
(p.Asn466Lys)	I-DNAMutation
was	O
observed	O
in	O
the	O
second	O
family	O
.	O

No	O
extraocular	O
findings-except	O
for	O
nevus	O
flammeus	O
in	O
one	O
affected	O
individual	O
and	O
a	O
variant	O
of	O
Dandy-Walker	O
malformation	O
in	O
another	O
affected	O
individual-were	O
observed	O
.	O

Autistic-like	O
behaviour	O
and	O
mental	O
retardation	O
were	O
observed	O
in	O
three	O
cases	O
.	O

CONCLUSIONS	O
:	O
In	O
conclusion	O
,	O
novel	B-DNAMutation
ALDH1A3	I-DNAMutation
mutations	O
identified	O
in	O
the	O
present	O
study	O
confirm	O
the	O
pivotal	O
role	O
of	B-DNAMutation
ALDH1A3	I-DNAMutation
in	O
human	O
eye	O
development	O
.	O

Autistic	O
features	O
,	O
previously	O
reported	O
as	O
an	O
associated	O
finding	O
,	O
were	O
considered	O
to	O
be	O
the	O
result	O
of	O
social	O
deprivation	O
and	O
inadequate	O
parenting	O
during	O
early	O
infancy	O
in	O
the	O
presented	O
families	O
.	O

An	O
amino	O
acid	O
substitution	O
in	O
the	O
putative	O
second	O
extracellular	O
loop	O
of	O
RBC	O
band	O
3	O
accounts	O
for	O
the	O
Froese	O
blood	O
group	O
polymorphism	O
.	O

BACKGROUND	O
:	O
The	O
low	O
incidence	O
RBC	O
antigen	O
Fr(a)	O
has	O
been	O
excluded	O
from	O
17	O
of	O
the	O
25	O
established	O
blood	O
group	O
systems	O
.	O

Previous	O
genetic	O
analysis	O
assigned	O
the	O
gene	O
controlling	O
Fr(a)	O
expression	O
to	O
the	O
same	O
chromosomal	O
region	O
as	O
the	O
solute	O
carrier	O
family	O
4	O
,	O
anion	O
exchanger	O
member	O
1	O
gene	O
(SLC4A1)	O
.	O

Because	O
SLC4A1	O
encodes	O
RBC	O
band	O
3	O
and	O
controls	O
the	O
expression	O
of	O
Diego	O
blood	O
group	O
system	O
antigens	O
,	O
the	O
possible	O
relationship	O
of	O
Fr(a)	O
to	O
the	O
Diego	O
blood	O
group	O
system	O
was	O
investigated	O
by	O
molecular	O
analysis	O
of	O
SLC4A1	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Blood	O
samples	O
were	O
obtained	O
from	O
the	O
members	O
of	O
two	O
unrelated	O
Mennonite	O
kindreds	O
segregating	O
for	O
Fr(a)	O
.	O

DNA	O
was	O
extracted	O
,	O
amplified	O
by	O
PCR	O
using	O
intronic	O
primer	O
sets	O
flanking	O
exons	O
11-20	O
of	O
SLC4A1	O
,	O
and	O
screened	O
by	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
.	O

Those	O
exons	O
displaying	O
SSCPs	O
were	O
subjected	O
to	O
DNA	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
An	O
exon	O
13	O
SSCP	O
mobility	O
shift	O
was	O
observed	O
in	O
the	O
DNA	O
from	O
all	O
Fr(a+)	O
persons	O
that	O
was	O
not	O
seen	O
in	O
the	O
DNA	O
from	O
Fr(a-)	O
family	O
members	O
or	O
control	O
subjects	O
.	O

Linkage	O
between	O
the	O
exon	O
13	O
SSCP	O
and	O
FR:(a)	O
was	O
established	O
,	O
with	O
peak	O
lods	O
=	O
3.62	O
at	O
theta	O
=	O
0.00	O
for	O
combined	O
paternal	O
and	O
maternal	O
meioses	O
.	O

DNA	O
sequencing	O
revealed	O
a	O
GAG	B-DNAMutation
-->	I-DNAMutation
AAG	I-DNAMutation
mutation	I-DNAMutation
that	O
underlies	O
a	O
Glu480Lys	B-DNAMutation
substitution	O
in	O
RBC	O
band	O
3	O
.	O

CONCLUSIONS	O
:	O
A	O
point	O
mutation	O
in	O
exon	O
13	O
of	O
SLC4A1	O
accounting	O
for	O
a	O
Glu480Lys	B-DNAMutation
substitution	O
in	O
band	O
3	O
controls	O
Fr(a)	O
expression	O
.	O

On	O
the	O
basis	O
of	O
these	O
our	O
results	O
,	O
the	O
International	O
Society	O
of	O
Blood	O
Transfusion	O
Working	O
Party	O
on	O
Terminology	O
for	O
Red	O
Cell	O
Surface	O
Antigens	O
has	O
assigned	O
Fr(a)	O
to	O
the	O
Diego	O
blood	O
group	O
system	O
,	O
with	O
the	O
designation	O
DI20	O
.	O

The	O
N-terminal	O
region	O
of	O
the	O
human	O
5-HTâC	I-DNAMutation
receptor	O
has	O
as	O
a	O
cleavable	O
signal	O
peptide	O
.	O

The	O
5-hydroxytryptamine	O
2C	B-DNAMutation
(5-HT(2C))	I-DNAMutation
receptor	O
has	O
a	I-DNAMutation
single	I-DNAMutation
nucleotide	I-DNAMutation
polymorphism	I-DNAMutation
(SNP)	I-DNAMutation
site	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
23	I-DNAMutation
in	I-DNAMutation
its	I-DNAMutation
N-terminal	I-DNAMutation
tail	I-DNAMutation
.	O

The	O
polymorphism	O
involves	O
conversion	O
of	O
a	O
cysteine	O
to	O
serine	O
.	O

The	O
site	O
,	O
designated	O
C23S	O
,	O
is	O
located	O
within	O
a	O
32	O
amino	O
acid	O
long	O
predicted	O
signal	O
peptide	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
the	B-DNAMutation
5-HT(2C)	I-DNAMutation
receptor	O
indeed	O
has	O
a	O
functional	O
cleavable	O
signal	O
peptide	O
.	O

For	O
this	O
purpose	O
,	O
ten	O
N-terminally	O
modified	B-DNAMutation
5-HT(2C)	I-DNAMutation
receptors	O
were	O
constructed	O
.	O

Modifications	O
included	O
addition	O
of	O
the	O
influenza	O
virus	O
hemagglutinin	O
signal	O
peptide	O
,	O
addition	O
of	O
a	O
FLAG	O
epitope	B-DNAMutation
,	I-DNAMutation
truncation	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
N-terminal	I-DNAMutation
tail	I-DNAMutation
,	O
and	O
combinations	O
of	O
these	O
changes	O
.	O

The	O
receptors	O
were	O
transiently	O
expressed	O
in	O
COS-7	O
cells	O
.	O

The	O
relative	O
amounts	O
of	O
receptors	O
expressed	O
at	O
the	O
membranes	O
were	O
quantified	O
by	O
[(3)H]-mesulergine	O
radioligand	O
binding	O
.	O

In	O
one	O
of	O
the	O
receptor	O
constructs	O
the	O
FLAG	O
epitope	O
was	O
inserted	O
just	O
after	O
the	O
endogenous	O
putative	O
signal	O
peptide	O
.	O

Immunostaining	O
with	O
the	O
M1	O
antibody	O
,	O
which	O
recognizes	O
the	O
FLAG	O
epitope	O
only	O
as	O
free	O
N-terminal	O
entity	O
,	O
was	O
used	O
to	O
detect	O
whether	O
the	O
putative	O
signal	O
peptide	O
preceding	O
the	O
FLAG	O
epitope	O
was	O
cleaved	O
off	O
.	O

The	O
results	O
suggest	O
the	O
following	O
conclusions	O
.	O

The	O
predicted	O
signal	O
peptide	O
in	O
the	O
N-terminal	O
tail	O
of	O
the	B-DNAMutation
5-HT(2C)	I-DNAMutation
receptor	O
acts	O
as	O
a	O
cleavable	O
signal	O
peptide	O
.	O

Cleaving	O
of	O
the	O
signal	O
peptide	O
is	O
important	O
for	O
translocation	O
of	O
the	O
wild	O
type	O
receptor	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
two	O
amino	O
acids	O
differentially	O
encoded	O
by	O
the	O
C23S	O
SNP	O
are	O
likely	O
absent	O
from	O
the	O
mature	B-DNAMutation
5-HT(2C)	I-DNAMutation
receptor	O
.	O

Genetic	O
diversity	O
from	O
a	O
limited	O
repertoire	O
of	O
mutations	O
on	O
different	O
common	O
allelic	O
backgrounds	O
:	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
deficiency	O
variant	O
Pduarte	O
.	O

alpha	B-DNAMutation
1-Antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
is	O
one	O
of	O
the	O
most	O
polymorphic	O
gene	O
loci	O
in	O
the	O
human	O
genome	O
.	O

alpha	B-DNAMutation
1AT	I-DNAMutation
variants	O
are	O
typically	O
identified	O
by	O
their	O
migration	O
position	O
in	O
an	O
isoelectric	O
focusing	O
gel	O
at	O
pH	B-DNAMutation
4-5	I-DNAMutation
.	O

Heterogeneity	O
of	O
the	O
isoelectric	O
point	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
variants	O
,	O
hence	O
variant	O
migration	O
,	O
most	O
often	O
results	O
from	O
amino	O
acid	O
substitutions	O
which	O
alter	O
the	O
net	O
charge	O
of	O
the	O
molecule	O
.	O

We	O
identified	O
an	O
individual	O
heterozygous	O
for	O
an	O
alpha	B-DNAMutation
1AT	I-DNAMutation
variant	O
migrating	O
in	O
the	O
"P"	O
variant	O
region	O
which	O
differs	O
from	O
other	O
known	O
"P"	O
variants	O
.	O

Using	O
isoelectric	O
focusing	O
on	O
an	O
immobilized	O
pH	O
gradient	O
at	O
pH	O
4.50-4.85	O
the	O
novel	O
P	O
allele	O
,	O
Pduarte	O
,	O
migrates	O
between	O
Pst	O
.	O

albans	O
and	O
Plowell	O
.	O

Densitometric	O
analysis	O
of	O
normal	O
"M"	O
type	O
alpha	B-DNAMutation
1AT	I-DNAMutation
and	O
the	O
deficiency	O
variant	O
Plowell	O
major	O
bands	O
separated	O
by	O
isoelectric	O
focusing	O
demonstrates	O
that	O
Pduarte	O
contributes	O
approximately	O
41%	O
as	O
much	O
alpha	B-DNAMutation
1AT	I-DNAMutation
to	O
the	O
total	O
serum	O
alpha	B-DNAMutation
1AT	I-DNAMutation
concentration	O
as	O
the	O
normal	O
"M"	O
alpha	B-DNAMutation
1AT	I-DNAMutation
,	O
similar	O
to	O
Plowell	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
the	O
proband's	O
genomic	O
DNA	O
demonstrates	O
that	O
the	O
Pduarte	O
allele	O
differs	O
from	O
the	O
normal	O
M1	O
(V213)	O
allele	O
by	O
two	O
amino	O
acid	O
substitutions	O
,	O
R101	B-DNAMutation
(CGT)-->H(CAT)	I-DNAMutation
and	O
D256	B-DNAMutation
(GAT)-->V(GTT)	I-DNAMutation
.	O

Individually	O
,	O
these	O
amino	O
acid	O
substitutions	O
characterize	O
the	O
normal	O
M4	O
allele	O
R101-->H	B-DNAMutation
and	O
the	O
deficient	O
Plowell	O
allele	O
D256-->V	B-DNAMutation
.	O

Thus	O
the	O
Pduarte	O
allele	O
differs	O
from	O
the	O
Plowell	O
allele	O
only	O
by	O
the	O
normal	O
allelic	O
background	O
in	O
which	O
the	O
V256	O
mutation	O
occurs	O
.	O

Comparison	O
of	O
amino	O
acid	O
sequences	O
among	O
several	O
alpha	B-DNAMutation
1AT	I-DNAMutation
variants	O
demonstrates	O
that	O
Pduarte	O
is	O
an	O
example	O
of	O
a	O
more	O
general	O
observation	O
regarding	O
diversity	O
within	O
the	O
PI	O
(	O
protease	O
inhibitor	O
)	O
system.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
heparin-binding	O
domain	O
in	O
the	O
amyloid	B-DNAMutation
protein	I-DNAMutation
precursor	I-DNAMutation
of	O
Alzheimer's	O
disease	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
neurite	O
outgrowth	O
.	O

The	O
amyloid	B-DNAMutation
protein	I-DNAMutation
precursor	I-DNAMutation
(APP)	O
of	O
Alzheimer's	O
disease	O
is	O
synthesized	O
as	O
an	O
integral	O
transmembrane	O
protein	O
that	O
is	O
released	O
from	O
cells	O
in	O
culture	O
following	O
proteolytic	O
cleavage	O
.	O

The	O
function	O
of	O
released	O
APP	O
is	O
not	O
known	O
,	O
although	O
there	O
is	O
evidence	O
that	O
the	O
protein	O
may	O
bind	O
to	O
components	O
of	O
the	O
extracellular	O
matrix	O
(ECM)	O
.	O

In	O
the	O
present	O
study	O
,	O
substratum-bound	O
APP	O
stimulated	O
neurite	O
outgrowth	O
in	O
cultures	O
of	O
chick	O
sympathetic	O
and	O
mouse	O
hippocampal	O
neurons	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
substratum-bound	O
heparan	O
sulfate	O
proteoglycans	O
(HSPG)	O
.	O

The	O
effect	O
of	O
APP	O
on	O
neurite	O
outgrowth	O
was	O
comparable	O
to	O
that	O
of	O
laminin	O
.	O

A	O
14	O
K	O
N-terminal	O
fragment	O
of	O
APP	O
was	O
found	O
to	O
bind	O
heparin	O
and	O
a	O
region	O
close	O
to	O
the	O
N-terminus	O
of	O
APP	O
(	O
residues	O
96-110	O
)	O
identified	O
as	O
a	O
potential	O
heparin-binding	O
domain	O
based	O
on	O
secondary	O
structure	O
predictions	O
and	O
molecular	O
modeling	O
.	O

Mutagenesis	B-DNAMutation
of	I-DNAMutation
three	I-DNAMutation
basic	I-DNAMutation
residues	I-DNAMutation
(	I-DNAMutation
lysine-99	I-DNAMutation
,	I-DNAMutation
arginine-100	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
arginine-102	I-DNAMutation
)	O
resulted	O
in	O
a	O
recombinant	O
protein	O
(APPhep)	O
with	O
decreased	O
heparin-binding	O
capacity	O
.	O

A	O
peptide	O
homologous	O
to	O
the	O
heparin-binding	O
domain	O
was	O
synthesized	O
and	O
found	O
to	O
bind	O
strongly	O
to	O
heparin	O
and	O
to	O
inhibit	O
binding	O
of	O
125I-labeled	O
APP	O
to	O
heparin	O
(	O
IC50	O
approximately	O
10(-7)	O
M	O
)	O
.	O

The	O
peptide	O
blocked	O
the	O
effect	O
of	O
APP	O
on	O
neurite	O
outgrowth	O
(	O
IC50	O
approximately	O
10(-7)	O
M	O
)	O
,	O
whereas	O
two	O
other	O
peptides	O
homologous	O
to	O
other	O
domains	O
in	O
APP	O
had	O
no	O
effect	O
.	O

The	O
results	O
indicate	O
that	O
the	O
binding	O
of	O
APP	O
to	O
HSPG	O
in	O
the	O
ECM	O
may	O
stimulate	O
the	O
effects	O
of	O
APP	O
on	O
neurite	O
outgrowth	O
.	O

Activation	O
of	O
Bruton's	O
tyrosine	O
kinase	O
(BTK)	O
by	O
a	O
point	O
mutation	O
in	O
its	O
pleckstrin	O
homology	O
(PH)	O
domain	O
.	O

Bruton's	O
tyrosine	O
kinase	O
(BTK)	O
is	O
a	O
nonreceptor	O
tyrosine	O
kinase	O
critical	O
for	O
B	O
cell	O
development	O
and	O
function	O
.	O

Mutations	O
in	O
BTK	O
result	O
in	O
X-linked	O
agammaglobulinemia	O
(XLA)	O
in	O
humans	O
and	O
X-linked	O
immunodeficiency	O
(xid)	O
in	O
mice	O
.	O

Using	O
a	O
random	O
mutagenesis	O
scheme	O
,	O
we	O
isolated	O
a	O
gain-of-function	O
mutant	O
called	O
BTK*	O
whose	O
expression	O
drives	O
growth	O
of	O
NIH	O
3T3	O
cells	O
in	O
soft	O
agar	O
.	O

BTK*	O
results	O
from	O
a	O
single	O
point	O
mutation	O
in	O
the	O
pleckstrin	O
homology	O
(PH)	O
domain	O
,	O
where	O
a	O
Glu	B-DNAMutation
is	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
Lys	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
41	I-DNAMutation
.	O

BTK*	O
shows	O
an	O
increase	O
in	O
phosphorylation	O
on	O
tyrosine	O
residues	O
and	O
an	O
increase	O
in	O
membrane	O
targeting	O
.	O

Transforming	O
activity	O
requires	O
kinase	O
activity	O
,	O
a	O
putative	O
autophosphorylation	O
site	O
,	O
and	O
a	O
functional	O
PH	O
domain	O
.	O

Mutation	O
of	O
the	O
SH2	O
or	O
SH3	O
domains	O
did	O
not	O
affect	O
the	O
activity	O
of	O
BTK*	O
.	O

Expression	O
of	O
BTK*	O
could	O
also	O
relieve	O
IL-5	B-DNAMutation
dependence	O
of	O
a	O
B	O
lineage	O
cell	O
line	O
.	O

These	O
results	O
show	O
that	O
transformation	O
activation	O
and	O
regulation	O
of	O
BTK	O
are	O
critically	O
dependent	O
on	O
the	O
PH	O
domain	O
.	O

Citrullination	O
regulates	O
pluripotency	O
and	O
histone	O
H1	O
binding	O
to	O
chromatin	O
.	O

Citrullination	O
is	O
the	O
post-translational	O
conversion	O
of	O
an	O
arginine	O
residue	O
within	O
a	O
protein	O
to	O
the	O
non-coded	O
amino	O
acid	O
citrulline	O
.	O

This	O
modification	O
leads	O
to	O
the	O
loss	O
of	O
a	O
positive	O
charge	O
and	O
reduction	O
in	O
hydrogen-bonding	O
ability	O
.	O

It	O
is	O
carried	O
out	O
by	O
a	O
small	O
family	O
of	O
tissue-specific	O
vertebrate	O
enzymes	O
called	O
peptidylarginine	O
deiminases	O
(PADIs)	O
and	O
is	O
associated	O
with	O
the	O
development	O
of	O
diverse	O
pathological	O
states	O
such	O
as	O
autoimmunity	O
,	O
cancer	O
,	O
neurodegenerative	O
disorders	O
,	O
prion	O
diseases	O
and	O
thrombosis	O
.	O

Nevertheless	O
,	O
the	O
physiological	O
functions	O
of	O
citrullination	O
remain	O
ill-defined	O
,	O
although	O
citrullination	O
of	O
core	O
histones	O
has	O
been	O
linked	O
to	O
transcriptional	O
regulation	O
and	O
the	O
DNA	O
damage	O
response	O
.	O

PADI4	B-DNAMutation
(	O
also	O
called	O
PAD4	B-DNAMutation
or	O
PADV	O
)	O
,	O
the	O
only	O
PADI	O
with	O
a	O
nuclear	O
localization	O
signal	O
,	O
was	O
previously	O
shown	O
to	O
act	O
in	O
myeloid	O
cells	O
where	O
it	O
mediates	O
profound	O
chromatin	O
decondensation	O
during	O
the	O
innate	O
immune	O
response	O
to	O
infection	O
.	O

Here	O
we	O
show	O
that	O
the	O
expression	O
and	O
enzymatic	O
activity	O
of	O
Padi4	B-DNAMutation
are	O
also	O
induced	O
under	O
conditions	O
of	O
ground-state	O
pluripotency	O
and	O
during	O
reprogramming	O
in	O
mouse	O
.	O

Padi4	B-DNAMutation
is	O
part	O
of	O
the	O
pluripotency	O
transcriptional	O
network	O
,	O
binding	O
to	O
regulatory	O
elements	O
of	O
key	O
stem-cell	O
genes	O
and	O
activating	O
their	O
expression	O
.	O

Its	O
inhibition	O
lowers	O
the	O
percentage	O
of	O
pluripotent	O
cells	O
in	O
the	O
early	O
mouse	O
embryo	O
and	O
significantly	O
reduces	O
reprogramming	O
efficiency	O
.	O

Using	O
an	O
unbiased	O
proteomic	O
approach	O
we	O
identify	O
linker	O
histone	O
H1	O
variants	O
,	O
which	O
are	O
involved	O
in	O
the	O
generation	O
of	O
compact	O
chromatin	O
,	O
as	O
novel	O
PADI4	B-DNAMutation
substrates	O
.	O

Citrullination	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
arginine	I-DNAMutation
residue	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
DNA-binding	I-DNAMutation
site	I-DNAMutation
of	O
H1	O
results	O
in	O
its	O
displacement	O
from	O
chromatin	O
and	O
global	O
chromatin	O
decondensation	O
.	O

Together	O
,	O
these	O
results	O
uncover	O
a	O
role	O
for	O
citrullination	O
in	O
the	O
regulation	O
of	O
pluripotency	O
and	O
provide	O
new	O
mechanistic	O
insights	O
into	O
how	O
citrullination	O
regulates	O
chromatin	O
compaction	O
.	O

Late-onset	O
Stargardt	O
disease	O
is	O
associated	O
with	O
missense	O
mutations	O
that	O
map	O
outside	O
known	O
functional	O
regions	O
of	O
ABCR	B-DNAMutation
ABCA4	B-DNAMutation
.	O

Based	O
on	O
recent	O
studies	O
of	O
the	O
photoreceptor-specific	O
ABC	O
transporter	O
gene	O
ABCR	B-DNAMutation
ABCA4	B-DNAMutation
in	O
Stargardt	O
disease	O
(STGD1)	O
and	O
other	O
retinal	O
dystrophies	O
,	O
we	O
and	O
others	O
have	O
developed	O
a	O
model	O
in	O
which	O
the	O
severity	O
of	O
retinal	O
disease	O
correlates	O
inversely	O
with	O
residual	O
ABCR	B-DNAMutation
activity	O
.	O

This	O
model	O
predicts	O
that	O
patients	O
with	O
late-onset	O
STGDI	O
may	O
retain	O
partial	O
ABCR	B-DNAMutation
activity	O
attributable	O
to	O
mild	O
missense	O
alleles	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
used	O
late-onset	O
STGDI	O
patients	O
(	O
onset	O
:	O
>	O
or	O
=35	O
years	O
)	O
to	O
provide	O
an	O
in	O
vivo	O
functional	O
analysis	O
of	O
various	O
combinations	O
of	O
mutant	O
alleles	O
.	O

We	O
sequenced	O
directly	O
the	O
entire	O
coding	O
region	O
of	O
ABCR	B-DNAMutation
and	O
detected	O
mutations	O
in	O
33/50	O
(66%)	O
disease	O
chromosomes	O
,	O
but	O
surprisingly	O
,	O
11/33	O
(33%)	O
were	O
truncating	O
alleles	O
.	O

Importantly	O
,	O
all	O
22	O
missense	O
mutations	O
were	O
located	O
outside	O
the	O
known	O
functional	O
domains	O
of	O
ABCR	B-DNAMutation
(	O
ATP-binding	O
or	O
transmembrane	O
)	O
,	O
whereas	O
in	O
our	O
general	O
cohort	O
of	O
STGDI	O
subjects	O
,	O
alterations	O
occurred	O
with	O
equal	O
frequency	O
across	O
the	O
entire	O
protein	O
.	O

We	O
suggest	O
that	O
these	O
missense	O
mutations	O
in	O
regions	O
of	O
unknown	O
function	O
are	O
milder	O
alleles	O
and	O
more	O
susceptible	O
to	O
modifier	O
effects	O
.	O

Thus	O
,	O
we	O
have	O
corroborated	O
a	O
prediction	O
from	O
the	O
model	O
of	O
ABCR	B-DNAMutation
pathogenicity	O
that	O
(1)	O
one	O
mutant	O
ABCR	B-DNAMutation
allele	O
is	O
always	O
missense	O
in	O
late-onset	O
STGD1	O
patients	O
,	O
and	O
(2)	O
the	O
age-of-onset	O
is	O
correlated	O
with	O
the	O
amount	O
of	O
ABCR	B-DNAMutation
activity	O
of	O
this	O
allele	O
.	O

In	O
addition	O
,	O
we	O
report	O
three	O
new	O
pseudodominant	O
families	O
that	O
now	O
comprise	O
eight	O
of	O
178	O
outbred	O
STGD1	O
families	O
and	O
suggest	O
a	O
carrier	O
frequency	O
of	O
STGD1-associated	O
ABCR	B-DNAMutation
mutations	O
of	O
about	O
4.5%	O
(	O
approximately	O
1/22	O
)	O
.	O

ARHGDIA	B-DNAMutation
:	O
a	O
novel	O
gene	O
implicated	O
in	O
nephrotic	O
syndrome	O
.	O

BACKGROUND	O
:	O
Congenital	O
nephrotic	O
syndrome	O
arises	O
from	O
a	O
defect	O
in	O
the	O
glomerular	O
filtration	O
barrier	O
that	O
permits	O
the	O
unrestricted	O
passage	O
of	O
protein	O
across	O
the	O
barrier	O
,	O
resulting	O
in	O
proteinuria	O
,	O
hypoalbuminaemia	O
,	O
and	O
severe	O
oedema	O
.	O

While	O
most	O
cases	O
are	O
due	O
to	O
mutations	O
in	O
one	O
of	O
five	O
genes	O
,	O
in	O
up	O
to	O
15%	O
of	O
cases	O
,	O
a	O
genetic	O
cause	O
is	O
not	O
identified	O
.	O

We	O
investigated	O
two	O
sisters	O
with	O
a	O
presumed	O
recessive	O
form	O
of	O
congenital	O
nephrotic	O
syndrome	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Whole	O
exome	O
sequencing	O
identified	O
five	O
genes	O
with	O
diallelic	O
mutations	O
that	O
were	O
shared	O
by	O
the	O
sisters	O
,	O
and	O
Sanger	O
sequencing	O
revealed	O
that	O
ARHGDIA	B-DNAMutation
that	O
encodes	O
Rho	O
GDP	O
(	O
guanosine	O
diphosphate	O
)	O
dissociation	O
inhibitor	O
Î±	O
(	I-DNAMutation
RhoGDIÎ±	I-DNAMutation
,	O
OMIM	O
601925	O
)	O
was	O
the	O
most	O
likely	O
candidate	O
.	O

Mice	O
with	O
targeted	O
inactivation	O
of	B-DNAMutation
ARHGDIA	I-DNAMutation
are	O
known	O
to	O
develop	O
severe	O
proteinuria	O
and	O
nephrotic	O
syndrome	O
,	O
therefore	O
this	O
gene	O
was	O
pursued	O
in	O
functional	O
studies	O
.	O

The	O
sisters	O
harbour	O
a	O
homozygous	O
in-frame	O
deletion	O
that	O
is	O
predicted	O
to	B-DNAMutation
remove	I-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
residue	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
interface	I-DNAMutation
where	O
the	O
protein	B-DNAMutation
,	I-DNAMutation
RhoGDIÎ±	I-DNAMutation
,	O
interacts	O
with	O
the	O
Rho	O
family	O
of	O
small	O
GTPases	B-DNAMutation
(c.553_555del(p.Asp185del))	I-DNAMutation
.	O

Rho-GTPases	O
are	O
critical	O
regulators	O
of	O
the	O
actin	O
cytoskeleton	O
and	O
when	O
bound	O
to	I-DNAMutation
RhoGDIÎ±	I-DNAMutation
,	O
they	O
are	O
sequestered	O
in	O
an	O
inactive	O
,	O
cytosolic	O
pool	O
.	O

In	O
the	O
mouse	O
kidney	B-DNAMutation
,	I-DNAMutation
RhoGDIÎ±	I-DNAMutation
was	O
highly	O
expressed	O
in	O
podocytes	O
,	O
a	O
critical	O
cell	O
within	O
the	O
glomerular	O
filtration	O
barrier	O
.	O

When	O
transfected	O
in	O
HEK293T	O
cells	O
,	O
the	O
mutant	B-DNAMutation
RhoGDIÎ±	I-DNAMutation
was	O
unable	O
to	O
bind	O
to	O
the	O
Rho-GTPases	O
,	B-DNAMutation
RhoA	I-DNAMutation
,	O
Rac1	B-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Cdc42	O
,	O
unlike	O
the	O
wild-type	O
construct	O
.	I-DNAMutation
When	I-DNAMutation
RhoGDIÎ±	O
was	O
knocked	O
down	O
in	O
podocytes	O
,	I-DNAMutation
RhoA	I-DNAMutation
,	O
Rac1	B-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Cdc42	O
were	O
hyperactivated	O
and	O
podocyte	O
motility	O
was	O
impaired	O
.	O

The	O
proband's	O
fibroblasts	O
demonstrated	O
mislocalisation	B-DNAMutation
of	I-DNAMutation
RhoGDIÎ±	O
to	O
the	O
nucleus	O
,	O
hyperactivation	O
of	O
the	O
three	O
Rho-GTPases	O
,	O
and	O
impaired	O
cell	O
motility	O
,	O
suggesting	O
that	O
the	O
in-frame	O
deletion	O
leads	O
to	O
a	O
loss	O
of	O
function	O
.	O

CONCLUSIONS	O
:	O
Mutations	B-DNAMutation
in	I-DNAMutation
ARHGDIA	O
need	O
to	O
be	O
considered	O
in	O
the	O
aetiology	O
of	O
heritable	O
forms	O
of	O
nephrotic	O
syndrome	O
.	O

Homozygosity	O
for	O
a	O
missense	O
mutation	O
G20R	B-DNAMutation
associated	O
with	O
neonatal	O
onset	O
adenosine	B-DNAMutation
deaminase-deficient	I-DNAMutation
severe	O
combined	O
immunodeficiency	O
ADA-SCID	B-DNAMutation
.	O

Mutations	O
at	O
the	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
locus	O
can	O
result	O
in	O
varying	O
degrees	O
of	O
immunodeficiency	O
,	O
including	O
rapidly	O
fulminant	O
severe	O
combined	O
immunodeficiency	O
(SCID)	O
as	O
well	O
as	O
a	O
slowly	O
progressive	O
immunodeficiency	O
not	O
diagnosed	O
until	O
later	O
in	O
childhood	O
.	O

Genetic	O
heterogeneity	O
is	O
a	O
factor	O
in	O
the	O
clinical	O
heterogeneity	O
.	O

We	O
have	O
now	O
identified	O
,	O
by	O
direct	O
sequencing	O
of	O
PCR-amplified	O
genomic	O
DNA	O
,	O
a	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
a	I-DNAMutation
CpG	I-DNAMutation
dinucleotide	O
predicting	O
a	O
glycine	B-DNAMutation
to	I-DNAMutation
arginine	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
20	I-DNAMutation
G20R	B-DNAMutation
.	O

The	O
mutation	O
,	O
in	O
homozygosity	O
,	O
was	O
associated	O
with	O
neonatal-onset	O
rapidly	O
fatal	O
SCID	O
.	O

Consistent	O
with	O
homozygosity	O
,	O
the	O
child	O
was	O
derived	O
from	O
a	O
small	O
isolated	O
inbred	O
community	O
in	O
Newfoundland	O
.	O

The	O
mutation	O
abolishes	O
a	O
site	O
for	O
the	O
restriction	O
enzyme	O
BamHI	O
and	O
can	O
be	O
simply	O
detected	O
by	O
agarose	O
gel	O
electrophoresis	O
following	O
amplification	O
of	O
exon	O
2	O
from	O
genomic	O
DNA	O
and	O
digestion	O
with	O
BamHI	O
.	O

The	O
majority	O
of	O
ADA	B-DNAMutation
missense	O
mutations	O
can	O
now	O
be	O
detected	O
by	O
similar	O
amplification	O
and	O
enzyme	O
digestion	O
.	O

We	O
demonstrated	O
that	O
the	O
G20R	B-DNAMutation
mutation	O
is	O
deleterious	O
since	O
introduction	O
of	O
the	O
mutation	O
into	O
a	O
normal	O
ADA	B-DNAMutation
minigene	O
abolished	O
enzyme	O
activity	O
,	O
as	O
determined	O
by	O
transient	O
expression	O
in	O
monkey	O
kidney	O
(Cos)	O
cells	O
.	O

The	O
amino	O
acid	O
substitution	O
occurs	O
in	O
an	O
area	O
of	O
the	O
molecule	O
conserved	O
from	O
Escherichia	O
coli	O
to	O
man	O
and	O
that	O
,	O
as	O
shown	O
by	O
crystallographic	O
analysis	O
,	O
is	O
involved	O
in	O
the	O
binding	O
of	O
Zn2+	O
at	O
the	O
catalytic	O
site	O
.	O

Although	O
the	O
mutation	O
is	O
in	O
a	O
CpG	O
dinucleotide	O
,	O
known	O
"hotspots"	O
for	O
G	O
to	O
A	O
transitions	O
,	O
it	O
was	O
not	O
found	O
in	O
a	O
series	O
of	O
43	O
additional	O
ADA-	B-DNAMutation
chromosomes	O
.	O

Identification	O
of	O
mutations	O
in	O
additional	O
ADA-	B-DNAMutation
patients	O
with	O
immunodeficiency	O
of	O
varying	O
severity	O
should	O
further	O
define	O
the	O
role	O
that	O
genotype	O
plays	O
in	O
determining	O
the	O
extent	O
of	O
immunologic	O
dysfunction	O
.	O

Site	O
directed	O
mutagenesis	O
of	O
amino	O
acid	O
residues	O
at	O
the	O
active	O
site	O
of	O
mouse	O
aldehyde	O
oxidase	O
AOX1	B-DNAMutation
.	O

Mouse	O
aldehyde	O
oxidase	O
mAOX1	B-DNAMutation
forms	O
a	O
homodimer	O
and	O
belongs	O
to	O
the	O
xanthine	O
oxidase	O
family	O
of	O
molybdoenzymes	O
which	O
are	O
characterized	O
by	O
an	O
essential	O
equatorial	O
sulfur	O
ligand	O
coordinated	O
to	O
the	O
molybdenum	O
atom	O
.	O

In	O
general	O
,	O
mammalian	O
AOs	O
are	O
characterized	O
by	O
broad	O
substrate	O
specificity	O
and	O
an	O
yet	O
obscure	O
physiological	O
function	O
.	O

To	O
define	O
the	O
physiological	O
substrates	O
and	O
the	O
enzymatic	O
characteristics	O
of	O
mAOX1	B-DNAMutation
,	O
we	O
established	O
a	O
system	O
for	O
the	O
heterologous	O
expression	O
of	O
the	O
enzyme	O
in	O
Escherichia	O
coli	O
.	O

The	O
recombinant	O
protein	O
showed	O
spectral	O
features	O
and	O
a	O
range	O
of	O
substrate	O
specificity	O
similar	O
to	O
the	O
native	O
protein	O
purified	O
from	O
mouse	O
liver	O
.	O

The	O
EPR	O
data	O
of	O
recombinant	O
mAOX1	B-DNAMutation
were	O
similar	O
to	O
those	O
of	O
AO	O
from	O
rabbit	O
liver	O
,	O
but	O
differed	O
from	O
the	O
homologous	O
xanthine	O
oxidoreductase	O
enzymes	O
.	O

Site-directed	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
Val806	I-DNAMutation
,	I-DNAMutation
Met884	I-DNAMutation
and	I-DNAMutation
Glu1265	I-DNAMutation
at	O
the	O
active	O
site	O
resulted	O
in	O
a	O
drastic	O
decrease	O
in	O
the	O
oxidation	O
of	O
aldehydes	O
with	O
no	O
increase	O
in	O
the	O
oxidation	O
of	O
purine	O
substrates	O
.	O

The	O
double	O
mutant	O
V806E/M884R	B-DNAMutation
and	O
the	O
single	O
mutant	O
E1265Q	B-DNAMutation
were	O
catalytically	O
inactive	O
enzymes	O
regardless	O
of	O
the	O
aldehyde	O
or	O
purine	O
substrates	O
tested	O
.	O

Our	O
results	O
show	O
that	O
only	O
Glu1265	O
is	O
essential	O
for	O
the	O
catalytic	O
activity	O
by	O
initiating	O
the	O
base-catalyzed	O
mechanism	O
of	O
substrate	O
oxidation	O
.	O

In	O
addition	O
,	O
it	O
is	O
concluded	O
that	O
the	O
substrate	O
specificity	O
of	O
molybdo-flavoenzymes	O
is	O
more	O
complex	O
and	O
not	O
only	O
defined	O
by	O
the	O
three	O
characterized	O
amino	O
acids	O
in	O
the	O
active	O
site	O
.	O

Identification	O
and	O
tissue	O
expression	O
of	O
a	O
splice	O
variant	O
for	O
the	O
growth	O
arrest-specific	O
gene	O
gas6	B-DNAMutation
.	O

The	O
growth	O
arrest-specific	O
gene	O
gas6	B-DNAMutation
encodes	O
a	O
secreted	O
protein	O
Gas6	B-DNAMutation
which	O
is	O
a	O
member	O
of	O
the	O
vitamin	O
K-dependent	O
protein	O
family	O
and	O
was	O
identified	O
as	O
a	O
ligand	O
for	O
the	O
Ax1	O
tyrosine	O
kinase	O
receptor	O
family	O
.	O

Gas6	B-DNAMutation
shares	O
significant	O
similarity	O
with	O
protein	O
S	O
and	O
a	O
similar	O
domain	O
organisation	O
:	O
an	O
extensively	O
gamma-carboxylated	O
amino-terminal	O
,	O
four	O
epidermal	O
growth	O
factor-like	O
motifs	O
and	O
a	O
large	O
carboxy-terminal	O
region	O
,	O
known	O
as	O
the	O
D	O
domain	O
.	O

Here	O
we	O
report	O
on	O
the	O
isolation	O
of	O
a	O
splice	O
variant	O
(gas6SV)	O
characterised	O
by	O
an	O
in-frame	B-DNAMutation
129	I-DNAMutation
bp	I-DNAMutation
insertion	I-DNAMutation
between	I-DNAMutation
the	I-DNAMutation
fourth	I-DNAMutation
EGF	I-DNAMutation
domain	I-DNAMutation
and	I-DNAMutation
the	I-DNAMutation
D	I-DNAMutation
domain	I-DNAMutation
.	O

The	O
gene	O
gas6	B-DNAMutation
was	O
previously	O
mapped	O
on	O
chromosome	O
13	O
.	O

The	O
genomic	O
organisation	O
of	O
gas6	B-DNAMutation
has	O
been	O
investigated	O
demonstrating	O
the	O
presence	O
of	O
alternative	O
splicing	O
consensus	O
sites	O
.	O

Expression	O
of	O
gas6SV	O
has	O
been	O
investigated	O
in	O
various	O
human	O
tissues	O
and	O
found	O
to	O
have	O
a	O
similar	O
distribution	O
pattern	O
as	O
gas6	B-DNAMutation
,	O
with	O
the	O
exception	O
of	O
the	O
spleen	O
where	O
gas6SV	O
seems	O
to	O
be	O
the	O
predominant	O
form	O
.	O

Mutations	O
in	O
a	O
new	O
photoreceptor-pineal	O
gene	O
on	O
17p	O
cause	O
Leber	O
congenital	O
amaurosis	O
.	O

Leber	O
congenital	O
amaurosis	O
(	O
LCA	O
,	O
MIM	O
204000	O
)	O
accounts	O
for	O
at	O
least	O
5%	O
of	O
all	O
inherited	O
retinal	O
disease	O
and	O
is	O
the	O
most	O
severe	O
inherited	O
retinopathy	O
with	O
the	O
earliest	O
age	O
of	O
onset	O
.	O

Individuals	O
affected	O
with	O
LCA	O
are	O
diagnosed	O
at	O
birth	O
or	O
in	O
the	O
first	O
few	O
months	O
of	O
life	O
with	O
severely	O
impaired	O
vision	O
or	O
blindness	O
,	O
nystagmus	O
and	O
an	O
abnormal	O
or	O
flat	O
electroretinogram	O
(ERG)	O
.	O

Mutations	O
in	O
GUCY2D	B-DNAMutation
(	O
ref	O
.	O

3	O
)	O
,	O
RPE65	B-DNAMutation
(	O
ref	O
.	O

4	O
)	O
and	O
CRX	B-DNAMutation
(	O
ref	O
.	O

5	O
)	O
are	O
known	O
to	O
cause	O
LCA	O
,	O
but	O
one	O
study	O
identified	O
disease-causing	O
GUCY2D	B-DNAMutation
mutations	O
in	O
only	O
8	O
of	O
15	O
families	O
whose	O
LCA	O
locus	O
maps	O
to	O
17p13.1	O
(	O
ref	O
.	O

3	O
)	O
,	O
suggesting	O
another	O
LCA	O
locus	O
might	O
be	O
located	O
on	O
17p13.1	O
.	O

Confirming	O
this	O
prediction	O
,	O
the	O
LCA	O
in	O
one	O
Pakistani	O
family	O
mapped	O
to	O
17p13.1	O
,	O
between	O
D17S849	B-DNAMutation
and	O
D17S960-a	B-DNAMutation
region	O
that	O
excludes	O
GUCY2D	B-DNAMutation
.	O

The	O
LCA	O
in	O
this	O
family	O
has	O
been	O
designated	O
LCA4	B-DNAMutation
(	O
ref	O
.	O

6	O
)	O
.	O

We	O
describe	O
here	O
a	O
new	O
photoreceptor/pineal-expressed	O
gene	O
,	O
AIPL1	B-DNAMutation
(	O
encoding	O
aryl-hydrocarbon	B-DNAMutation
interacting	I-DNAMutation
protein-like	I-DNAMutation
1	I-DNAMutation
)	O
,	O
that	O
maps	O
within	O
the	O
LCA4	B-DNAMutation
candidate	O
region	O
and	O
whose	O
protein	O
contains	O
three	O
tetratricopeptide	O
(TPR)	O
motifs	O
,	O
consistent	O
with	O
nuclear	O
transport	O
or	O
chaperone	O
activity	O
.	O

A	O
homozygous	O
nonsense	O
mutation	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
278	I-DNAMutation
is	O
present	O
in	O
all	O
affected	O
members	O
of	O
the	O
original	O
LCA4	O
family	O
.	O

AIPL1	B-DNAMutation
mutations	O
may	O
cause	O
approximately	O
20%	O
of	O
recessive	O
LCA	O
,	O
as	O
disease-causing	O
mutations	O
were	O
identified	O
in	O
3	O
of	O
14	O
LCA	O
families	O
not	O
tested	O
previously	O
for	O
linkage	O
.	O

Topological	O
orientation	O
of	O
acyl-CoA:diacylglycerol	B-DNAMutation
acyltransferase-1	I-DNAMutation
DGAT1	B-DNAMutation
and	O
identification	O
of	O
a	O
putative	O
active	O
site	O
histidine	O
and	O
the	O
role	O
of	O
the	O
n	O
terminus	O
in	O
dimer/tetramer	O
formation	O
.	O

Acyl	O
CoA:diacylglycerol	B-DNAMutation
acyltransferase	I-DNAMutation
DGAT	B-DNAMutation
is	O
an	O
integral	O
membrane	O
protein	O
of	O
the	O
endoplasmic	O
reticulum	O
that	O
catalyzes	O
the	O
synthesis	O
of	O
triacylglycerols	O
.	O

Two	O
DGAT	B-DNAMutation
enzymes	O
have	O
been	O
identified	O
(	O
DGAT1	B-DNAMutation
and	O
DGAT2	B-DNAMutation
)	O
with	O
unique	O
roles	O
in	O
lipid	O
metabolism	O
.	O

DGAT1	B-DNAMutation
is	O
a	O
multifunctional	O
acyltransferase	O
capable	O
of	O
synthesizing	O
diacylglycerol	O
,	O
retinyl	O
,	O
and	O
wax	O
esters	O
in	O
addition	O
to	O
triacylglycerol	O
.	O

Here	O
,	O
we	O
report	O
the	O
membrane	O
topology	O
for	O
murine	O
DGAT1	B-DNAMutation
using	O
protease	O
protections	O
assays	O
and	O
indirect	O
immunofluorescence	O
in	O
conjunction	O
with	O
selective	O
permeabilization	O
of	O
cellular	O
membranes	O
.	O

Topology	O
models	O
based	O
on	O
prediction	O
algorithms	O
suggested	O
that	O
DGAT1	B-DNAMutation
had	O
eight	O
transmembrane	O
domains	O
.	O

In	O
contrast	O
,	O
our	O
data	O
indicate	O
that	O
DGAT1	B-DNAMutation
has	O
three	O
transmembrane	O
domains	O
with	O
the	O
N	O
terminus	O
oriented	O
toward	O
the	O
cytosol	O
.	O

The	O
C-terminal	O
region	O
of	O
DGAT1	B-DNAMutation
,	O
which	O
accounts	O
for	O
â¼50%	O
of	O
the	O
protein	O
,	O
is	O
present	O
in	O
the	O
endoplasmic	O
reticulum	O
lumen	O
and	O
contains	O
a	O
highly	O
conserved	O
histidine	O
residue	O
(His-426)	O
that	O
may	O
be	O
part	O
of	O
the	O
active	O
site	O
.	O

Mutagenesis	O
of	B-DNAMutation
His-426	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
impaired	O
the	O
ability	O
of	B-DNAMutation
DGAT1	I-DNAMutation
to	O
synthesize	O
triacylglycerols	O
as	O
well	O
as	O
retinyl	O
and	O
wax	O
esters	O
in	O
an	O
in	O
vitro	O
acyltransferase	O
assay	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
N-terminal	O
domain	O
of	B-DNAMutation
DGAT1	I-DNAMutation
is	O
not	O
required	O
for	O
the	O
catalytic	O
activity	O
of	B-DNAMutation
DGAT1	I-DNAMutation
but	O
,	O
instead	O
,	O
may	O
be	O
involved	O
in	O
regulating	O
enzyme	O
activity	O
and	O
dimer/tetramer	O
formation	O
.	O

Mutation	O
causing	O
congenital	O
myasthenia	O
reveals	O
acetylcholine	O
receptor	O
beta/delta	O
subunit	O
interaction	O
essential	O
for	O
assembly	O
.	O

We	O
describe	O
a	O
severe	O
postsynaptic	O
congenital	O
myasthenic	O
syndrome	O
with	O
marked	O
endplate	O
acetylcholine	O
receptor	O
AChR	B-DNAMutation
deficiency	O
caused	O
by	O
2	O
heteroallelic	O
mutations	O
in	O
the	O
beta	O
subunit	O
gene	O
.	O

One	O
mutation	O
causes	O
skipping	O
of	O
exon	O
8	O
,	O
truncating	O
the	O
beta	O
subunit	O
before	O
its	O
M1	O
transmembrane	O
domain	O
,	O
and	O
abolishing	O
surface	O
expression	O
of	O
pentameric	O
AChR	B-DNAMutation
.	O

The	O
other	O
mutation	O
,	O
a	O
3-codon	B-DNAMutation
deletion	I-DNAMutation
(beta426delEQE)	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
long	I-DNAMutation
cytoplasmic	I-DNAMutation
loop	I-DNAMutation
between	I-DNAMutation
the	I-DNAMutation
M3	I-DNAMutation
and	I-DNAMutation
M4	I-DNAMutation
domains	I-DNAMutation
,	O
curtails	O
but	O
does	O
not	O
abolish	O
expression	O
.	O

By	O
coexpressing	O
beta426delEQE	B-DNAMutation
with	O
combinations	O
of	O
wild-type	O
subunits	O
in	O
293	O
HEK	O
cells	O
,	O
we	O
demonstrate	O
that	O
beta426delEQE	B-DNAMutation
impairs	O
AChR	B-DNAMutation
assembly	O
by	O
disrupting	O
a	O
specific	O
interaction	O
between	O
beta	O
and	O
delta	O
subunits	O
.	O

Studies	O
with	O
related	O
deletion	O
and	O
missense	O
mutants	O
indicate	O
that	O
secondary	O
structure	O
in	O
this	O
region	O
of	O
the	O
beta	O
subunit	O
is	O
crucial	O
for	O
interaction	O
with	O
the	O
delta	O
subunit	O
.	O

The	O
findings	O
imply	O
that	O
the	O
mutated	O
residues	O
are	O
positioned	O
at	O
the	O
interface	O
between	O
beta	O
and	O
delta	O
subunits	O
and	O
demonstrate	O
contribution	O
of	O
this	O
local	O
region	O
of	O
the	O
long	O
cytoplasmic	O
loop	O
to	O
AChR	B-DNAMutation
assembly	O
.	O

SIRT5	B-DNAMutation
regulates	O
the	O
mitochondrial	O
lysine	O
succinylome	O
and	O
metabolic	O
networks	O
.	O

Reversible	O
posttranslational	O
modifications	O
are	O
emerging	O
as	O
critical	O
regulators	O
of	O
mitochondrial	O
proteins	O
and	O
metabolism	O
.	O

Here	O
,	O
we	O
use	O
a	O
label-free	O
quantitative	O
proteomic	O
approach	O
to	O
characterize	O
the	O
lysine	O
succinylome	O
in	O
liver	O
mitochondria	O
and	O
its	O
regulation	O
by	O
the	O
desuccinylase	O
SIRT5	B-DNAMutation
.	O

A	O
total	O
of	O
1,190	O
unique	O
sites	O
were	O
identified	O
as	O
succinylated	O
,	O
and	O
386	O
sites	O
across	O
140	O
proteins	O
representing	O
several	O
metabolic	O
pathways	O
including	O
Î²-oxidation	O
and	O
ketogenesis	O
were	O
significantly	O
hypersuccinylated	O
in	B-DNAMutation
Sirt5(-/-)	I-DNAMutation
animals	O
.	I-DNAMutation
Loss	I-DNAMutation
of	O
SIRT5	I-DNAMutation
leads	O
to	O
accumulation	O
of	O
medium-	O
and	O
long-chain	O
acylcarnitines	O
and	O
decreased	O
Î²-hydroxybutyrate	O
production	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	B-DNAMutation
SIRT5	I-DNAMutation
regulates	O
succinylation	O
of	O
the	O
rate-limiting	O
ketogenic	O
enzyme	O
3-hydroxy-3-methylglutaryl-CoA	O
synthase	O
2	B-DNAMutation
(HMGCS2)	I-DNAMutation
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Finally	B-DNAMutation
,	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
hypersuccinylated	I-DNAMutation
residues	I-DNAMutation
K83	I-DNAMutation
and	I-DNAMutation
K310	I-DNAMutation
on	B-DNAMutation
HMGCS2	I-DNAMutation
to	O
glutamic	O
acid	O
strongly	O
inhibits	O
enzymatic	O
activity	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
establish	B-DNAMutation
SIRT5	I-DNAMutation
as	O
a	O
global	O
regulator	O
of	O
lysine	O
succinylation	O
in	O
mitochondria	O
and	O
present	O
a	O
mechanism	O
for	O
inhibition	O
of	O
ketogenesis	O
through	B-DNAMutation
HMGCS2	I-DNAMutation
.	O

Identification	O
of	O
essential	O
regions	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
interleukin-1	B-DNAMutation
receptor	I-DNAMutation
accessory	I-DNAMutation
protein	I-DNAMutation
critical	O
for	O
interleukin-1	O
signaling	O
.	O

Interleukin	O
(IL)-1	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
and	O
regulation	O
of	O
immune	O
responses	O
.	O

The	O
activated	O
IL-1	O
receptor	O
complex	O
,	O
which	O
consists	O
of	O
the	O
IL-1	O
receptor	O
type	O
I	O
and	O
the	O
IL-1	B-DNAMutation
receptor	I-DNAMutation
accessory	I-DNAMutation
protein	I-DNAMutation
IL-1RAcP	B-DNAMutation
,	O
generates	O
multiple	O
cellular	O
responses	O
including	O
NF-kappaB	O
activation	O
,	O
IL-2	B-DNAMutation
secretion	O
,	O
and	O
IL-2	B-DNAMutation
promoter	O
activation	O
.	O

Reconstitution	O
experiments	O
in	O
EL4D6/76	O
cells	O
lacking	O
IL-1RAcP	B-DNAMutation
expression	O
and	O
IL-1	B-DNAMutation
responsiveness	O
were	O
used	O
to	O
analyze	O
structure-function	O
relationships	O
of	O
the	O
IL-1RAcP	B-DNAMutation
cytoplasmic	O
tail	O
.	O

Mutating	O
a	O
potential	O
tyrosine	O
kinase	O
phosphorylation	O
motif	O
and	O
various	O
conserved	O
amino	O
acid	O
(aa)	O
residues	O
had	O
no	O
effect	O
on	O
IL-1	B-DNAMutation
responsiveness	O
.	O

Truncation	O
analyses	O
revealed	O
that	O
box	O
3	O
of	O
the	O
TIR	O
domain	O
was	O
required	O
for	O
NF-kappaB	O
activation	O
,	O
IL-2	B-DNAMutation
production	O
,	O
and	O
c-Jun	B-DNAMutation
N-terminal	I-DNAMutation
kinase	I-DNAMutation
(JNK)	O
activation	O
,	O
whereas	O
IL-2	B-DNAMutation
promoter	O
activation	O
was	O
only	O
partially	O
inhibited	O
.	O

Surprisingly	O
,	O
deletion	B-DNAMutation
of	I-DNAMutation
aa	I-DNAMutation
527-534	I-DNAMutation
resulted	O
in	O
almost	O
complete	O
loss	O
of	O
all	O
IL-1	B-DNAMutation
responsiveness	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
aa	I-DNAMutation
with	I-DNAMutation
alanyl	I-DNAMutation
residues	I-DNAMutation
did	O
not	O
reconstitute	O
NF-kappaB	O
activation	O
,	O
IL-2	B-DNAMutation
production	O
,	O
or	O
JNK	O
activation	O
but	O
partly	O
restored	O
IL-2	B-DNAMutation
promoter	O
activation	O
.	O

Immunoprecipitation	O
data	O
revealed	O
a	O
strong	O
correlation	O
between	O
MyD88	B-DNAMutation
binding	O
with	O
NF-kappaB	O
activation	O
and	O
IL-2	B-DNAMutation
production	O
but	O
not	O
with	O
IL-2	B-DNAMutation
promoter	O
activation	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
box	O
3	O
of	O
IL-1RAcP	B-DNAMutation
is	O
critical	O
for	O
IL-1-dependent	B-DNAMutation
NF-kappaB	O
activation	O
and	O
stabilization	O
of	O
IL-2	B-DNAMutation
mRNA	O
via	O
JNK	O
,	O
whereas	O
aa	O
527-534	O
largely	O
contribute	O
to	O
IL-2	B-DNAMutation
promoter	O
activation	O
.	O

A	O
mutation	O
of	O
beta	O
-actin	O
that	O
alters	O
depolymerization	O
dynamics	O
is	O
associated	O
with	O
autosomal	O
dominant	O
developmental	O
malformations	O
,	O
deafness	O
,	O
and	O
dystonia	O
.	O

Actin	O
,	O
one	O
of	O
the	O
major	O
filamentous	O
cytoskeletal	O
molecules	O
,	O
is	O
involved	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

Whereas	O
an	O
association	O
between	O
muscle	O
actin	O
mutations	O
and	O
skeletal	O
and	O
cardiac	O
myopathies	O
has	O
been	O
well	O
documented	O
,	O
reports	O
of	O
human	O
disease	O
arising	O
from	O
mutations	O
of	O
nonmuscle	O
actin	O
genes	O
have	O
been	O
rare	O
.	O

We	O
have	O
identified	O
a	O
missense	O
point	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
beta	O
-actin	O
that	O
results	O
in	O
an	O
arginine-to-tryptophan	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
183	I-DNAMutation
.	O

The	O
disease	O
phenotype	O
includes	O
developmental	O
midline	O
malformations	O
,	O
sensory	O
hearing	O
loss	O
,	O
and	O
a	O
delayed-onset	O
generalized	O
dystonia	O
syndrome	O
in	O
monozygotic	O
twins	O
.	O

Cellular	O
studies	O
of	O
a	O
lymphoblastoid	O
cell	O
line	O
obtained	O
from	O
an	O
affected	O
patient	O
demonstrated	O
morphological	O
abnormalities	O
of	O
the	O
actin	O
cytoskeleton	O
and	O
altered	O
actin	O
depolymerization	O
dynamics	O
in	O
response	O
to	O
latrunculin	O
A	O
,	O
an	O
actin	O
monomer-sequestering	O
drug	O
.	O

Resistance	O
to	O
latrunculin	O
A	O
was	O
also	O
observed	O
in	O
NIH	O
3T3	O
cells	O
expressing	O
the	O
mutant	O
actin	O
.	O

These	O
findings	O
suggest	O
that	O
mutations	O
in	O
nonmuscle	O
actins	O
may	O
be	O
associated	O
with	O
a	O
broad	O
spectrum	O
of	O
developmental	O
malformations	O
and/or	O
neurological	O
abnormalities	O
such	O
as	O
dystonia	O
.	O

Identification	O
and	O
structural	O
determination	O
of	O
the	O
M(3)	O
muscarinic	O
acetylcholine	O
receptor	O
basolateral	O
sorting	O
signal	O
.	O

Muscarinic	O
acetylcholine	O
receptors	O
comprise	O
a	O
family	O
of	O
G-protein-coupled	O
receptors	O
that	O
display	O
differential	O
localization	O
in	O
polarized	O
epithelial	O
cells	O
.	O

We	O
identify	O
a	O
seven-residue	O
sequence	O
,	O
Ala(275)-Val(281)	O
,	O
in	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
M(3)	O
muscarinic	O
receptor	O
that	O
mediates	O
dominant	O
,	O
position-independent	O
basolateral	O
targeting	O
in	O
Madin-Darby	O
canine	O
kidney	O
cells	O
.	O

Mutational	O
analyses	O
identify	O
Glu(276)	O
,	O
Phe(280)	O
,	O
and	O
Val(281)	O
as	O
critical	O
residues	O
within	O
this	O
sorting	O
motif	O
.	O

Phe(280)	O
and	O
Val(281)	O
comprise	O
a	O
novel	O
dihydrophobic	O
sorting	O
signal	O
as	O
mutations	O
of	O
either	O
residue	O
singly	O
or	O
together	O
with	O
leucine	O
do	O
not	O
disrupt	O
basolateral	O
targeting	O
.	O

Conversely	O
,	O
Glu(276)	O
is	O
required	O
and	O
cannot	O
be	O
substituted	O
with	O
alanine	O
or	O
aspartic	O
acid	O
.	O

A	O
19-amino	O
acid	O
peptide	O
representing	O
the	O
M(3)	O
sorting	O
signal	O
and	O
surrounding	O
sequence	O
was	O
analyzed	O
via	O
two-dimensional	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
.	O

Solution	O
structures	O
show	O
that	O
Glu(276)	O
resides	O
in	O
a	O
type	O
IV	O
beta-turn	O
and	O
the	O
dihydrophobic	O
sequence	O
Phe(280)Val(281)	O
adopts	O
either	O
a	O
type	O
I	O
or	O
IV	O
beta-turn	O
.	O

Signal	O
transduction	O
by	O
normal	O
isoforms	O
and	O
W	O
mutant	O
variants	O
of	O
the	O
Kit	O
receptor	O
tyrosine	O
kinase	O
.	O

Germline	O
mutations	O
at	O
the	O
Dominant	O
White	O
Spotting	O
(W)	O
and	O
Steel	O
(Sl)	O
loci	O
have	O
provided	O
conclusive	O
genetic	O
evidence	O
that	O
c-kit	B-DNAMutation
mediated	O
signal	O
transduction	O
pathways	O
are	O
essential	O
for	O
normal	O
mouse	O
development	O
.	O

We	O
have	O
analysed	O
the	O
interactions	O
of	O
normal	O
and	O
mutant	O
W/c-kit	B-DNAMutation
gene	O
products	O
with	O
cytoplasmic	O
signalling	O
proteins	O
,	O
using	O
transient	O
c-kit	B-DNAMutation
expression	O
assays	O
in	O
COS	O
cells	O
.	O

In	O
addition	O
to	O
the	O
previously	O
identified	O
c-kit	B-DNAMutation
gene	O
product	O
(Kit+)	O
,	O
a	O
second	O
normal	O
Kit	O
isoform	O
(KitA+)	O
containing	O
an	O
in-frame	B-DNAMutation
insertion	I-DNAMutation
,	I-DNAMutation
Gly-Asn-Asn-Lys	I-DNAMutation
,	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
extracellular	I-DNAMutation
domain	I-DNAMutation
,	O
was	O
detected	O
in	O
murine	O
mast	O
cell	O
cultures	O
and	O
mid-gestation	O
placenta	O
.	O

Both	O
Kit+	O
and	O
KitA+	O
isoforms	O
showed	O
increased	O
autophosphorylation	O
and	O
enhanced	O
association	O
with	O
phosphatidylinositol	O
(PI)	O
3'	O
kinase	O
and	O
PLC	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
,	O
when	O
stimulated	O
with	O
recombinant	O
soluble	O
Steel	O
factor	O
.	O

No	O
association	O
or	O
increase	O
in	O
phosphorylation	O
of	O
GAP	O
and	O
two	O
GAP-associated	O
proteins	O
,	O
p62	B-DNAMutation
and	O
p190	B-DNAMutation
,	O
was	O
observed	O
.	O

The	O
two	O
isoforms	O
had	O
distinct	O
activities	O
in	O
the	O
absence	O
of	O
exogenous	O
soluble	O
Steel	O
factor	O
;	O
Kit+	O
,	O
but	O
not	O
KitA+	O
,	O
showed	O
constitutive	O
tyrosine	O
phosphorylation	O
that	O
was	O
accompanied	O
by	O
a	O
low	O
constitutive	O
level	O
of	O
association	O
with	O
PI-3'	B-DNAMutation
kinase	O
and	O
PLC	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
.	O

Introduction	O
of	O
the	O
point	O
substitutions	O
associated	O
with	O
W37	B-DNAMutation
Glu582----Lys	B-DNAMutation
or	O
W41	B-DNAMutation
Val831----Met	B-DNAMutation
mutant	O
alleles	O
into	O
c-kit	B-DNAMutation
expression	O
constructs	O
abolished	O
W37	B-DNAMutation
or	O
reduced	O
W41	B-DNAMutation
the	O
Steel	O
factor-induced	O
association	O
of	O
the	O
Kit	O
receptor	O
with	O
signalling	O
proteins	O
in	O
a	O
manner	O
proportional	O
to	O
the	O
overall	O
severity	O
of	O
the	O
corresponding	O
W	O
mutant	O
phenotype	O
.	O

These	O
data	O
suggest	O
a	O
diversity	O
of	O
normal	O
Kit	O
signalling	O
pathways	O
and	O
indicate	O
that	O
W	O
mutant	O
phenotypes	O
result	O
from	O
primary	O
defects	O
in	O
the	O
Kit	O
receptor	O
that	O
affect	O
its	O
interaction	O
with	O
cytoplasmic	O
signalling	O
proteins	O
.	O

Spectrum	O
of	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
FALDH	B-DNAMutation
gene	O
in	O
patients	O
with	O
SjÃ¶gren-Larsson	O
syndrome	O
.	O

The	O
gene	O
encoding	O
the	O
human	B-DNAMutation
fatty	I-DNAMutation
aldehyde	I-DNAMutation
dehydrogenase	I-DNAMutation
(FALDH)	I-DNAMutation
is	O
located	O
on	O
17p11.2	O
,	O
causing	O
SjÃ¶gren-Larsson	O
syndrome	O
(SLS)	O
when	O
mutated	O
.	O

SLS	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
a	O
combination	O
of	O
mental	O
retardation	O
,	O
congenital	O
ichthyosis	O
,	O
and	O
spastic	O
di-	O
or	O
tetraplegia	O
.	O

We	O
report	O
here	O
on	O
studies	O
of	O
16	O
SLS	O
families	O
from	O
Europe	O
and	O
the	O
Middle	O
East	O
,	O
which	O
resulted	O
in	O
identification	O
of	O
11	O
different	O
mutations	O
.	O

The	O
spectrum	O
of	O
mutations	O
characterized	O
in	O
the	O
present	O
study	O
are	O
five	O
nucleotide	O
substitutions	O
resulting	O
in	O
amino	O
acid	O
changes	O
,	O
five	O
frameshift	O
mutations	O
introducing	O
a	O
stop	O
codon	O
,	O
and	O
one	O
in-frame	O
deletion	O
with	O
insertion	O
at	O
the	O
same	O
position	O
.	O

We	O
also	O
observed	O
silent	O
sequence	O
variants	O
in	O
the	B-DNAMutation
FALDH	I-DNAMutation
gene	O
and	O
a	I-DNAMutation
base	I-DNAMutation
pair	I-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
that	I-DNAMutation
alters	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
to	I-DNAMutation
asparagine	I-DNAMutation
,	O
all	O
of	O
which	O
are	O
considered	O
polymorphisms	O
.	O

A	O
dominant-negative	O
ESCRT-III	B-DNAMutation
protein	O
perturbs	O
cytokinesis	O
and	O
trafficking	O
to	O
lysosomes	O
.	O

In	O
eukaryotic	O
cells	O
,	O
the	O
completion	O
of	O
cytokinesis	O
is	O
dependent	O
on	O
membrane	O
trafficking	O
events	O
to	O
deliver	O
membrane	O
to	O
the	O
site	O
of	O
abscission	O
.	O

Golgi	O
and	O
recycling	O
endosomal-derived	O
proteins	O
are	O
required	O
for	O
the	O
terminal	O
stages	O
of	O
cytokinesis	O
.	O

Recently	O
,	O
protein	O
subunits	O
of	O
the	O
ESCRT	B-DNAMutation
(	O
endosomal	O
sorting	O
complexes	O
required	O
for	O
transport	O
)	O
that	O
are	O
normally	O
involved	O
in	O
late	O
endosome	O
to	O
lysosome	O
trafficking	O
have	O
also	O
been	O
implicated	O
in	O
abscission	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
subunit	O
,	O
CHMP3	B-DNAMutation
(	O
charged	B-DNAMutation
multivesicular	I-DNAMutation
body	I-DNAMutation
protein-3	I-DNAMutation
)	O
,	O
of	O
ESCRT-III	B-DNAMutation
localizes	O
at	O
the	O
midbody	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
autoinhibitory	O
domain	O
of	O
CHMP3	B-DNAMutation
inhibits	O
cytokinesis	O
.	O

At	O
the	O
midbody	O
,	O
CHMP3	B-DNAMutation
does	O
not	O
co-localize	O
with	O
Rab11	B-DNAMutation
,	O
suggesting	O
that	O
it	O
is	O
not	O
present	O
on	O
recycling	O
endosomes	O
.	O

These	O
results	O
combined	O
provide	O
compelling	O
evidence	O
that	O
proteins	O
involved	O
in	O
late	O
endosomal	O
function	O
are	O
necessary	O
for	O
the	O
end	O
stages	O
of	O
cytokinesis	O
.	O

Cloning	O
of	O
the	O
human	O
aspartoacylase	B-DNAMutation
cDNA	O
and	O
a	O
common	O
missense	O
mutation	O
in	O
Canavan	O
disease	O
.	O

Canavan	O
disease	O
,	O
an	O
autosomal	O
recessive	O
leukodystrophy	O
,	O
is	O
caused	O
by	O
deficiency	O
of	O
aspartoacylase	B-DNAMutation
and	O
accumulation	O
of	O
N-acetylaspartic	O
acid	O
in	O
brain	O
.	O

We	O
have	O
cloned	O
the	O
human	O
aspartoacylase	B-DNAMutation
ASP	B-DNAMutation
cDNA	O
spanning	O
1,435	O
basepairs	O
,	O
and	O
show	O
that	O
the	O
isolated	O
cDNA	O
expresses	O
aspartoacylase	B-DNAMutation
activity	O
in	O
bacteria	O
.	O

Furthermore	O
,	O
an	O
A	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
base	I-DNAMutation
change	I-DNAMutation
,	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
854	I-DNAMutation
,	O
has	O
been	O
found	O
in	O
85%	O
of	O
the	O
34	O
Canavan	O
alleles	O
tested	O
so	O
far	O
.	O

This	O
base	O
change	O
results	O
in	O
a	O
missense	B-DNAMutation
Glu285Ala	I-DNAMutation
mutation	O
that	O
is	O
predicted	O
to	O
be	O
part	O
of	O
the	O
catalytic	O
domain	O
of	O
aspartoacylase	B-DNAMutation
.	O

The	O
data	O
suggest	O
that	O
the	O
catalytic	O
centre	O
of	O
aspartoacylase	B-DNAMutation
involves	O
a	O
triad	O
of	O
Ser	O
,	O
His	O
and	O
Glu	O
residues	O
.	O

Our	O
findings	O
have	O
implications	O
for	O
diagnosis	O
and	O
screening	O
of	O
Canavan	O
disease	O
.	O

A	O
transforming	O
mutation	O
in	O
the	O
pleckstrin	O
homology	O
domain	O
of	O
AKT1	B-DNAMutation
in	O
cancer	O
.	O

Although	O
AKT1	B-DNAMutation
(	O
v-akt	O
murine	O
thymoma	O
viral	O
oncogene	O
homologue	O
1	O
)	O
kinase	O
is	O
a	O
central	O
member	O
of	O
possibly	O
the	O
most	O
frequently	O
activated	O
proliferation	O
and	O
survival	O
pathway	O
in	O
cancer	O
,	O
mutation	O
of	O
AKT1	B-DNAMutation
has	O
not	O
been	O
widely	O
reported	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
somatic	O
mutation	O
in	O
human	O
breast	O
,	O
colorectal	O
and	O
ovarian	O
cancers	O
that	O
results	O
in	O
a	O
glutamic	B-DNAMutation
acid	I-DNAMutation
to	I-DNAMutation
lysine	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
17	I-DNAMutation
E17K	B-DNAMutation
in	O
the	O
lipid-binding	O
pocket	O
of	O
AKT1	B-DNAMutation
.	O

Lys	O
17	O
alters	O
the	O
electrostatic	O
interactions	O
of	O
the	O
pocket	O
and	O
forms	O
new	O
hydrogen	O
bonds	O
with	O
a	O
phosphoinositide	O
ligand	O
.	O

This	O
mutation	O
activates	O
AKT1	B-DNAMutation
by	O
means	O
of	O
pathological	O
localization	O
to	O
the	O
plasma	O
membrane	O
,	O
stimulates	O
downstream	O
signalling	O
,	O
transforms	O
cells	O
and	O
induces	O
leukaemia	O
in	O
mice	O
.	O

This	O
mechanism	O
indicates	O
a	O
direct	O
role	O
of	O
AKT1	B-DNAMutation
in	O
human	O
cancer	O
,	O
and	O
adds	O
to	O
the	O
known	O
genetic	O
alterations	O
that	O
promote	O
oncogenesis	O
through	O
the	O
phosphatidylinositol-3-OH	O
kinase/AKT	O
pathway	O
.	O

Furthermore	O
,	O
the	O
E17K	B-DNAMutation
substitution	O
decreases	O
the	O
sensitivity	O
to	O
an	O
allosteric	O
kinase	O
inhibitor	O
,	O
so	O
this	O
mutation	O
may	O
have	O
important	O
clinical	O
utility	O
for	O
AKT	O
drug	O
development	O
.	O

Nucleotide	O
sequence	O
of	O
the	O
ADH2(3)	B-DNAMutation
gene	O
encoding	O
the	O
human	O
alcohol	O
dehydrogenase	O
beta	B-DNAMutation
3	I-DNAMutation
subunit	O
.	O

All	O
nine	O
exons	O
of	O
the	O
ADH2(3)	B-DNAMutation
allele	O
,	O
which	O
encodes	O
the	O
human	O
alcohol	O
dehydrogenase	O
beta	B-DNAMutation
3	I-DNAMutation
subunit	O
,	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

Comparison	O
of	O
this	O
sequence	O
to	O
the	O
ADH2(1)	B-DNAMutation
nucleotide	O
sequence	O
revealed	O
only	O
a	O
single	O
difference	O
that	O
results	O
in	O
an	O
amino	O
acid	O
change	O
,	O
thus	O
proving	O
that	O
the	O
significant	O
kinetic	O
differences	O
between	O
these	O
two	O
isozymes	O
is	O
due	O
to	O
the	O
Cys	B-DNAMutation
for	I-DNAMutation
Arg	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
369	I-DNAMutation
.	O

There	O
are	O
also	O
two	O
silent	O
polymorphisms	O
,	O
and	O
two	O
changes	O
in	O
noncoding	O
regions	O
.	O

Identification	O
of	O
threonine	O
66	O
as	O
a	O
functionally	O
critical	O
residue	O
of	O
the	O
interleukin-1	O
receptor-associated	O
kinase	O
.	O

We	O
have	O
mutated	O
a	O
conserved	O
residue	O
of	O
the	O
death	O
domain	O
of	O
the	O
interleukin-1	O
(IL-1)	O
receptor-associated	O
kinase	O
IRAK	B-DNAMutation
,	O
threonine	O
66	O
.	O

The	O
substitution	B-DNAMutation
of	I-DNAMutation
Thr-66	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
or	I-DNAMutation
glutamate	I-DNAMutation
prevented	O
spontaneous	O
activation	O
of	O
NF-kappaB	O
by	O
overexpressed	O
IRAK	B-DNAMutation
but	O
enhanced	O
IL-1-induced	O
activation	O
of	O
the	O
factor	O
.	O

Like	O
the	O
kinase-inactivating	O
mutation	O
,	O
K239S	B-DNAMutation
,	O
the	O
T66A	B-DNAMutation
and	O
T66E	B-DNAMutation
mutations	O
interfered	O
with	O
the	O
ability	O
of	O
IRAK	B-DNAMutation
to	O
autophosphorylate	O
and	O
facilitated	O
the	O
interactions	O
of	O
IRAK	B-DNAMutation
with	O
TRAF6	B-DNAMutation
and	O
with	O
the	O
IL-1	O
receptor	O
accessory	O
protein	O
,	O
AcP	B-DNAMutation
.	O

Wild-type	O
IRAK	B-DNAMutation
constructs	O
tagged	O
with	O
fluorescent	O
proteins	O
formed	O
complexes	O
that	O
adopted	O
a	O
punctate	O
distribution	O
in	O
the	O
cytoplasm	O
.	O

The	O
Thr-66	B-DNAMutation
mutations	I-DNAMutation
prevented	O
the	O
formation	O
of	O
these	O
complexes	O
.	O

Measurements	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
among	O
fluorescent	O
constructs	O
showed	O
that	O
the	O
Thr-66	B-DNAMutation
mutations	I-DNAMutation
abolished	O
the	O
capacity	O
of	O
IRAK	B-DNAMutation
to	O
dimerize	O
.	O

In	O
contrast	O
,	O
the	O
K239S	B-DNAMutation
mutation	O
did	O
not	O
inhibit	O
dimerization	O
of	O
IRAK	B-DNAMutation
as	O
evidenced	O
by	O
fluorescence	O
resonance	O
energy	O
transfer	O
measurements	O
,	O
even	O
though	O
microscopy	O
showed	O
that	O
it	O
prevented	O
the	O
formation	O
of	O
punctate	O
complexes	O
.	O

Our	O
results	O
show	O
that	O
Thr-66	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
ability	O
of	O
IRAK	B-DNAMutation
to	O
form	O
homodimers	O
and	O
that	O
its	O
kinase	O
activity	O
regulates	O
its	O
ability	O
to	O
form	O
high	O
molecular	O
weight	O
complexes	O
.	O

These	O
properties	O
in	O
turn	O
determine	O
key	O
aspects	O
of	O
the	O
signaling	O
function	O
of	O
IRAK	B-DNAMutation
.	O

Analysis	O
of	O
ALK-1	B-DNAMutation
and	O
endoglin	B-DNAMutation
in	O
newborns	O
from	O
families	O
with	O
hereditary	O
hemorrhagic	O
telangiectasia	O
type	O
2	O
.	O

ALK-1	B-DNAMutation
(	O
activin	B-DNAMutation
receptor-like	I-DNAMutation
kinase-1	I-DNAMutation
)	O
,	O
a	O
type	O
I	O
receptor	O
of	O
the	O
transforming	O
growth	O
factor	O
(TGF)-beta	O
superfamily	O
,	O
is	O
the	O
gene	O
mutated	O
in	O
hereditary	O
hemorrhagic	O
telangiectasia	O
type	O
2	O
(HHT2)	O
while	O
endoglin	B-DNAMutation
is	O
mutated	O
in	O
HHT1	B-DNAMutation
.	O

Using	O
a	O
novel	O
polyclonal	O
antibody	O
to	O
ALK-1	B-DNAMutation
,	O
we	O
measured	O
ALK-1	B-DNAMutation
expression	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(HUVEC)	O
of	O
newborns	O
from	O
HHT	O
families	O
whose	O
affected	O
members	O
had	O
normal	O
endoglin	B-DNAMutation
levels	O
.	O

ALK-1	B-DNAMutation
levels	O
were	O
specifically	O
reduced	O
in	O
three	O
HUVEC	O
with	O
ALK-1	B-DNAMutation
missense	O
mutant	O
codons	O
,	O
and	O
normal	O
in	O
two	O
newborns	O
not	O
carrying	O
the	O
missense	O
mutations	O
present	O
in	O
the	O
clinically	O
affected	O
relatives	O
.	O

Levels	O
were	O
also	O
normal	O
in	O
a	O
HUVEC	O
with	O
deletion	B-DNAMutation
of	I-DNAMutation
S232	I-DNAMutation
in	O
the	O
ATP	O
binding	O
site	O
of	O
ALK-1	B-DNAMutation
.	O

Thus	O
HHT2	O
appears	O
to	O
be	O
associated	O
with	O
a	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
due	O
to	O
a	O
reduction	O
in	O
either	O
protein	O
level	O
or	O
activity	O
.	O

We	O
also	O
report	O
three	O
new	O
ALK-1	B-DNAMutation
missense	O
mutations	O
leading	O
to	O
G48E/A49P	B-DNAMutation
,	O
C344Y	B-DNAMutation
and	O
E407D	B-DNAMutation
substitutions	O
.	O

In	O
COS-1	O
transfected	O
cells	O
,	O
ALK-1	B-DNAMutation
was	O
found	O
in	O
the	O
TGF-beta1	B-DNAMutation
and	I-DNAMutation
-beta3	I-DNAMutation
receptor	I-DNAMutation
complexes	O
in	O
association	O
with	O
endoglin	B-DNAMutation
and	O
TbetaRII	B-DNAMutation
,	O
but	O
not	O
in	O
activin	O
receptor	O
complexes	O
containing	O
endoglin	B-DNAMutation
.	O

In	O
HUVEC	O
,	O
ALK-1	B-DNAMutation
was	O
not	O
detectable	O
in	O
the	O
TGF-beta1	B-DNAMutation
or	I-DNAMutation
-beta3	I-DNAMutation
receptor	I-DNAMutation
complexes	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
ligand	O
,	O
ALK-1	B-DNAMutation
and	O
endoglin	B-DNAMutation
interactions	O
were	O
observed	O
by	O
immunoprecipitation/western	O
blot	O
in	O
HUVEC	O
from	O
normal	O
as	O
well	O
as	O
HHT1	B-DNAMutation
and	O
HHT2	O
patients	O
.	O

Our	O
data	O
suggest	O
a	O
transient	O
association	O
between	O
these	O
two	O
proteins	O
of	O
the	O
TGF-beta	O
superfamily	O
,	O
both	O
required	O
at	O
a	O
critical	O
level	O
to	O
ensure	O
vessel	O
wall	O
integrity	O
.	O

Missense	O
mutations	O
in	O
the	O
ABCB6	B-DNAMutation
transporter	O
cause	O
dominant	O
familial	O
pseudohyperkalemia	O
.	O

Familial	O
Pseudohyperkalemia	O
(FP)	O
is	O
a	O
dominant	O
red	O
cell	O
trait	O
characterized	O
by	O
increased	O
serum	O
[K(+)]	O
in	O
whole	O
blood	O
stored	O
at	O
or	O
below	O
room	O
temperature	O
,	O
without	O
additional	O
hematological	O
abnormalities	O
.	O

Functional	O
gene	O
mapping	O
and	O
sequencing	O
analysis	O
of	O
the	O
candidate	O
genes	O
within	O
the	O
2q35-q36	O
critical	O
interval	O
identified-in	O
20	O
affected	O
individuals	O
among	O
three	O
multigenerational	O
FP	O
families-two	O
novel	O
heterozygous	O
missense	O
mutations	O
in	O
the	O
ABCB6	B-DNAMutation
gene	O
that	O
cosegregated	O
with	O
disease	O
phenotype	O
.	O

The	O
two	B-DNAMutation
genomic	I-DNAMutation
substitutions	I-DNAMutation
altered	I-DNAMutation
two	I-DNAMutation
adjacent	I-DNAMutation
nucleotides	I-DNAMutation
within	I-DNAMutation
codon	I-DNAMutation
375	I-DNAMutation
of	O
ABCB6	B-DNAMutation
,	O
a	O
porphyrin	O
transporter	O
that	O
,	O
in	O
erythrocyte	O
membranes	O
,	O
bears	O
the	O
Langereis	O
blood	O
group	O
antigen	O
system	O
.	O

The	O
ABCB6	B-DNAMutation
R375Q	B-DNAMutation
mutation	O
did	O
not	O
alter	O
the	O
levels	O
of	O
mRNA	O
or	O
protein	O
,	O
or	O
protein	O
localization	O
in	O
mature	O
erythrocytes	O
or	O
erythroid	O
precursor	O
cells	O
,	O
but	O
it	O
is	O
predicted	O
to	O
modestly	O
alter	O
protein	O
structure	O
.	O

ABCB6	B-DNAMutation
mRNA	O
and	O
protein	O
levels	O
increase	O
during	O
in	O
vitro	O
erythroid	O
differentiation	O
of	O
CD34(+)	O
erythroid	O
precursors	O
and	O
the	O
erythroleukemia	O
cell	O
lines	O
HEL	O
and	O
K562	O
.	O

These	O
data	O
suggest	O
that	O
the	O
two	B-DNAMutation
missense	I-DNAMutation
mutations	I-DNAMutation
in	I-DNAMutation
residue	I-DNAMutation
375	I-DNAMutation
of	O
the	O
ABCB6	B-DNAMutation
polypeptide	O
found	O
in	O
affected	O
individuals	O
of	O
families	O
with	O
chromosome	O
2-linked	O
FP	O
could	O
contribute	O
to	O
the	O
red	O
cell	O
K(+)	O
leak	O
characteristic	O
of	O
this	O
condition	O
.	O

Protein	O
kinase	O
A	O
increases	O
type-2	O
inositol	O
1,4,5-trisphosphate	O
receptor	O
activity	O
by	O
phosphorylation	O
of	O
serine	O
937	O
.	O

Protein	O
kinase	O
A	O
(PKA)	O
phosphorylation	O
of	O
inositol	O
1,4,5-trisphosphate	O
receptors	O
(InsP(3)Rs)	O
represents	O
a	O
mechanism	O
for	O
shaping	O
intracellular	O
Ca(2+)	O
signals	O
following	O
a	O
concomitant	O
elevation	O
in	O
cAMP	O
.	O

Activation	O
of	O
PKA	O
results	O
in	O
enhanced	O
Ca(2+)	O
release	O
in	O
cells	O
that	O
express	O
predominantly	O
InsP(3)R2	B-DNAMutation
.	O

PKA	O
is	O
known	O
to	O
phosphorylate	O
InsP(3)R2	B-DNAMutation
,	O
but	O
the	O
molecular	O
determinants	O
of	O
this	O
effect	O
are	O
not	O
known	O
.	O

We	O
have	O
expressed	O
mouse	O
InsP(3)R2	B-DNAMutation
in	O
DT40-3KO	O
cells	O
that	O
are	O
devoid	O
of	O
endogenous	O
InsP(3)R	O
and	O
examined	O
the	O
effects	O
of	O
PKA	O
phosphorylation	O
on	O
this	O
isoform	O
in	O
unambiguous	O
isolation	O
.	O

Activation	O
of	O
PKA	O
increased	O
Ca(2+)	O
signals	O
and	O
augmented	O
the	O
single	O
channel	O
open	O
probability	O
of	O
InsP(3)R2	B-DNAMutation
.	O

A	O
PKA	O
phosphorylation	O
site	O
unique	O
to	O
the	O
InsP(3)R2	B-DNAMutation
was	O
identified	O
at	O
Ser(937)	O
.	O

The	O
enhancing	O
effects	O
of	O
PKA	O
activation	O
on	O
this	O
isoform	O
required	O
the	O
phosphorylation	O
of	O
Ser(937)	B-DNAMutation
,	I-DNAMutation
since	I-DNAMutation
replacing	I-DNAMutation
this	I-DNAMutation
residue	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
eliminated	O
the	O
positive	O
effects	O
of	O
PKA	O
activation	O
.	O

These	O
results	O
provide	O
a	O
mechanism	O
responsible	O
for	O
the	O
enhanced	O
Ca(2+)	O
signaling	O
following	O
PKA	O
activation	O
in	O
cells	O
that	O
express	O
predominantly	O
InsP(3)R2	B-DNAMutation
.	O

Selection	O
of	O
differentiating	O
cells	O
by	O
different	O
levels	O
of	O
delta-like	B-DNAMutation
1	I-DNAMutation
among	O
neural	O
precursor	O
cells	O
in	O
the	O
developing	O
mouse	O
telencephalon	O
.	O

During	O
the	O
neurogenic	O
phase	O
of	O
mammalian	O
brain	O
development	O
,	O
only	O
a	O
subpopulation	O
of	O
neural	O
precursor	O
cells	O
(NPCs)	O
differentiates	O
into	O
neurons	O
.	O

The	O
mechanisms	O
underlying	O
this	O
selection	O
remain	O
unclear	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
the	O
Notch-Delta	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
this	O
selection	O
in	O
the	O
developing	O
mouse	O
telencephalon	O
.	O

We	O
found	O
that	O
the	O
expression	O
patterns	O
of	O
the	O
Notch	O
ligand	O
delta-like	B-DNAMutation
1	I-DNAMutation
Dll1	B-DNAMutation
and	O
of	O
the	O
active	O
form	O
of	O
Notch1	B-DNAMutation
were	O
mutually	O
exclusive	O
and	O
segregated	O
into	O
distinct	O
NPC	O
subpopulations	O
in	O
the	O
ventricular	O
zone	O
of	O
the	O
telencephalon	O
.	O

When	O
Dll1	B-DNAMutation
was	O
overexpressed	O
in	O
a	O
small	O
,	O
but	O
not	O
a	O
large	O
,	O
proportion	O
of	O
NPCs	O
,	O
these	O
cells	O
underwent	O
neuronal	O
differentiation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

This	O
Dll1-induced	B-DNAMutation
neuronal	O
differentiation	O
did	O
not	O
occur	O
when	O
cells	O
were	O
plated	O
at	O
lower	O
densities	O
in	O
an	O
in	O
vitro	O
culture	O
.	O

Importantly	O
,	O
conditional	O
deletion	B-DNAMutation
of	I-DNAMutation
the	O
Dll1	B-DNAMutation
gene	O
in	O
a	O
small	O
proportion	O
of	O
NPCs	O
reduced	O
neurogenesis	O
in	O
vivo	O
,	O
whereas	O
deletion	O
in	O
a	O
large	O
proportion	O
promoted	O
premature	O
neurogenesis	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
different	O
levels	O
of	O
Dll1	B-DNAMutation
expression	O
determine	O
the	O
fate	O
of	O
NPCs	O
through	O
cell-cell	O
interactions	O
,	O
most	O
likely	O
through	O
the	O
Notch-Delta	O
lateral	O
inhibitory	O
signaling	O
pathway	O
,	O
thus	O
contributing	O
to	O
the	O
selection	O
of	O
differentiating	O
cells	O
.	O

Identification	O
of	O
four	O
novel	O
mutations	O
in	O
five	O
unrelated	O
Korean	O
families	O
with	O
Fabry	O
disease	O
.	O

Fabry	O
disease	O
is	O
a	O
X-linked	O
recessively	O
inherited	O
metabolic	O
disorder	O
,	O
which	O
results	O
from	O
the	O
deficient	O
activity	O
of	O
the	O
lysosomal	O
hydrolase	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
leading	O
to	O
the	O
systemic	O
deposition	O
of	O
glycosphingolipids	O
with	O
terminal	O
alpha-galactosyl	O
moieties	O
.	O

Single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
was	O
performed	O
,	O
followed	O
by	O
DNA	O
sequencing	O
of	O
PCR	O
amplified	O
exons	O
of	O
the	O
human	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
5	O
unrelated	O
Korean	O
patients	O
with	O
classic	O
Fabry	O
disease	O
.	O

Five	O
different	O
mutations	O
were	O
identified	O
;	O
two	O
nonsense	O
mutations	O
(	O
Y86X	B-DNAMutation
and	O
R342X	B-DNAMutation
)	O
,	O
one	O
missense	O
mutation	O
D266N	B-DNAMutation
,	O
and	O
two	O
small	O
deletions	O
(	O
296del2	B-DNAMutation
and	O
802del4	B-DNAMutation
)	O
.	O

Except	O
for	O
R342X	B-DNAMutation
mutation	O
,	O
four	O
were	O
novel	O
mutations	O
(	O
Y86X	B-DNAMutation
,	O
D266N	B-DNAMutation
,	O
296del2	B-DNAMutation
,	O
802del4	B-DNAMutation
)	O
.	O

A	B-DNAMutation
T	I-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
5157	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
2	I-DNAMutation
caused	O
a	O
tyrosine-to-stop	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
86	I-DNAMutation
.	O

A	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
10287	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
substituted	O
an	O
asparagine	B-DNAMutation
for	I-DNAMutation
an	I-DNAMutation
aspartate	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
266	I-DNAMutation
.	O

Mutation	O
296del2	B-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
2	I-DNAMutation
resulted	O
in	O
a	O
frame	B-DNAMutation
shift	I-DNAMutation
with	I-DNAMutation
a	I-DNAMutation
stop	I-DNAMutation
signal	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
22th	I-DNAMutation
codon	I-DNAMutation
downstream	I-DNAMutation
from	I-DNAMutation
the	I-DNAMutation
mutation	I-DNAMutation
,	O
whereas	O
mutation	O
802del4	B-DNAMutation
resulted	O
in	O
a	O
stop	B-DNAMutation
codon	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
site	I-DNAMutation
of	I-DNAMutation
4	I-DNAMutation
bp	I-DNAMutation
deletion	I-DNAMutation
.	O

In	O
addition	O
,	O
the	O
802del4	B-DNAMutation
was	O
found	O
to	O
be	O
a	O
de	O
novo	O
mutation	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
mutation	O
analysis	O
of	O
the	O
human	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
Korean	O
patients	O
with	O
Fabry	O
disease	O
.	O

Early-onset	O
Alzheimer	O
disease	O
caused	O
by	O
a	O
new	O
mutation	O
V717L	B-DNAMutation
in	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
.	O

CONTEXT	O
:	O
Alzheimer	O
disease	O
is	O
the	O
most	O
common	O
form	O
of	O
dementia	O
.	O

Mutations	O
in	O
the	O
genes	O
amyloid	O
precursor	O
protein	O
(APP)	O
,	O
presenilin	B-DNAMutation
1(PS1)	I-DNAMutation
and	O
presenilin	B-DNAMutation
2(PS2)	I-DNAMutation
have	O
been	O
found	O
in	O
early-onset	O
familial	O
forms	O
of	O
Alzheimer	O
disease	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
cause	O
of	O
dementia	O
in	O
a	O
family	O
with	O
early-onset	O
illness	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
A	O
family	O
with	O
a	O
history	O
of	O
dementia	O
was	O
referred	O
to	O
the	O
Indiana	O
Alzheimer	O
Disease	O
Center	O
,	O
Indianapolis	O
.	O

All	O
the	O
research	O
in	O
this	O
study	O
was	O
done	O
in	O
a	O
university	O
or	O
university	O
hospital	O
.	O

The	O
proband	O
and	O
her	B-DNAMutation
4	I-DNAMutation
siblings	O
took	O
part	O
in	O
the	O
study	O
.	O

The	O
proband	O
,	O
who	O
is	O
still	O
alive	O
,	O
showed	O
symptoms	O
of	O
Alzheimer	O
disease	O
at	O
38	O
years	O
of	O
age	O
.	O

Genomic	O
DNA	O
was	O
obtained	O
from	O
blood	O
samples	O
of	O
5	O
family	O
members	O
.	O

The	O
APPandPS1genes	O
of	O
the	O
proband	O
were	O
screened	O
for	O
mutations	O
by	O
amplification	O
followed	O
by	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Sequence	O
of	O
exon	O
17	O
of	O
the	O
APPgene	O
revealed	O
a	O
single	O
nucleotide	O
(	O
guanine	O
to	O
cytosine	O
)	O
substitution	O
in	O
1	O
allele	O
,	O
resulting	O
in	O
an	O
amino	B-DNAMutation
acid	I-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
(	I-DNAMutation
valine	I-DNAMutation
to	I-DNAMutation
leucine	I-DNAMutation
)	O
.	O

Each	O
of	O
the	O
proband's	O
siblings	O
were	O
tested	O
for	O
this	O
mutation	O
by	O
direct	O
sequencing	O
.	O

Two	O
of	O
the	O
4	O
were	O
found	O
to	O
have	O
the	O
mutation	O
;	O
one	O
of	O
whom	O
was	O
recently	O
clinically	O
diagnosed	O
at	O
the	O
age	O
of	O
36	O
years	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
mutation	O
in	O
the	O
APPgene	O
V717L	B-DNAMutation
has	O
been	O
found	O
in	O
a	O
family	O
with	O
a	O
history	O
of	O
dementia	O
,	O
beginning	O
in	O
the	O
mid	O
to	O
late	O
30s	O
.	O

The	O
age	O
of	O
onset	O
in	O
this	O
family	O
is	O
earlier	O
than	O
most	O
of	O
the	O
other	O
families	O
with	O
Alzheimer	O
disease	O
who	O
also	O
have	O
APPmutations	O
.	O

Arch	O
Neurol	O
.	O

2000	O
.	O

AGAP1	B-DNAMutation
,	O
an	O
endosome-associated	O
,	O
phosphoinositide-dependent	O
ADP-ribosylation	O
factor	O
GTPase-activating	O
protein	O
that	O
affects	O
actin	O
cytoskeleton	O
.	O

We	O
have	O
identified	O
three	O
members	O
of	O
the	O
AGAP	O
subfamily	O
of	O
ASAP	O
family	O
ADP-ribosylation	O
factor	O
GTPase-activating	O
proteins	O
(	O
Arf	O
GAPs	O
)	O
.	O

In	O
addition	O
to	O
the	O
Arf	O
GAP	O
domain	O
,	O
these	O
proteins	O
contain	O
GTP-binding	O
protein-like	O
,	O
ankyrin	O
repeat	O
and	O
pleckstrin	O
homology	O
domains	O
.	O

Here	O
,	O
we	O
have	O
characterized	O
the	O
ubiquitously	O
expressed	O
AGAP1/KIAA1099	B-DNAMutation
.	O

AGAP1	B-DNAMutation
had	O
Arf	O
GAP	O
activity	O
toward	O
Arf1>Arf5>Arf6	B-DNAMutation
.	O

Phosphatidylinositol	O
4,5-bisphosphate	O
and	O
phosphatidic	O
acid	O
synergistically	O
stimulated	O
GAP	O
activity	O
.	O

As	O
found	O
for	O
other	O
ASAP	O
family	O
Arf	O
GAPs	O
,	O
the	O
pleckstrin	O
homology	O
domain	O
was	O
necessary	O
for	O
activity	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
GTP-binding	I-DNAMutation
protein-like	I-DNAMutation
domain	I-DNAMutation
affected	O
lipid	O
dependence	O
of	O
Arf	O
GAP	O
activity	O
.	O

In	O
vivo	O
effects	O
of	O
AGAP1	B-DNAMutation
were	O
distinct	O
from	O
other	O
ASAP	O
family	O
Arf	O
GAPs	O
.	O

Overexpressed	O
AGAP1	B-DNAMutation
induced	O
the	O
formation	O
of	O
and	O
was	O
associated	O
with	O
punctate	O
structures	O
containing	O
the	O
endocytic	O
markers	O
transferrin	B-DNAMutation
and	O
Rab4	B-DNAMutation
.	O

AP1	O
was	O
redistributed	O
from	O
the	O
trans-Golgi	O
to	O
the	O
punctate	O
structures	O
.	O

Like	O
other	O
ASAP	O
family	O
members	O
,	O
AGAP1	B-DNAMutation
overexpression	O
inhibited	O
the	O
formation	O
of	O
PDGF-induced	O
ruffles	O
.	O

However	O
,	O
distinct	O
from	O
other	O
ASAP	O
family	O
members	O
,	O
AGAP1	B-DNAMutation
also	O
induced	O
the	O
loss	O
of	O
actin	O
stress	O
fibers	O
.	O

Thus	O
,	O
AGAP1	B-DNAMutation
is	O
a	O
phosphoinositide-dependent	O
Arf	O
GAP	O
that	O
impacts	O
both	O
the	O
endocytic	O
compartment	O
and	O
actin	O
.	O

Foxe3	B-DNAMutation
haploinsufficiency	O
in	O
mice	O
:	O
a	O
model	O
for	O
Peters'	O
anomaly	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
importance	O
in	O
anterior	O
segment	O
dysgenesis	O
of	O
genetic	O
variation	O
in	O
Foxe3	B-DNAMutation
,	O
a	O
gene	O
encoding	O
a	O
forkhead	O
transcription	O
factor	O
specifically	O
expressed	O
in	O
the	O
lens	O
.	O

METHODS	O
:	O
The	O
phenotype	O
of	O
mice	O
heterozygous	O
for	O
a	O
mutation	O
in	O
the	O
DNA-binding	O
domain	O
of	O
Foxe3	B-DNAMutation
was	O
examined	O
from	O
histologic	O
sections	O
,	O
and	O
DNA	O
binding	O
by	O
the	O
encoded	O
protein	O
was	O
investigated	O
by	O
gel-shift	O
assay	O
.	O

FOXE3	B-DNAMutation
from	O
human	O
patients	O
with	O
Peters'	O
anomaly	O
was	O
PCR	O
amplified	O
and	O
sequenced	O
.	O

RESULTS	O
:	O
The	O
dysgenetic	O
lens	O
(dyl)	O
allele	O
of	O
Foxe3	B-DNAMutation
was	O
found	O
to	O
encode	O
a	O
protein	O
unable	O
to	O
bind	O
DNA	O
.	O

Approximately	O
40%	O
of	O
mice	O
heterozygous	O
for	O
Foxe3(dyl)	B-DNAMutation
have	O
corneal	O
and	O
lenticular	O
defects	O
.	O

The	O
phenotype	O
is	O
variable	O
but	O
typically	O
consists	O
of	O
the	O
equivalent	O
of	O
Peters'	O
anomaly	O
in	O
humans	O
,	O
with	O
central	O
corneal	O
opacity	O
,	O
keratolenticular	O
adhesion	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
anterior	O
polar	O
cataract	O
.	O

In	O
a	O
small	O
cohort	O
(	O
n	O
=	O
13	O
)	O
of	O
patients	O
with	O
Peters'	O
anomaly	O
,	O
shown	O
to	O
be	O
normal	O
in	O
the	O
PAX6	B-DNAMutation
locus	O
,	O
one	O
individual	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
nonconservative	O
missense	O
mutation	O
in	O
FOXE3	B-DNAMutation
.	O

The	O
mutation	O
,	O
which	O
does	O
not	O
occur	O
in	O
116	O
chromosomes	O
from	O
a	O
control	O
population	O
,	O
substitutes	O
leucine	B-DNAMutation
for	I-DNAMutation
arginine	I-DNAMutation
90	I-DNAMutation
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
forkhead	O
domain	O
.	O

CONCLUSIONS	O
:	O
Haploinsufficiency	O
of	O
Foxe3	B-DNAMutation
in	O
a	O
mouse	O
model	O
causes	O
anterior	O
segment	O
dysgenesis	O
similar	O
to	O
Peters'	O
anomaly	O
.	O

Although	O
causality	O
could	O
not	O
be	O
shown	O
in	O
the	O
human	O
case	O
,	O
the	O
presence	O
of	O
a	O
rare	O
,	O
nonconservative	O
substitution	O
in	O
FOXE3	B-DNAMutation
of	O
a	O
patient	O
with	O
Peters'	O
anomaly	O
is	O
interesting	O
,	O
in	O
light	O
of	O
the	O
phenotypic	O
similarities	O
with	O
the	O
mutant	O
mice	O
.	O

A	O
new	O
pathogenic	O
mutation	O
in	O
the	O
APP	O
gene	O
I716V	B-DNAMutation
increases	O
the	O
relative	O
proportion	O
of	O
A	O
beta	O
42(43)	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
(	O
APP	O
I716V	B-DNAMutation
)	O
which	O
probably	O
leads	O
to	O
familial	O
early	O
onset	O
Alzheimer's	O
disease	O
with	O
an	O
onset	O
age	O
in	O
the	O
mid	O
50s	O
.	O

Cells	O
transfected	O
with	O
cDNAs	O
bearing	O
this	O
mutation	O
produce	O
more	O
A	O
beta	O
1-42(43)	O
than	O
those	O
transfected	O
with	O
wild-type	O
APP	O
and	O
this	O
effect	O
is	O
additive	O
with	O
that	O
of	O
the	O
previously	O
reported	O
APP	O
V717I	B-DNAMutation
mutation	O
thus	O
providing	O
a	O
novel	O
approach	O
for	O
further	O
increasing	O
A	O
beta	O
1-42(43)	O
in	O
model	O
systems	O
.	O

Human	O
orosomucoid	O
polymorphism	O
:	O
molecular	O
basis	O
of	O
the	O
three	O
common	O
ORM1	O
alleles	O
,	O
ORM1*F1	O
,	O
ORM1*F2	O
,	O
and	O
ORM1*S	O
.	O

The	O
human	O
orosomucoid	O
(ORM)	O
is	O
controlled	O
by	O
two	O
closely	O
linked	O
loci	O
,	O
ORM1	O
and	O
ORM2	B-DNAMutation
,	O
and	O
two	O
tandem	O
genes	O
,	O
AGP1	B-DNAMutation
and	O
AGP2	B-DNAMutation
,	O
encoding	O
the	O
proteins	O
produced	O
by	O
the	O
two	O
loci	O
,	O
have	O
been	O
cloned	O
.	O

In	O
this	O
study	O
the	O
molecular	O
basis	O
of	O
ORM1	O
polymorphism	O
was	O
investigated	O
.	O

For	O
the	O
detection	O
of	O
mutations	O
the	O
products	O
of	O
the	O
six	O
exons	O
of	O
each	O
gene	O
,	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
,	O
were	O
screened	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
.	O

Subsequently	O
,	O
the	O
exons	O
with	O
an	O
altered	O
migration	O
pattern	O
were	O
gene-specifically	O
amplified	O
by	O
nested	O
PCR	O
.	O

Sequencing	O
of	O
the	O
gene-specific	O
PCR	O
products	O
showed	O
that	O
the	O
three	O
common	O
ORM1	O
alleles	O
result	O
from	O
A-->G	B-DNAMutation
transitions	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
codons	I-DNAMutation
for	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
positions	I-DNAMutation
20	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
1	I-DNAMutation
and	O
156	B-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
of	O
the	O
AGP1	B-DNAMutation
gene	O
:	O
ORM1*F1	B-DNAMutation
was	I-DNAMutation
characterized	I-DNAMutation
by	I-DNAMutation
CAG	I-DNAMutation
(Gln)	I-DNAMutation
and	I-DNAMutation
GTG	I-DNAMutation
(Val)	I-DNAMutation
,	O
ORM1*F2	B-DNAMutation
,	I-DNAMutation
by	I-DNAMutation
CAG	I-DNAMutation
(Gln)	I-DNAMutation
and	I-DNAMutation
ATG	I-DNAMutation
(Met)	I-DNAMutation
,	O
and	O
ORM1*S	B-DNAMutation
,	I-DNAMutation
by	I-DNAMutation
CGG	I-DNAMutation
(Arg)	I-DNAMutation
and	I-DNAMutation
GTG	I-DNAMutation
(Val)	I-DNAMutation
.	O

The	O
phylogenesis	O
of	O
the	O
genes	O
encoding	O
these	O
three	O
ORM1	O
alleles	O
is	O
discussed	O
.	O

Novel	O
ATP8B1	B-DNAMutation
mutation	O
in	O
an	O
adult	O
male	O
with	O
progressive	O
familial	O
intrahepatic	O
cholestasis	O
.	O

Progressive	O
familial	O
intrahepatic	O
cholestasis	O
type	O
1	O
is	O
a	O
rare	O
disease	O
that	O
is	O
characterized	O
by	O
low	O
serum	O
Î³-glutamyltransferase	O
levels	O
due	O
to	O
mutation	O
in	B-DNAMutation
ATP8B1	I-DNAMutation
.	O

We	O
present	O
a	O
23-year-old	O
male	O
who	O
experienced	O
persistent	O
marked	O
pruritus	O
for	O
eighteen	O
years	O
and	O
recurrent	O
jaundice	O
for	O
thirteen	O
years	O
,	O
in	O
addition	O
to	O
cholestasis	O
that	O
eventually	O
became	O
fatal	O
.	O

Genetic	O
sequencing	O
studies	O
of	O
the	O
entire	O
coding	O
(exon)	O
sequences	O
of	B-DNAMutation
ATP8B1	I-DNAMutation
and	B-DNAMutation
ABCB11	I-DNAMutation
uncovered	O
a	O
novel	B-DNAMutation
heterozygous	I-DNAMutation
missense	I-DNAMutation
3035G>T	I-DNAMutation
mutation	O
(S1012I)	I-DNAMutation
and	O
a	B-DNAMutation
synonymous	I-DNAMutation
696T>C	I-DNAMutation
mutation	O
in	B-DNAMutation
ATP8B1	I-DNAMutation
.	O

The	O
patient's	O
progression	O
was	O
associated	O
with	O
not	O
only	O
impaired	B-DNAMutation
familial	I-DNAMutation
intrahepatic	I-DNAMutation
cholestasis	I-DNAMutation
1	O
(FIC1)	I-DNAMutation
function	O
but	O
also	O
impaired	O
bile	O
salt	O
export	O
pump	O
expression	O
due	O
to	O
the	O
impaired	B-DNAMutation
FIC1	I-DNAMutation
function	O
.	O

Our	O
findings	O
show	O
that	O
patients	O
with	O
intermittent	O
cholestasis	O
can	O
develop	O
progressive	O
liver	O
disease	O
even	O
after	O
several	O
decades	O
and	O
require	O
regular	O
follow	O
up	O
.	O

A	O
new	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
mutation	O
,	O
Thr-Met	B-DNAMutation
85	I-DNAMutation
,	O
(	O
PI	O
Zbristol	O
)	O
associated	O
with	O
novel	O
electrophoretic	O
properties	O
.	O

A	O
new	O
AAT	O
allele	O
(	O
PI	O
Zbristol	O
)	O
has	O
been	O
discovered	O
in	O
a	O
woman	O
with	O
an	O
obstetric	O
history	O
of	O
three	O
perinatal	O
deaths	O
from	O
fulminant	O
liver	O
disease	O
and	O
no	O
living	O
offspring	O
.	O

She	O
and	O
her	O
father	O
were	O
both	O
PI	O
M1Zbristol	O
heterozygotes	O
.	O

The	O
Zbristol	O
protein	O
is	O
active	O
as	O
a	O
proteinase	O
inhibitor	O
but	O
appeared	O
to	O
be	O
deficient	O
in	O
the	O
plasma	O
to	O
about	O
the	O
same	O
degree	O
as	O
the	O
S	O
protein	O
in	O
MS	O
heterozygotes	O
.	O

It	O
focuses	O
on	O
the	O
basic	O
side	O
of	O
Z	O
and	O
lacks	O
the	O
normal	O
pattern	O
of	O
secondary	O
isoforms	O
associated	O
with	O
the	O
commonly	O
occurring	O
AAT	O
variants	O
and	O
migrates	O
faster	O
than	O
normal	O
on	O
an	O
SDS	O
electrophoresis	O
gel	O
.	O

The	O
Zbristol	O
mutation	O
was	O
found	O
to	O
be	O
a	O
C	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
85	I-DNAMutation
changing	I-DNAMutation
ACG	I-DNAMutation
(Thr)	I-DNAMutation
to	I-DNAMutation
ATG	I-DNAMutation
(Met)	I-DNAMutation
.	O

This	O
disrupts	O
the	O
N-glycosylation	O
site	O
starting	O
at	O
Asn	O
83	O
preventing	O
glycosylation	O
at	O
residue	O
83	O
in	O
the	O
PI	O
Zbristol	O
protein	O
and	O
explains	O
the	O
protein	O
isoelectric	O
focusing	O
and	O
SDS	O
gel	O
electrophoresis	O
results	O
.	O

An	O
analysis	O
of	O
haplotypes	O
in	O
the	O
propositus	O
and	O
her	O
father	O
indicated	O
that	O
the	O
Zbristol	O
mutation	O
occurred	O
on	O
the	O
common	O
M1(Val	B-DNAMutation
213	I-DNAMutation
)	O
genetic	O
background	O
.	O

The	O
new	O
mutation	O
also	O
led	O
to	O
the	O
generation	O
of	O
an	O
NlaIII	O
restriction	O
endonuclease	O
recognition	O
site	O
.	O

Cell	O
lines	O
from	O
two	O
offspring	O
tested	O
for	O
the	O
presence	O
of	O
this	O
NlaIII	O
site	O
revealed	O
that	O
one	O
had	O
the	O
variant	O
and	O
the	O
other	O
did	O
not	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
Zbristol	O
and	O
fulminant	O
liver	O
disease	O
in	O
the	O
offspring	O
is	O
unclear	O
.	O

The	O
bile	O
acid	O
synthetic	O
gene	O
3beta-hydroxy-Delta(5)-C(27)-steroid	O
oxidoreductase	O
is	O
mutated	O
in	O
progressive	O
intrahepatic	O
cholestasis	O
.	O

We	O
used	O
expression	O
cloning	O
to	O
isolate	O
cDNAs	O
encoding	O
a	O
microsomal	O
3beta-hydroxy-Delta(5)-C(27)-steroid	O
oxidoreductase	O
(	O
C(27	B-DNAMutation
)	I-DNAMutation
3beta-HSD	I-DNAMutation
)	O
that	O
is	O
expressed	O
predominantly	O
in	O
the	O
liver	O
.	O

The	O
predicted	O
product	O
shares	O
34%	O
sequence	O
identity	O
with	O
the	O
C(19)	O
and	O
C(21)	O
3beta-HSD	O
enzymes	O
,	O
which	O
participate	O
in	O
steroid	O
hormone	O
metabolism	O
.	O

When	O
transfected	O
into	O
cultured	O
cells	O
,	O
the	O
cloned	O
C(27)	B-DNAMutation
3beta-HSD	I-DNAMutation
cDNA	O
encodes	O
an	O
enzyme	O
that	O
is	O
active	O
against	O
four	O
7alpha-hydroxylated	O
sterols	O
,	O
indicating	O
that	O
a	O
single	O
C(27)	B-DNAMutation
3beta-HSD	I-DNAMutation
enzyme	O
can	O
participate	O
in	O
all	O
known	O
pathways	O
of	O
bile	O
acid	O
synthesis	O
.	O

The	O
expressed	O
enzyme	O
did	O
not	O
metabolize	O
several	O
different	O
C(19/21)	O
steroids	O
as	O
substrates	O
.	O

The	O
levels	O
of	O
hepatic	O
C(27)	B-DNAMutation
3beta-HSD	I-DNAMutation
mRNA	O
in	O
the	O
mouse	O
are	O
not	O
sexually	O
dimorphic	O
and	O
do	O
not	O
change	O
in	O
response	O
to	O
dietary	O
cholesterol	O
or	O
to	O
changes	O
in	O
bile	O
acid	O
pool	O
size	O
.	O

The	O
corresponding	O
human	O
gene	O
on	O
chromosome	O
16p11.2-12	O
contains	O
six	O
exons	O
and	O
spans	O
3	O
kb	O
of	O
DNA	O
,	O
and	O
we	O
identified	O
a	O
2-bp	O
deletion	O
in	O
the	O
C27	B-DNAMutation
3beta-HSD	I-DNAMutation
gene	O
of	O
a	O
patient	O
with	O
neonatal	O
progressive	O
intrahepatic	O
cholestasis	O
.	O

This	O
mutation	O
eliminates	O
the	O
activity	O
of	O
the	O
enzyme	O
in	O
transfected	O
cells	O
.	O

These	O
findings	O
establish	O
the	O
central	O
role	O
of	O
C(27)	B-DNAMutation
3beta-HSD	I-DNAMutation
in	O
the	O
biosynthesis	O
of	O
bile	O
acids	O
and	O
provide	O
molecular	O
tools	O
for	O
the	O
diagnosis	O
of	O
a	O
third	O
type	O
of	O
neonatal	O
progressive	O
intrahepatic	O
cholestasis	O
associated	O
with	O
impaired	O
bile	O
acid	O
synthesis	O
.	O

The	O
chondroitin	O
sulfate	O
attachment	O
site	O
of	O
appican	O
is	O
formed	O
by	O
splicing	O
out	O
exon	O
15	O
of	O
the	O
amyloid	O
precursor	O
gene	O
.	O

Appicans	O
are	O
secreted	O
and	O
cell-associated	O
chondroitin	O
sulfate	O
proteoglycans	O
containing	O
Alzheimer	O
amyloid	O
precursor	O
(APP)	O
as	O
their	O
core	O
protein	O
.	O

Appicans	O
are	O
found	O
in	O
brain	O
tissue	O
,	O
and	O
in	O
cell	O
cultures	O
their	O
expression	O
depends	O
on	O
both	O
cell	O
type	O
and	O
growth	O
conditions	O
.	O

Here	O
we	O
report	O
that	O
the	O
core	O
protein	O
of	O
appicans	O
derives	O
from	O
an	O
APP	O
mRNA	O
lacking	B-DNAMutation
exon	I-DNAMutation
15	I-DNAMutation
.	O

Splicing	O
out	O
of	O
this	O
exon	O
creates	O
a	O
new	O
consensus	O
sequence	O
for	O
the	O
attachment	O
of	O
a	O
chondroitin	O
sulfate	O
chain	O
in	O
the	O
resulting	O
APP	O
product	O
.	O

Transfection	O
of	O
C6	O
glioma	O
or	O
293	O
kidney	O
fibroblast	O
cells	O
with	O
APP	O
cDNAs	O
containing	O
exon	O
15	O
produced	O
no	O
appican	O
,	O
while	O
transfection	O
with	O
an	O
APP	O
cDNA	O
lacking	O
this	O
exon	O
induced	O
high	O
levels	O
of	O
appican	O
production	O
.	O

Polymerase	O
chain	O
reactions	O
indicated	O
that	O
appican-producing	O
cells	O
contained	O
an	O
APP	O
mRNA	O
species	O
without	B-DNAMutation
exon	I-DNAMutation
15	I-DNAMutation
,	O
whereas	O
cells	O
without	O
this	O
mRNA	O
produced	O
no	O
appican	O
.	O

Site-directed	O
mutagenesis	O
combined	O
with	O
immunoreactivity	O
experiments	O
showed	O
that	O
the	O
chondroitin	O
sulfate	O
chain	O
is	O
attached	B-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
serine	I-DNAMutation
residue	I-DNAMutation
16	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
upstream	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
amino	I-DNAMutation
terminus	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
A	I-DNAMutation
beta	I-DNAMutation
sequence	I-DNAMutation
of	O
APP	O
.	O

The	B-DNAMutation
attachment	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
glycosaminoglycan	I-DNAMutation
chain	I-DNAMutation
close	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
A	I-DNAMutation
beta	I-DNAMutation
sequence	I-DNAMutation
of	O
APP	O
may	O
affect	O
the	O
proteolytic	O
processing	O
of	O
APP	O
and	O
production	O
of	O
A	O
beta	O
.	O

The	O
proteoglycan	O
nature	O
of	O
APP	O
suggests	O
that	O
addition	O
of	O
the	O
chondroitin	O
sulfate	O
glycosaminoglycan	O
is	O
important	O
for	O
the	O
implementation	O
of	O
the	O
biological	O
function	O
of	O
these	O
proteins	O
.	O

A	O
leucine-to-proline	O
substitution	O
causes	O
a	O
defective	O
alpha	O
1-antichymotrypsin	O
allele	O
associated	O
with	O
familial	O
obstructive	O
lung	O
disease	O
.	O

Using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
and	O
direct	O
sequencing	O
of	O
amplified	O
genomic	O
DNA	O
,	O
we	O
have	O
identified	O
two	O
defective	O
mutants	O
of	O
the	O
human	O
alpha	O
1-antichymotrypsin	O
ACT	B-DNAMutation
gene	O
associated	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(COPD)	O
.	O

A	O
leucine	B-DNAMutation
55-to-proline	I-DNAMutation
substitution	O
causing	O
a	O
defective	O
ACT	B-DNAMutation
allele	O
(Bochum-1)	O
was	O
observed	O
in	O
a	O
family	O
with	O
COPD	O
in	O
three	O
subsequent	O
generations	O
.	O

Another	O
mutation	O
,	O
proline	B-DNAMutation
229-to-alanine	I-DNAMutation
(Bonn-1)	O
,	O
was	O
associated	O
with	O
ACT	B-DNAMutation
serum	O
deficiency	O
in	O
four	O
patients	O
with	O
a	O
positive	O
family	O
history	O
.	O

These	O
mutations	O
were	O
not	O
detected	O
among	O
100	O
healthy	O
control	O
subjects	O
,	O
suggesting	O
a	O
possible	O
pathogenetic	O
role	O
of	O
ACT	B-DNAMutation
gene	O
defects	O
in	O
a	O
subset	O
of	O
patients	O
with	O
COPD	O
.	O

Molecular	O
basis	O
of	O
an	O
adult	O
form	O
of	O
Sandhoff	O
disease	O
:	O
substitution	B-DNAMutation
of	I-DNAMutation
glutamine	I-DNAMutation
for	I-DNAMutation
arginine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
505	I-DNAMutation
of	O
the	O
beta-chain	O
of	O
beta-hexosaminidase	O
results	O
in	O
a	O
labile	O
enzyme	O
.	O

Sandhoff	O
disease	O
is	O
a	O
lysosomal	O
storage	O
disorder	O
characterized	O
by	O
accumulation	O
of	O
GM2	O
ganglioside	O
due	O
to	O
mutations	O
in	O
the	O
beta-chain	O
of	O
beta-hexosaminidase	O
.	O

Hexosaminidase	O
activity	O
is	O
negligible	O
in	O
infantile	O
Sandhoff	O
disease	O
whereas	O
residual	O
activity	O
is	O
present	O
in	O
juvenile	O
and	O
adult	O
forms	O
.	O

Here	O
we	O
report	O
the	O
molecular	O
basis	O
of	O
the	O
first	O
described	O
adult	O
form	O
of	O
Sandhoff	O
disease	O
.	O

Southern	O
analysis	O
of	O
chromosomal	O
DNA	O
indicated	O
the	O
absence	O
of	O
chromosomal	O
deletions	O
in	O
the	O
gene	O
encoding	O
the	O
beta-chain	O
.	O

Northern	O
analysis	O
of	O
RNA	O
from	O
cultured	O
fibroblasts	O
demonstrated	O
that	O
at	O
least	O
one	O
of	O
the	O
beta-chain	O
alleles	O
was	O
transcribed	O
into	O
normal-length	O
mRNA	O
.	O

Sequence	O
analysis	O
of	O
the	O
entire	O
cDNA	O
prepared	O
from	O
poly-adenylated	O
RNA	O
showed	O
that	O
only	O
one	O
point	O
mutation	O
was	O
present	O
,	O
consisting	O
of	O
a	O
G-->A	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
1514	I-DNAMutation
.	O

This	O
mutation	O
changes	B-DNAMutation
the	I-DNAMutation
electric	I-DNAMutation
charge	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
505	I-DNAMutation
by	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
glutamine	I-DNAMutation
for	I-DNAMutation
arginine	I-DNAMutation
in	O
a	O
highly	O
conserved	O
part	O
of	O
the	O
beta-chain	O
,	O
present	O
even	O
in	O
the	O
slime	O
mold	O
Dictyostelium	O
discoideum	O
.	O

The	O
nucleotide	O
transition	O
generated	O
a	O
new	O
restriction	O
site	O
for	O
DdeI	O
,	O
which	O
was	O
present	O
in	O
only	O
one	O
of	O
the	O
alleles	O
of	O
the	O
patient	O
.	O

Reverse	O
transcription	O
of	O
mRNA	O
followed	O
by	O
restriction	O
with	O
DdeI	O
resulted	O
in	O
complete	O
digestion	O
at	O
the	O
mutation	O
site	O
,	O
demonstrating	O
that	O
the	O
second	O
allele	O
was	O
of	O
an	O
mRNA-negative	O
type	O
.	O

Transfection	O
of	O
COS	O
cells	O
with	O
a	O
cDNA	O
construct	O
containing	O
the	O
mutation	O
but	O
otherwise	O
the	O
normal	O
sequence	O
resulted	O
in	O
the	O
expression	O
of	O
a	O
labile	O
form	O
of	O
beta-hexosaminidase	O
.	O

These	O
results	O
show	O
that	O
the	O
patient's	O
is	O
a	O
genetic	O
compound	O
,	O
and	O
that	O
the	O
lability	O
of	O
beta-hexosaminidase	O
found	O
in	O
this	O
form	O
of	O
Sandhoff	O
disease	O
is	O
based	O
on	O
a	O
single	O
nucleotide	O
transition	O
.	O

Identification	O
of	O
two	O
novel	O
missense	O
mutations	O
in	O
the	O
KAL1	O
gene	O
in	O
Han	O
Chinese	O
subjects	O
with	O
Kallmann	O
Syndrome	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
KAL1	O
,	O
the	O
KAL2	B-DNAMutation
,	O
and	O
PROKR2/PROK2	B-DNAMutation
genes	O
and	O
to	O
characterize	O
phenotypic	O
features	O
in	O
5	O
Chinese	O
subjects	O
with	O
Kallmann	O
Syndrome	O
(KS)	O
and	O
6	O
subjects	O
with	O
normosmic	O
hypogonadotrophic	O
hypogonadism	O
(NHH)	O
in	O
Taiwan	O
.	O

DESIGN	O
AND	O
PATIENTS	O
:	O
Five	O
unrelated	O
males	O
(	O
age	O
range	O
22-52	O
yr	O
)	O
with	O
clinical	O
manifestations	O
of	O
KS	O
and	O
6	O
unrelated	O
males	O
(	O
age	O
range	O
24-47	O
yr	O
)	O
with	O
NHH	O
were	O
analyzed	O
.	O

In	O
addition	O
,	O
5	O
relatives	O
of	O
KS	O
subjects	O
were	O
also	O
evaluated	O
.	O

Genomic	O
DNA	O
extraction	O
,	O
PCR	O
,	O
and	O
DNA	O
sequence	O
analyses	O
were	O
performed	O
using	O
standard	O
procedures	O
.	O

RESULTS	O
:	O
The	O
1st	O
patient	O
had	O
a	O
single	O
missense	O
mutation	O
in	O
his	O
copy	O
of	O
the	O
KAL1	O
gene	O
,	B-DNAMutation
a	I-DNAMutation
TâG	I-DNAMutation
transversion	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
134	I-DNAMutation
that	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
replacement	I-DNAMutation
of	I-DNAMutation
cysteine	I-DNAMutation
by	I-DNAMutation
gly	I-DNAMutation
cine	I-DNAMutation
.	O

The	O
2nd	O
affected	O
subject	O
had	O
a	O
single	O
missense	O
mutation	O
in	O
the	O
KAL1	O
gene	O
,	B-DNAMutation
a	I-DNAMutation
TâC	I-DNAMutation
transition	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
163	I-DNAMutation
that	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
replacement	I-DNAMutation
of	I-DNAMutation
cysteine	I-DNAMutation
by	I-DNAMutation
arginine	I-DNAMutation
.	O

The	O
3rd	O
case	O
was	O
hemizygous	O
for	B-DNAMutation
a	I-DNAMutation
nonsense	I-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
424	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
9	I-DNAMutation
(c.CGAâTGA)	I-DNAMutation
of	O
the	O
KAL1	O
gene	O
.	O

This	O
mutation	O
predicts	O
a	O
markedly	O
truncated	O
protein	O
.	O

Two	O
of	O
the	O
mutations	B-DNAMutation
(	I-DNAMutation
p.C134G	B-DNAMutation
and	I-DNAMutation
p.C163R	O
)	O
we	O
identified	O
in	O
the	O
KAL1	O
gene	O
are	O
novel	O
.	O

CONCLUSIONS	O
:	O
We	O
identified	O
3	O
mutations	O
,	O
including	O
2	O
novel	O
mutations	O
,	O
in	O
the	O
KAL1	O
gene	O
in	O
patients	O
with	O
KS	O
in	O
Taiwan	O
.	O

These	O
data	O
extend	O
the	O
variety	O
of	O
KAL1	O
gene	O
mutations	O
in	O
KS	O
and	O
further	O
define	O
the	O
role	O
of	O
the	O
KAL1	O
protein	O
in	O
olfactory	O
bulb	O
development	O
.	O

A	O
case	O
of	O
Fabry's	O
disease	O
in	O
a	O
patient	O
with	O
no	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
activity	O
caused	O
by	O
a	O
single	O
amino	O
acid	O
substitution	O
of	O
Pro-40	B-DNAMutation
by	I-DNAMutation
Ser	I-DNAMutation
.	O

We	O
analyzed	O
a	O
male	O
patient	O
with	O
Fabry's	O
disease	O
who	O
had	O
no	O
activity	O
of	O
the	O
lysosomal	O
hydrolase	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
alpha-GalA	B-DNAMutation
and	O
female	O
members	O
of	O
his	O
family	O
.	O

We	O
cloned	O
a	O
cDNA	O
that	O
encoded	O
the	O
mutant	O
alpha-GalA	B-DNAMutation
,	O
determined	O
its	O
nucleotide	O
sequence	O
,	O
and	O
found	O
two	O
nucleotide	O
differences	O
between	O
the	O
mutant	O
and	O
the	O
wild-type	O
cDNAs	O
.	O

Although	O
one	O
difference	O
was	O
silent	O
,	O
the	O
other	O
difference	O
,	O
a	O
C-to-T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
number	I-DNAMutation
118	I-DNAMutation
,	O
resulted	O
in	O
an	O
amino	O
acid	O
substitution	O
of	O
Pro-40	B-DNAMutation
by	I-DNAMutation
Ser	I-DNAMutation
.	O

A	O
transient	O
expression	O
assay	O
demonstrated	O
that	O
this	O
missense	O
mutation	O
was	O
the	O
cause	O
of	O
the	O
deficiency	O
of	O
alpha-GalA	B-DNAMutation
activity	O
in	O
the	O
patient	O
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
Pro-40	O
is	O
critical	O
for	O
the	O
appearance	O
of	O
alpha-GalA	B-DNAMutation
activity	O
.	O

Genetic	O
variant	O
BDNF	B-DNAMutation
Val66Met	B-DNAMutation
polymorphism	O
alters	O
anxiety-related	O
behavior	O
.	O

A	O
common	O
single-nucleotide	O
polymorphism	O
in	O
the	O
brain-derived	B-DNAMutation
neurotrophic	I-DNAMutation
factor	I-DNAMutation
BDNF	B-DNAMutation
gene	O
,	O
a	O
methionine	B-DNAMutation
(Met)	I-DNAMutation
substitution	I-DNAMutation
for	I-DNAMutation
valine	I-DNAMutation
(Val)	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
66	I-DNAMutation
Val66Met	B-DNAMutation
,	O
is	O
associated	O
with	O
alterations	O
in	O
brain	O
anatomy	O
and	O
memory	O
,	O
but	O
its	O
relevance	O
to	O
clinical	O
disorders	O
is	O
unclear	O
.	O

We	O
generated	O
a	O
variant	O
BDNF	B-DNAMutation
mouse	O
BDNF(Met/Met)	B-DNAMutation
that	O
reproduces	O
the	O
phenotypic	O
hallmarks	O
in	O
humans	O
with	O
the	O
variant	O
allele	O
.	O

BDNF(Met)	B-DNAMutation
was	O
expressed	O
in	O
brain	O
at	O
normal	O
levels	O
,	O
but	O
its	O
secretion	O
from	O
neurons	O
was	O
defective	O
.	O

When	O
placed	O
in	O
stressful	O
settings	O
,	O
BDNF(Met/Met)	B-DNAMutation
mice	O
exhibited	O
increased	O
anxiety-related	O
behaviors	O
that	O
were	O
not	O
normalized	O
by	O
the	O
antidepressant	O
,	O
fluoxetine	O
.	O

A	O
variant	O
BDNF	B-DNAMutation
may	O
thus	O
play	O
a	O
key	O
role	O
in	O
genetic	O
predispositions	O
to	O
anxiety	O
and	O
depressive	O
disorders	O
.	O

Quantitative	O
phosphoproteomics	O
unravels	O
biased	O
phosphorylation	O
of	O
serotonin	O
2A	O
receptor	O
at	O
Ser280	O
by	O
hallucinogenic	O
versus	O
nonhallucinogenic	O
agonists	O
.	O

The	O
serotonin	O
5-HT(2A)	B-DNAMutation
receptor	I-DNAMutation
is	O
a	O
primary	O
target	O
of	O
psychedelic	O
hallucinogens	O
such	O
as	O
lysergic	O
acid	O
diethylamine	O
,	O
mescaline	O
,	O
and	O
psilocybin	O
,	O
which	O
reproduce	O
some	O
of	O
the	O
core	O
symptoms	O
of	O
schizophrenia	O
.	O

An	O
incompletely	O
resolved	O
paradox	O
is	O
that	O
only	O
some	O
5-HT(2A)	B-DNAMutation
receptor	I-DNAMutation
agonists	O
exhibit	O
hallucinogenic	O
activity	O
,	O
whereas	O
structurally	O
related	O
agonists	O
with	O
comparable	O
affinity	O
and	O
activity	O
lack	O
such	O
a	O
psychoactive	O
activity	O
.	O

Using	O
a	O
strategy	O
combining	O
stable	O
isotope	O
labeling	O
by	O
amino	O
acids	O
in	O
cell	O
culture	O
with	O
enrichment	O
in	O
phosphorylated	O
peptides	O
by	O
means	O
of	O
hydrophilic	O
interaction	O
liquid	O
chromatography	O
followed	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
,	O
we	O
compared	O
the	O
phosphoproteome	O
in	O
HEK-293	O
cells	O
transiently	O
expressing	O
the	O
5-HT(2A)	B-DNAMutation
receptor	I-DNAMutation
and	O
exposed	O
to	O
either	O
vehicle	O
or	O
the	O
synthetic	O
hallucinogen	O
1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane	O
(DOI)	O
or	O
the	O
nonhallucinogenic	O
5-HT(2A)	O
agonist	O
lisuride	O
.	O

Among	O
the	O
5995	O
identified	O
phosphorylated	O
peptides	O
,	O
16	O
sites	O
were	O
differentially	O
phosphorylated	O
upon	O
exposure	O
of	O
cells	O
to	O
DOI	O
versus	O
lisuride	O
.	O

These	O
include	O
a	O
serine	O
(Ser(280))	O
located	O
in	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
5-HT(2A)	B-DNAMutation
receptor	I-DNAMutation
,	O
a	O
region	O
important	O
for	O
its	O
desensitization	O
.	O

The	O
specific	O
phosphorylation	O
of	O
Ser(280)	O
by	O
hallucinogens	O
was	O
further	O
validated	O
by	O
quantitative	O
mass	O
spectrometry	O
analysis	O
of	O
immunopurified	O
receptor	O
digests	O
and	O
by	O
Western	O
blotting	O
using	O
a	O
phosphosite	O
specific	O
antibody	O
.	O

The	O
administration	O
of	O
DOI	O
,	O
but	O
not	O
of	O
lisuride	O
,	O
to	O
mice	O
,	O
enhanced	O
the	O
phosphorylation	O
of	O
5-HT(2A)	O
receptors	O
at	O
Ser(280)	O
in	O
the	O
prefrontal	O
cortex	O
.	O

Moreover	O
,	O
hallucinogens	O
induced	O
a	O
less	O
pronounced	O
desensitization	O
of	O
receptor-operated	O
signaling	O
in	O
HEK-293	O
cells	O
and	O
neurons	O
than	O
did	O
nonhallucinogenic	O
agonists	O
.	O

The	O
mutation	B-DNAMutation
of	I-DNAMutation
Ser(280)	I-DNAMutation
to	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
(	O
to	O
mimic	O
phosphorylation	O
)	O
reduced	O
receptor	O
desensitization	O
by	O
nonhallucinogenic	O
agonists	O
,	O
whereas	O
its	O
mutation	O
to	O
alanine	O
increased	O
the	O
ability	O
of	O
hallucinogens	O
to	O
desensitize	O
the	O
receptor	O
.	O

This	O
study	O
reveals	O
a	O
biased	O
phosphorylation	O
of	O
the	O
5-HT(2A)	B-DNAMutation
receptor	I-DNAMutation
in	O
response	O
to	O
hallucinogenic	O
versus	O
nonhallucinogenic	O
agonists	O
,	O
which	O
underlies	O
their	O
distinct	O
capacity	O
to	O
desensitize	O
the	O
receptor	O
.	O

The	O
dominant	O
W42	O
spotting	O
phenotype	O
results	O
from	O
a	O
missense	O
mutation	O
in	O
the	O
c-kit	B-DNAMutation
receptor	O
kinase	O
.	O

The	O
murine	O
white	O
spotting	O
locus	O
(W)	O
is	O
allelic	O
with	O
the	O
proto-oncogene	B-DNAMutation
c-kit	I-DNAMutation
,	O
which	O
encodes	O
a	O
transmembrane	O
tyrosine	O
protein	O
kinase	O
receptor	O
for	O
an	O
unknown	O
ligand	O
.	O

Mutations	O
at	O
the	O
W	O
locus	O
affect	O
various	O
aspects	O
of	O
hematopoiesis	O
and	O
the	O
proliferation	O
and	O
migration	O
of	O
primordial	O
germ	O
cells	O
and	O
melanoblasts	O
during	O
development	O
to	O
varying	O
degrees	O
of	O
severity	O
.	O

The	O
W42	O
mutation	O
has	O
a	O
particularly	O
severe	O
effect	O
in	O
both	O
the	O
homozygous	O
and	O
the	O
heterozygous	O
states	O
.	O

The	O
molecular	O
basis	O
of	O
the	O
W42	O
mutation	O
was	O
determined	O
.	O

The	O
c-kit	B-DNAMutation
protein	O
products	O
in	O
homozygous	O
mutant	O
mast	O
cells	O
were	O
expressed	O
normally	O
but	O
displayed	O
a	O
defective	O
tyrosine	O
kinase	O
activity	O
in	O
vitro	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
mutant	O
complementary	O
DNAs	O
revealed	O
a	O
missense	B-DNAMutation
mutation	I-DNAMutation
that	I-DNAMutation
replaces	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
with	I-DNAMutation
asparagine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
790	I-DNAMutation
in	O
the	O
c-kit	B-DNAMutation
protein	O
product	O
.	O

Aspartic	O
acid-790	O
is	O
a	O
conserved	O
residue	O
in	O
all	O
protein	O
kinases	O
.	O

These	O
results	O
provide	O
an	O
explanation	O
for	O
the	O
dominant	O
nature	O
of	O
the	O
W42	O
mutation	O
and	O
provide	O
insight	O
into	O
the	O
mechanism	O
of	O
c-kit-mediated	B-DNAMutation
signal	O
transduction	O
.	O

Dimeric	O
structure	O
of	O
a	O
human	O
apolipoprotein	B-DNAMutation
B	I-DNAMutation
mRNA	O
editing	O
protein	O
and	O
cloning	O
and	O
chromosomal	O
localization	O
of	O
its	O
gene	O
.	O

Apolipoprotein	B-DNAMutation
B	I-DNAMutation
apoB	B-DNAMutation
mRNA	O
editing	O
consists	O
of	O
a	O
posttranscriptional	O
C-->U	O
conversion	O
involving	O
the	O
first	O
base	O
of	O
the	O
codon	B-DNAMutation
CAA	I-DNAMutation
encoding	I-DNAMutation
glutamine-2153	I-DNAMutation
to	I-DNAMutation
UAA	I-DNAMutation
,	I-DNAMutation
a	I-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
,	O
in	O
apoB	B-DNAMutation
mRNA	O
.	O

Using	O
a	O
cloned	O
rat	O
cDNA	O
as	O
a	O
probe	O
,	O
we	O
cloned	O
the	O
cDNA	O
and	O
genomic	O
sequences	O
of	O
the	O
gene	O
for	O
a	O
human	O
apoB	B-DNAMutation
mRNA	O
editing	O
protein	O
.	O

Expression	O
of	O
the	O
cDNA	O
in	O
HepG2	O
cells	O
results	O
in	O
editing	O
of	O
the	O
intracellular	O
apoB	B-DNAMutation
mRNA	O
.	O

By	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
we	O
localized	O
the	O
gene	O
for	O
the	O
editing	O
protein	O
to	O
chromosome	O
band	O
12p13.1-p13.2	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
it	O
was	O
shown	O
that	O
the	O
human	O
editing	O
protein	O
mRNA	O
is	O
expressed	O
exclusively	O
in	O
the	O
small	O
intestine	O
.	O

The	O
cDNA	O
sequence	O
predicts	O
a	O
translation	O
product	O
of	O
236-aa	O
residues	O
.	O

By	O
attaching	B-DNAMutation
an	I-DNAMutation
epitope	I-DNAMutation
tag	I-DNAMutation
sequence	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
C	I-DNAMutation
terminus	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
editing	I-DNAMutation
protein	I-DNAMutation
,	O
we	O
examined	O
the	O
polymerization	O
state	O
of	O
the	O
editing	O
protein	O
synthesized	O
in	O
vitro	O
.	O

We	O
found	O
that	O
the	O
editing	O
protein	O
undergoes	O
spontaneous	O
polymerization	O
.	O

The	O
migration	O
of	O
the	O
human	O
apoB	B-DNAMutation
mRNA	O
editing	O
protein	O
on	O
an	O
HPLC	O
column	O
and	O
the	O
stoichiometry	O
of	O
polymeric	O
epitope-tagged	O
to	O
untagged	O
protein	O
indicate	O
that	O
the	O
protein	O
exists	O
as	O
a	O
dimer	O
.	O

Dimerization	O
does	O
not	O
require	O
glycosylation	O
of	O
a	O
consensus	O
N-linked	O
glycosylation	O
sequence	O
present	O
in	O
the	O
protein	O
and	O
is	O
not	O
mediated	O
by	O
disulfide	O
bridge	O
formation	O
.	O

The	O
human	O
apoB	B-DNAMutation
mRNA	O
editing	O
protein	O
is	O
a	O
cytidine	O
deaminase	O
showing	O
structural	O
homology	O
to	O
some	O
known	O
mammalian	O
and	O
bacteriophage	O
deoxycytidylate	O
deaminases	O
.	O

The	O
latter	O
enzymes	O
exist	O
as	O
homopolymers	O
.	O

The	O
fact	O
that	O
the	O
apoB	B-DNAMutation
mRNA	O
editing	O
protein	O
also	O
exists	O
as	O
a	O
homodimer	O
has	O
important	O
implications	O
for	O
the	O
mechanism	O
of	O
apoB	B-DNAMutation
mRNA	O
editing	O
in	O
humans	O
.	O

Cysteine	O
144	O
is	O
a	O
key	O
residue	O
in	O
the	O
copper	O
reduction	O
by	O
the	O
beta-amyloid	O
precursor	O
protein	O
.	O

The	O
beta-amyloid	O
precursor	O
protein	O
(beta-APP)	O
contains	O
a	O
copper-binding	O
site	O
localized	O
between	O
amino	O
acids	O
135	O
and	O
156	O
(beta-APP(135-156))	O
.	O

We	O
have	O
employed	O
synthetic	O
beta-APP	O
peptides	O
to	O
characterize	O
their	O
capacities	O
to	O
reduce	O
Cu(II)	O
to	O
Cu(I)	O
.	O

Analogues	O
of	O
the	O
wild-type	O
beta-APP(135-156)	O
peptide	O
,	O
containing	O
specific	O
amino	O
acid	O
substitutions	O
,	O
were	O
used	O
to	O
establish	O
which	O
residues	O
are	O
specifically	O
involved	O
in	O
the	O
reduction	O
of	O
copper	O
by	O
beta-APP(135-156)	O
.	O

We	O
report	O
here	O
that	O
beta-APP's	O
copper-binding	O
domain	O
reduced	O
Cu(II)	O
to	O
Cu(I)	O
.	O

The	O
single-mutant	O
beta-APP(His147-->Ala)	B-DNAMutation
and	O
the	O
double-mutant	O
beta-APP(His147-->Ala/His149-->Ala)	B-DNAMutation
showed	O
a	O
small	O
decrease	O
in	O
copper	O
reduction	O
in	O
relation	O
to	O
the	O
wild-type	O
peptide	O
and	O
the	O
beta-APP(Cys144-->Ser)	B-DNAMutation
mutation	O
abolished	O
it	O
,	O
suggesting	O
that	O
Cys144	O
is	O
the	O
key	O
amino	O
acid	O
in	O
the	O
oxidoreduction	O
reaction	O
.	O

Our	O
results	O
confirm	O
that	O
soluble	O
beta-APP	O
is	O
involved	O
in	O
the	O
reduction	O
of	O
Cu(II)	O
to	O
Cu(I)	O
.	O

Integrin-mediated	O
signal	O
transduction	O
linked	O
to	O
Ras	O
pathway	O
by	O
GRB2	B-DNAMutation
binding	O
to	O
focal	O
adhesion	O
kinase	O
.	O

The	O
cytoplasmic	O
focal	B-DNAMutation
adhesion	I-DNAMutation
protein-tyrosine	I-DNAMutation
kinase	I-DNAMutation
(FAK)	O
localizes	O
with	O
surface	O
integrin	O
receptors	O
at	O
sites	O
where	O
cells	O
attach	O
to	O
the	O
extracellular	O
matrix	O
.	O

Increased	O
FAK	O
tyrosine	O
phosphorylation	O
occurs	O
upon	O
integrin	O
engagement	O
with	O
fibronectin	B-DNAMutation
.	O

Here	O
we	O
show	O
that	O
adhesion	O
of	O
murine	O
NIH3T3	O
fibroblasts	O
to	O
fibronectin	B-DNAMutation
promotes	O
SH2-domain-mediated	O
association	O
of	O
the	O
GRB2	B-DNAMutation
adaptor	O
protein	O
and	O
the	O
c-Src	O
protein-tyrosine	O
kinase	O
(PTK)	O
with	O
FAK	O
in	O
vivo	O
,	O
and	O
also	O
results	O
in	O
activation	O
of	O
mitogen-activated	O
protein	O
kinase	O
(MAPK)	O
.	O

In	O
v-Src-transformed	O
NIH3T3	O
,	O
the	O
association	O
of	O
v-Src	O
,	O
GRB2	B-DNAMutation
and	O
Sos	O
with	O
FAK	O
is	O
independent	O
of	O
cell	O
adhesion	O
to	O
fibronectin	B-DNAMutation
.	O

The	O
GRB2	B-DNAMutation
SH2	O
domain	O
binds	O
directly	O
to	O
tyrosine-phosphorylated	O
FAK	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
tyrosine	I-DNAMutation
residue	I-DNAMutation
925	I-DNAMutation
of	O
FAK	O
(	O
YENV	O
motif	O
)	O
to	O
phenylalanine	O
blocks	O
GRB2	B-DNAMutation
SH2-domain	O
binding	O
to	O
FAK	O
in	O
vitro	O
.	O

Our	O
results	O
show	O
that	O
fibronectin	B-DNAMutation
binding	O
to	O
integrins	O
on	O
NIH3T3	O
fibroblasts	O
promotes	O
c-Src	O
and	O
FAK	O
association	O
and	O
formation	O
of	O
an	O
integrin-activated	O
signalling	O
complex	O
.	O

Phosphorylation	O
of	O
FAK	O
at	O
Tyr	O
925	O
upon	O
fibronectin	B-DNAMutation
stimulation	O
creates	O
an	O
SH2-binding	O
site	O
for	O
GRB2	B-DNAMutation
which	O
may	O
link	O
integrin	O
engagement	O
to	O
the	O
activation	O
of	O
the	O
Ras/MAPK	O
signal	O
transduction	O
pathway	O
.	O

Scaffolding	O
by	O
ERK3	B-DNAMutation
regulates	O
MK5	B-DNAMutation
in	O
development	O
.	O

Extracellular-regulated	B-DNAMutation
kinase	I-DNAMutation
3	I-DNAMutation
(	O
ERK3	B-DNAMutation
,	O
MAPK6	B-DNAMutation
)	O
is	O
an	O
atypical	O
member	O
of	O
the	O
ERKs	O
,	O
lacking	B-DNAMutation
the	I-DNAMutation
threonine	I-DNAMutation
and	I-DNAMutation
tyrosine	I-DNAMutation
residues	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
activation	I-DNAMutation
loop	I-DNAMutation
,	O
carrying	O
a	O
unique	O
C-terminal	O
extension	O
and	O
being	O
mainly	O
regulated	O
by	O
its	O
own	O
protein	O
stability	O
and/or	O
by	O
autophosphorylation	O
.	O

Here	O
we	O
show	O
that	O
ERK3	B-DNAMutation
specifically	O
interacts	O
with	O
the	O
MAPK-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
5	I-DNAMutation
(	O
MK5	B-DNAMutation
or	O
PRAK	B-DNAMutation
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Expression	O
of	O
ERK3	B-DNAMutation
in	O
mammalian	O
cells	O
leads	O
to	O
nuclear-cytoplasmic	O
translocation	O
and	O
activation	O
of	O
MK5	B-DNAMutation
and	O
to	O
phosphorylation	O
of	O
both	O
ERK3	B-DNAMutation
and	O
MK5	B-DNAMutation
.	O

Remarkably	O
,	O
activation	O
of	O
MK5	B-DNAMutation
is	O
independent	O
of	O
ERK3	B-DNAMutation
enzymatic	O
activity	O
,	O
but	O
depends	O
on	O
its	O
own	O
catalytic	O
activity	O
as	O
well	O
as	O
on	O
a	O
region	O
in	O
the	O
C-terminal	O
extension	O
of	O
ERK3	B-DNAMutation
.	O

In	O
mouse	O
embryonic	O
development	O
,	O
mRNA	O
expression	O
patterns	O
of	O
ERK3	B-DNAMutation
and	O
MK5	B-DNAMutation
suggest	O
spatiotemporal	O
coexpression	O
of	O
both	O
kinases	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
MK5	I-DNAMutation
leads	O
to	O
strong	O
reduction	O
of	O
ERK3	B-DNAMutation
protein	O
levels	O
and	O
embryonic	O
lethality	O
at	O
about	O
stage	O
E11	O
,	O
where	O
ERK3	B-DNAMutation
expression	O
in	O
wild-type	O
mice	O
is	O
maximum	O
,	O
indicating	O
a	O
role	O
of	O
this	O
signalling	O
module	O
in	O
development	O
.	O

The	O
chromatin	O
remodeling	O
complex	O
NoRC	O
targets	O
HDAC1	B-DNAMutation
to	O
the	O
ribosomal	O
gene	O
promoter	O
and	O
represses	O
RNA	O
polymerase	O
I	O
transcription	O
.	O

Mammalian	O
chromatin	O
remodeling	O
complexes	O
are	O
involved	O
in	O
both	O
activation	O
and	O
repression	O
of	O
transcription	O
.	O

Here	O
,	O
we	O
show	O
that	O
NoRC	O
,	O
a	O
SNF2h-	O
containing	O
nucleolar	O
chromatin	O
remodeling	O
complex	O
,	O
represses	O
ribosomal	O
gene	O
transcription	O
.	O

NoRC-mediated	O
rDNA	O
silencing	O
was	O
alleviated	O
by	O
trichostatin	O
A	O
,	O
indicating	O
that	O
histone	O
deacetylation	O
is	O
causally	O
involved	O
in	O
silencing	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
demonstrate	O
that	O
overexpression	O
of	O
TIP5	B-DNAMutation
,	O
the	O
large	O
subunit	O
of	O
NoRC	O
,	O
mediates	O
deacetylation	O
of	O
nucleosomes	O
in	O
the	O
vicinity	O
of	O
the	O
rDNA	O
promoter	O
.	O

Protein-protein	O
interaction	O
assays	O
reveal	O
association	O
of	O
TIP5	B-DNAMutation
with	O
the	O
histone	O
deacetylase	O
HDAC1	B-DNAMutation
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
PHD	I-DNAMutation
finger	I-DNAMutation
and	O
bromodomain	O
abolishes	O
the	O
interaction	O
of	O
TIP5	B-DNAMutation
and	O
HDAC1	B-DNAMutation
,	O
and	O
abrogates	O
transcriptional	O
repression	O
.	O

The	O
results	O
suggest	O
that	O
NoRC	O
silences	O
the	O
rDNA	O
locus	O
by	O
targeting	O
the	O
SIN3	O
corepressor	O
complex	O
to	O
the	O
rDNA	O
promoter	O
,	O
thereby	O
establishing	O
a	O
repressed	O
chromatin	O
structure	O
.	O

Unusual	O
phenotypic	O
alteration	O
of	O
beta	O
amyloid	O
precursor	O
protein	O
(betaAPP)	O
maturation	O
by	O
a	O
new	O
Val-715	B-DNAMutation
-->	I-DNAMutation
Met	I-DNAMutation
betaAPP-770	O
mutation	O
responsible	O
for	O
probable	O
early-onset	O
Alzheimer's	O
disease	O
.	O

We	O
have	O
identified	O
a	O
novel	O
beta	O
amyloid	O
precursor	O
protein	O
(betaAPP)	O
mutation	O
V715M-betaAPP770	B-DNAMutation
that	O
cosegregates	O
with	O
early-onset	O
Alzheimer's	O
disease	O
(AD)	O
in	O
a	O
pedigree	O
.	O

Unlike	O
other	O
familial	O
AD-linked	O
betaAPP	O
mutations	O
reported	O
to	O
date	O
,	O
overexpression	O
of	O
V715M-betaAPP	B-DNAMutation
in	O
human	O
HEK293	O
cells	O
and	O
murine	O
neurons	O
reduces	O
total	O
Abeta	B-DNAMutation
production	O
and	O
increases	O
the	O
recovery	O
of	O
the	O
physiologically	O
secreted	O
product	O
,	O
APPalpha	O
.	O

V715M-betaAPP	B-DNAMutation
significantly	O
reduces	O
Abeta40	O
secretion	O
without	O
affecting	O
Abeta42	O
production	O
in	O
HEK293	O
cells	O
.	O

However	O
,	O
a	O
marked	O
increase	O
in	O
N-terminally	B-DNAMutation
truncated	I-DNAMutation
Abeta	I-DNAMutation
ending	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
42	I-DNAMutation
(x-42Abeta)	O
is	O
observed	O
,	O
whereas	O
its	O
counterpart	O
x-40Abeta	O
is	O
not	O
affected	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
some	O
cases	O
,	O
familial	O
AD	O
may	O
be	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
overall	O
production	O
of	O
Abeta	B-DNAMutation
but	O
may	O
be	O
caused	O
by	O
increased	O
production	O
of	O
truncated	O
forms	O
of	O
Abeta	B-DNAMutation
ending	O
at	O
the	O
42	O
position	O
.	O

Constitutive	O
activation	O
of	O
mitogen-activated	O
protein	O
kinase-activated	O
protein	O
kinase	O
2	O
by	O
mutation	O
of	O
phosphorylation	O
sites	O
and	O
an	O
A-helix	O
motif	O
.	O

A	O
recently	O
described	O
downstream	O
target	O
of	O
mitogen-activated	O
protein	O
kinases	O
(MAPKs)	O
is	O
the	O
MAPK-activated	O
protein	O
(MAPKAP)	O
kinase	O
2	O
which	O
has	O
been	O
shown	O
to	O
be	O
responsible	O
for	O
small	O
heat	O
shock	O
protein	O
phosphorylation	O
.	O

We	O
have	O
analyzed	O
the	O
mechanism	O
of	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
activation	O
by	O
MAPK	O
phosphorylation	O
using	O
a	O
recombinant	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2-fusion	I-DNAMutation
protein	O
,	O
p44MAPK	B-DNAMutation
and	O
p38/40MAPK	O
in	O
vitro	O
and	O
using	O
an	O
epitope-tagged	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
in	O
heat-shocked	O
NIH	O
3T3	O
cells	O
.	O

It	O
is	O
demonstrated	O
that	O
,	O
in	O
addition	O
to	O
the	O
known	O
phosphorylation	O
of	O
the	O
threonine	O
residue	O
carboxyl-terminal	O
to	O
the	O
catalytic	O
domain	O
,	O
Thr-317	O
,	O
activation	O
of	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
in	O
vitro	O
and	O
in	O
vivo	O
is	O
dependent	O
on	O
phosphorylation	O
of	O
a	O
second	O
threonine	O
residue	O
,	O
Thr-205	O
,	O
which	O
is	O
located	O
within	O
the	O
catalytic	O
domain	O
and	O
which	O
is	O
highly	O
conserved	O
in	O
several	O
protein	O
kinases	O
.	O

Constitutive	O
activation	O
of	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
is	O
obtained	O
by	O
replacement	B-DNAMutation
of	I-DNAMutation
both	I-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
threonine	I-DNAMutation
residues	I-DNAMutation
by	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
.	O

A	O
constitutively	O
active	O
form	O
of	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
is	O
also	O
obtained	O
by	O
deletion	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
carboxyl-terminal	I-DNAMutation
region	I-DNAMutation
containing	I-DNAMutation
Thr-317	I-DNAMutation
and	I-DNAMutation
the	I-DNAMutation
A-helix	I-DNAMutation
motif	I-DNAMutation
or	O
by	O
replacing	B-DNAMutation
the	I-DNAMutation
conserved	I-DNAMutation
residues	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
A-helix	I-DNAMutation
.	O

These	O
data	O
suggest	O
a	O
dual	O
mechanism	O
of	O
MAPKAP	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
activation	O
by	O
phosphorylation	O
of	O
Thr-205	O
inside	O
the	O
catalytic	O
domain	O
and	O
by	O
phosphorylation	O
of	O
Thr-317	O
outside	O
the	O
catalytic	O
domain	O
involving	O
an	O
autoinhibitory	O
A-helix	O
motif	O
.	O

Human	O
liver	O
alcohol	O
dehydrogenase	O
:	O
amino	O
acid	O
substitution	O
in	O
the	O
beta	O
2	O
beta	B-DNAMutation
2	I-DNAMutation
Oriental	O
isozyme	O
explains	O
functional	O
properties	O
,	O
establishes	O
an	O
active	O
site	O
structure	O
,	O
and	O
parallels	O
mutational	O
exchanges	O
in	O
the	O
yeast	O
enzyme	O
.	O

The	O
homodimeric	O
Oriental	O
beta	O
2	O
beta	B-DNAMutation
2	I-DNAMutation
isozyme	O
of	O
human	O
liver	O
alcohol	O
dehydrogenase	O
,	O
corresponding	O
to	O
an	O
allelic	O
variant	O
at	O
the	O
ADH2	B-DNAMutation
gene	O
locus	O
,	O
was	O
studied	O
in	O
order	O
to	O
define	O
the	O
amino	O
acid	O
exchange	O
in	O
relation	O
to	O
the	O
beta	O
1	O
beta	B-DNAMutation
1	I-DNAMutation
isozyme	O
,	O
the	O
predominant	O
allelic	O
form	O
among	O
Caucasians	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
the	O
amino	B-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
occurs	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
7	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
largest	I-DNAMutation
CNBr	I-DNAMutation
fragment	I-DNAMutation
,	I-DNAMutation
corresponding	I-DNAMutation
to	I-DNAMutation
position	I-DNAMutation
47	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
whole	I-DNAMutation
protein	I-DNAMutation
chain	I-DNAMutation
.	O

Here	O
,	O
the	O
beta	B-DNAMutation
2	I-DNAMutation
form	O
has	O
a	O
histidine	O
residue	O
,	O
while	O
,	O
in	O
common	O
with	O
other	O
characterized	O
mammalian	O
liver	O
alcohol	O
dehydrogenases	O
,	O
the	O
beta	B-DNAMutation
1	I-DNAMutation
form	O
has	O
an	O
arginine	O
residue	O
.	O

This	O
exchange	O
does	O
not	O
affect	O
the	O
adjacent	O
cysteine-46	O
residue	O
,	O
which	O
is	O
a	O
protein	O
ligand	O
to	O
the	O
active-site	O
zinc	O
atom	O
,	O
thus	O
clarifying	O
previously	O
inconsistent	O
results	O
.	O

The	O
histidine/arginine-47	B-DNAMutation
mutational	I-DNAMutation
replacement	I-DNAMutation
corresponds	O
to	O
a	O
position	O
that	O
binds	O
the	O
pyrophosphate	O
group	O
of	O
the	O
coenzyme	O
NAD(H)	O
;	O
this	O
explains	O
the	O
functional	O
differences	O
between	O
the	O
beta	O
1	O
beta	B-DNAMutation
1	I-DNAMutation
and	O
beta	O
2	O
beta	B-DNAMutation
2	I-DNAMutation
isozymes	O
,	O
including	O
both	O
a	O
lower	O
pH	O
optimum	O
and	O
higher	O
turnover	O
number	O
of	O
beta	O
2	O
beta	B-DNAMutation
2	I-DNAMutation
,	O
which	O
is	O
likely	O
to	O
be	O
the	O
mutant	O
form	O
.	O

The	O
exchange	O
demonstrates	O
the	O
existence	O
of	O
parallel	O
but	O
separate	O
mutations	O
in	O
the	O
evolution	O
of	O
alcohol	O
dehydrogenases	O
because	O
these	O
mammalian	O
enzymes	O
differ	O
at	O
exactly	O
the	O
same	O
position	O
by	O
the	O
same	O
type	O
of	O
substitution	O
as	O
is	O
found	O
between	O
a	O
mutant	O
and	O
the	O
wild-type	O
constitutive	O
forms	O
of	O
the	O
corresponding	O
yeast	O
enzyme	O
.	O

A	O
novel	O
missense	O
mutation	O
in	O
the	O
human	O
plasmin	B-DNAMutation
inhibitor	O
alpha2-antiplasmin	B-DNAMutation
gene	O
associated	O
with	O
a	O
bleeding	O
tendency	O
.	O

Heterozygosity	O
for	O
a	O
G	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
mutation	I-DNAMutation
converting	I-DNAMutation
Val384(GTG)	I-DNAMutation
to	I-DNAMutation
Met(ATG)	I-DNAMutation
associated	O
with	O
plasmin	B-DNAMutation
inhibitor	O
alpha2-antiplasmin	B-DNAMutation
deficiency	O
was	O
identified	O
in	O
three	O
family	O
members	O
with	O
bleeding	O
tendency	O
.	O

The	O
proband	O
had	O
traumatic	O
breast	O
haematoma	O
and	O
per-/postoperative	O
bleeds	O
.	O

An	O
affected	O
daughter	O
required	O
a	O
blood	O
transfusion	O
after	O
a	O
normal	O
delivery	O
and	O
a	O
son	O
had	O
prolonged	O
bleeding	O
after	O
tooth	O
extraction	O
.	O

The	O
plasma	O
plasmin	B-DNAMutation
inhibitor	O
activities	O
of	O
the	O
affected	O
family	O
members	O
were	O
reduced	O
to	O
49-66%	O
of	O
normal	O
.	O

The	O
antigenic	O
concentrations	O
determined	O
by	O
electroimmunoassay	O
were	O
reduced	O
to	O
57-68%	O
of	O
normal	O
.	O

Crossed	O
immunoelectrophoresis	O
of	O
plasma	O
from	O
the	O
proband	O
showed	O
a	O
normal	O
pattern	O
.	O

The	O
amino	O
acid	O
Val384	O
is	O
located	O
eight	O
residues	O
C-terminal	O
(P8')	O
of	O
the	O
P1	O
residue	O
(Arg376)	O
in	O
the	O
reactive	O
site	O
.	O

The	O
P8'	O
residues	O
of	O
bovine	O
and	O
mouse	O
plasmin	O
inhibitor	O
are	O
both	O
Val	O
.	O

Among	O
other	O
serpins	O
the	O
P8'	O
residue	O
is	O
unconserved	O
.	O

The	O
mutation	O
was	O
not	O
present	O
in	O
the	O
non-affected	O
family	O
member	O
or	O
30	O
blood	O
donors	O
.	O

In	O
addition	O
to	O
the	O
Val384Met	B-DNAMutation
mutation	I-DNAMutation
two	I-DNAMutation
new	I-DNAMutation
polymorphisms	I-DNAMutation
Ala-26(GCG)/Val(GTG)	I-DNAMutation
and	O
Arg407(AGG)/Lys(AAG)	B-DNAMutation
and	O
one	O
previously	O
reported	O
polymorphism	O
Arg6(CGG)/Trp(TGG)	B-DNAMutation
were	O
identified	O
in	O
the	O
plasmin	B-DNAMutation
inhibitor	O
gene	O
of	O
the	O
family	O
.	O

The	O
allelic	O
frequencies	O
among	O
30	O
blood	O
donors	O
with	O
normal	O
values	O
of	O
plasma	O
plasmin	B-DNAMutation
inhibitor	O
(functional)	O
were	O
0.84/0.16	O
for	O
C/T	O
in	O
codon	O
-26	O
,	O
0.81/0.19	O
for	O
C/T	O
in	O
codon	O
6	O
and	O
0.83/0.17	O
for	O
G/A	B-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
407	I-DNAMutation
.	O

Protein	B-DNAMutation
kinase	I-DNAMutation
A	I-DNAMutation
phosphorylates	O
and	O
regulates	O
dimerization	O
of	O
14-3-3	O
epsilon	O
.	O

Recognition	O
of	O
phosphorylated	O
serine/threonine-containing	O
motifs	O
by	O
14-3-3	O
depends	O
on	O
the	O
dimerization	O
of	O
14-3-3	O
.	O

However	O
,	O
the	O
molecular	O
cues	O
that	O
control	O
14-3-3	O
dimerization	O
are	O
not	O
well	O
understood	O
.	O

In	O
order	O
to	O
identify	O
proteins	O
that	O
control	O
14-3-3	O
dimerization	O
,	O
we	O
analyzed	O
proteins	O
that	O
have	O
effects	O
on	O
14-3-3	O
dimerization	O
and	O
report	O
that	O
protein	B-DNAMutation
kinase	I-DNAMutation
A	I-DNAMutation
PKA	B-DNAMutation
phosphorylates	O
14-3-3zeta	O
at	O
a	O
specific	O
residue	O
(Ser58)	O
.	O

Phosphorylation	O
by	O
PKA	B-DNAMutation
leads	O
to	O
modulation	O
of	O
14-3-3zeta	O
dimerization	O
and	O
affect	O
its	O
interaction	O
with	O
partner	O
proteins	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
Ser58	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
completely	O
abolished	O
phosphorylation	O
of	O
14-3-3zeta	O
by	O
PKA	B-DNAMutation
.	O

A	O
phospho-mimic	O
mutant	O
of	O
14-3-3zeta	O
,	O
Ser58	B-DNAMutation
to	I-DNAMutation
Glu	I-DNAMutation
substitution	I-DNAMutation
,	O
failed	O
to	O
form	O
homodimers	O
,	O
showed	O
reduced	O
interaction	O
with	O
14-3-3epsilon	O
and	O
p53	O
,	O
and	O
could	O
not	O
enhance	O
transcriptional	O
activity	O
of	O
p53	O
.	O

Moreover	O
,	O
activation	O
of	O
PKA	B-DNAMutation
decreases	O
and	O
inhibition	O
of	O
PKA	B-DNAMutation
increases	O
the	O
dimerization	O
of	O
14-3-3zeta	O
and	O
the	O
functional	O
interaction	O
of	O
14-3-3zeta	O
with	O
p53	O
.	O

Therefore	O
,	O
our	O
results	O
suggest	O
that	O
PKA	B-DNAMutation
is	O
a	O
new	O
member	O
of	O
protein	O
kinases	O
that	O
can	O
phosphorylate	O
and	O
impair	O
the	O
function	O
of	O
14-3-3	O
.	O

Novel	O
ABCA1	B-DNAMutation
compound	O
variant	O
associated	O
with	O
HDL	O
cholesterol	O
deficiency	O
.	O

The	O
recent	O
discovery	O
of	O
an	O
ATP-binding	O
cassette	O
transporter	O
,	O
ABCA1	B-DNAMutation
,	O
as	O
an	O
important	O
regulator	O
of	O
high	O
density	O
lipoprotein	O
(HDL)	O
metabolism	O
and	O
reverse	O
cholesterol	O
transport	O
has	O
facilitated	O
the	O
identification	O
of	O
novel	O
variants	O
associated	O
with	O
HDL	O
cholesterol	O
deficiency	O
states	O
.	O

We	O
identified	O
a	O
subject	O
with	O
HDL	O
cholesterol	O
deficiency	O
(	O
4	O
mg/dl	O
)	O
who	O
developed	O
and	O
died	O
of	O
complications	O
related	O
to	O
cerebral	O
amyloid	O
angiopathy	O
(CAA)	O
.	O

The	O
proband	O
had	O
a	O
compound	O
heterozygous	O
mutation	O
.	O

One	O
mutation	O
was	O
a	O
G3295T	B-DNAMutation
substitution	O
with	O
conversion	O
of	O
asparagine	B-DNAMutation
to	I-DNAMutation
tyrosine	I-DNAMutation
(D1099Y)	I-DNAMutation
in	O
ABCA1	B-DNAMutation
.	O

The	O
single-base	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
1099	I-DNAMutation
resulted	O
in	O
the	O
abolition	O
of	O
an	O
RsaI	O
cleavage	O
site	O
.	O

The	O
proband	O
and	O
affected	O
individuals	O
having	O
another	O
mutation	O
were	O
heterozygotes	O
for	O
T5966C	B-DNAMutation
with	O
phenylalanine	B-DNAMutation
converted	I-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
(F2009S)	I-DNAMutation
.	O

The	O
presence	O
of	O
the	O
T5966C	B-DNAMutation
mutation	O
was	O
detected	O
by	O
restriction	O
digestion	O
with	O
HinfI	O
.	O

These	O
variants	O
were	O
not	O
identified	O
in	O
over	O
400	O
chromosomes	O
of	O
healthy	O
subjects	O
.	O

In	O
the	O
kindred	O
,	O
family	O
members	O
heterozygous	O
for	O
the	O
ABCA1	B-DNAMutation
variant	O
exhibited	O
low	O
levels	O
of	O
HDL	O
cholesterol	O
.	O

Direct	O
sequencing	O
of	O
all	O
coding	O
regions	O
and	O
splice	O
site	O
junctions	O
of	O
other	O
HDL	O
candidate	O
genes	O
revealed	O
no	O
additional	O
mutations	O
,	O
indicating	O
that	O
combined	O
defective	O
ABCA1	B-DNAMutation
alleles	O
may	O
result	O
in	O
familial	O
HDL	O
deficiency	O
.	O

Two	O
novel	O
missense	O
mutations	O
causing	O
adrenoleukodystrophy	O
in	O
Italian	O
patients	O
.	O

The	O
authors	O
present	O
two	O
new	O
missense	O
mutations	O
in	O
exon	O
1	O
of	O
the	O
adrenoleukodystrophy	O
(ALD)	O
gene	O
.	O

The	O
first	O
,	O
a	O
C813T	B-DNAMutation
transition	O
,	O
results	O
in	O
the	O
substitution	O
Pro143	B-DNAMutation
Ser	I-DNAMutation
in	O
the	O
third	O
putative	O
transmembrane	O
domain	O
of	O
the	O
adrenoleukodystrophy	B-DNAMutation
protein	I-DNAMutation
ALDP	B-DNAMutation
in	O
an	O
adult	O
onset	O
case	O
.	O

The	O
second	O
,	O
a	O
de	O
novo	O
C709T	B-DNAMutation
transition	O
,	O
results	O
in	O
a	O
substitution	O
Ser	B-DNAMutation
108	I-DNAMutation
Leu	I-DNAMutation
between	O
the	O
second	O
and	O
the	O
third	O
putative	O
transmembrane	O
segments	O
,	O
in	O
a	O
childhood	O
case	O
.	O

Three-base	O
deletion	O
and	O
one-base	O
insertion	O
of	O
the	O
alpha(1,4)galactosyltransferase	B-DNAMutation
gene	O
responsible	O
for	O
the	O
P	O
phenotype	O
.	O

BACKGROUND	O
:	O
Recently	O
,	O
an	O
alpha(1,4)galactosyltransferase	B-DNAMutation
gene	O
that	O
is	O
responsible	O
for	O
synthesis	O
of	O
P(k)	O
(Gb3)	O
was	O
isolated	O
.	O

The	O
P	O
individuals	O
who	O
did	O
not	O
express	O
the	O
P(k)	O
,	O
P	O
,	O
and	O
P(1)	O
antigens	O
on	O
RBC	O
membranes	O
were	O
shown	O
to	O
lack	O
the	O
P(k)	O
(Gb3)	O
synthase	O
activity	O
because	O
of	O
multiple	O
distinct	O
mutations	O
in	O
the	O
alpha(1,4)galactosyltransferase	B-DNAMutation
gene	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
DNA	O
sequences	O
of	O
the	O
P(k)	O
(Gb3)	O
synthase	O
gene	O
in	O
three	O
Japanese	O
individuals	O
with	O
the	O
p	O
phenotype	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
One	O
individual	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
an	O
allele	O
containing	O
a	O
three-base	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
CTTCTTC	I-DNAMutation
to	I-DNAMutation
CTTC	I-DNAMutation
from	I-DNAMutation
bases	I-DNAMutation
237	I-DNAMutation
through	I-DNAMutation
243	I-DNAMutation
in	O
the	O
coding	O
region	O
.	O

The	O
other	O
two	O
individuals	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
an	O
allele	O
containing	O
a	O
single	B-DNAMutation
cytosine	I-DNAMutation
insertion	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
cytosine	I-DNAMutation
repeat	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
1026	I-DNAMutation
through	I-DNAMutation
1029	I-DNAMutation
,	O
resulting	O
in	O
a	O
reading	O
frame	O
shift	O
.	O

CONCLUSION	O
:	O
The	O
P	O
blood	O
group	O
phenotype	O
is	O
due	O
to	O
several	O
distinct	O
nonfunctional	O
alleles	O
without	O
any	O
predominant	O
allele	O
.	O

Molecular	O
analysis	O
of	O
the	O
gene	O
of	O
the	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
deficiency	O
variant	O
,	O
Mnichinan	O
.	O

Mnichinan	O
,	O
a	O
variant	O
of	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
)	O
was	O
detected	O
in	O
a	O
Japanese	O
individual	O
with	O
serum	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
deficiency	O
(	O
18	O
mg/dl	O
)	O
,	O
associated	O
with	O
aggregated	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
molecules	O
in	O
the	O
hepatocytes	O
.	O

Cloning	O
and	O
sequencing	O
of	O
the	O
10,627-bp-long	O
region	O
containing	O
the	O
Mnichinan	B-DNAMutation
gene	I-DNAMutation
and	O
the	O
normal	O
M1(Val213)	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
gene	O
revealed	O
all	O
five	O
exons	O
of	O
the	O
Mnichinan	B-DNAMutation
gene	I-DNAMutation
to	O
be	O
identical	O
with	O
the	O
M1(Val213)	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
gene	O
,	O
except	O
for	O
two	O
changes	O
:	O
a	O
TTC	B-DNAMutation
trinucleotide	I-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
for	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
Phe52	I-DNAMutation
and	O
a	O
G-A	B-DNAMutation
substitution	I-DNAMutation
,	I-DNAMutation
by	I-DNAMutation
which	I-DNAMutation
the	I-DNAMutation
normal	I-DNAMutation
Gly148	I-DNAMutation
(GGG)	I-DNAMutation
became	I-DNAMutation
Arg148	I-DNAMutation
(AGG)	I-DNAMutation
.	O

Dot	O
blot	O
analysis	O
of	O
the	O
polymerase	O
chain-reaction-amplified	O
DNA	O
derived	O
from	O
the	O
proband	O
and	O
other	O
family	O
members	O
showed	O
both	O
mutations	O
to	O
be	O
associated	O
with	O
an	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
deficiency	O
phenotype	O
.	O

Ninety-eight	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
alleles	O
were	O
all	O
negative	O
for	O
both	O
changes	O
.	O

Comparison	O
of	O
the	O
region	O
,	O
except	O
for	O
five	O
exons	O
between	O
the	O
Mnichinan	O
and	O
M1(Val213)	O
genes	O
,	O
demonstrated	O
one	O
base	O
difference	O
in	O
the	O
5'	O
flanking	O
region	O
and	O
14	O
base	O
changes	O
in	O
the	O
introns	O
.	O

All	O
exon-intron	O
junctions	O
were	O
identical	O
,	O
and	O
base	O
changes	O
in	O
the	O
5'	O
flanking	O
region	O
did	O
not	O
seem	O
significant	O
.	O

The	O
G-A	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
148	I-DNAMutation
of	O
the	O
Mnichinan	B-DNAMutation
gene	I-DNAMutation
could	O
not	O
be	O
responsible	O
for	O
the	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
deficiency	O
phenotype	O
because	O
Arg-	O
and	O
not	O
Gly-	O
was	O
located	O
at	O
the	O
corresponding	O
position	O
of	O
the	O
protein	O
C	O
inhibitor	O
belonging	O
to	O
the	O
serine	O
protease	O
inhibitor	O
superfamily	O
.	O

The	O
deletion	B-DNAMutation
of	I-DNAMutation
Phe52	I-DNAMutation
may	O
cause	O
the	O
newly	O
synthesized	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
protein	O
to	O
aggregate	O
,	O
resulting	O
in	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
deficiency	O
.	O

Comparison	O
of	O
the	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
gene	O
sequences	O
available	O
indicated	O
that	O
the	O
C-T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
CpG	I-DNAMutation
dinucleotide	I-DNAMutation
has	O
an	O
important	O
role	O
in	O
generation	O
of	O
variants	O
and	O
nucleotide	O
changes	O
in	O
the	O
noncoding	O
regions	O
of	O
the	O
alpha	B-DNAMutation
1-AT	I-DNAMutation
gene	O
.	O

HLA-A*6817	O
,	O
identified	O
in	O
the	O
Kolla	O
Amerindians	O
of	O
North-West	O
Argentina	O
possesses	O
a	O
novel	O
nucleotide	O
substitution	O
.	O

Analysis	O
of	O
HLA	O
polymorphism	O
of	O
the	O
indigenous	O
populations	O
of	O
Central	O
and	O
South	O
America	O
has	O
identified	O
many	O
alleles	O
not	O
seen	O
previously	O
in	O
other	O
populations	O
.	O

We	O
have	O
described	O
a	O
novel	O
allele	O
,	O
B*5113	O
,	O
previously	O
in	O
a	O
Kolla	O
Amerindian	O
individual	O
from	O
North-West	O
Argentina	O
.	O

Here	O
we	O
present	O
a	O
second	O
novel	O
allele	O
from	O
this	O
population	O
:	O
A*6817	O
,	O
which	O
differs	O
from	O
its	O
closest	O
neighbour	O
A*68012	O
by	O
a	O
single	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
419	I-DNAMutation
.	O

This	O
substitution	B-DNAMutation
of	I-DNAMutation
adenosine	I-DNAMutation
419	I-DNAMutation
A*68012	I-DNAMutation
for	I-DNAMutation
thymidine	I-DNAMutation
in	O
A*6817	O
results	O
in	O
a	O
novel	O
amino	O
acid	O
change	O
(	B-DNAMutation
aspartate	I-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
)	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
116	I-DNAMutation
.	O

Identification	O
of	O
a	O
common	O
mutation	O
in	O
patients	O
with	O
medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
.	O

Medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
deficiency	O
is	O
one	O
of	O
the	O
most	O
common	O
recessively	O
inherited	O
metabolic	O
diseases	O
in	O
man	O
.	O

We	O
have	O
studied	O
fibroblast	O
cultures	O
obtained	O
from	O
three	O
patients	O
with	O
MCAD	B-DNAMutation
deficiency	O
by	O
sequencing	O
the	O
entire	O
coding	O
region	O
of	O
MCAD	B-DNAMutation
mRNA	O
.	O

A	O
single	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
nucleotide	I-DNAMutation
replacement	I-DNAMutation
which	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
lysine329-to-glutamic	I-DNAMutation
acid329	I-DNAMutation
substitution	I-DNAMutation
of	O
the	O
MCAD	B-DNAMutation
protein	O
was	O
identified	O
in	O
all	O
cultures	O
.	O

Furthermore	O
,	O
this	O
point	O
mutation	O
was	O
present	O
in	O
91%	O
(	O
31	O
of	O
34	O
)	O
of	O
mutant	O
MCAD	B-DNAMutation
alleles	O
,	O
indicating	O
that	O
the	O
majority	O
of	O
cases	O
with	O
MCAD	B-DNAMutation
deficiency	O
are	O
caused	O
by	O
this	O
type	O
of	O
mutation	O
.	O

An	O
Ile	O
to	O
Met	O
polymorphism	O
in	O
the	O
catalytic	O
domain	O
of	O
adenylyl	O
cyclase	O
type	O
9	O
confers	O
reduced	O
beta2-adrenergic	B-DNAMutation
receptor	I-DNAMutation
stimulation	O
.	O

Adenylyl	O
cyclase	O
(AC)	O
mediates	O
signalling	O
following	O
activation	O
of	O
G(alphas)-coupled	O
receptors	O
such	O
as	O
the	O
beta2-adrenergic	B-DNAMutation
receptor	I-DNAMutation
beta2AR	B-DNAMutation
.	O

Genetic	O
variation	O
in	O
the	O
receptor	O
component	O
of	O
this	O
pathway	O
can	O
alter	O
signal	O
transduction	O
and	O
the	O
response	O
to	O
beta-agonists	O
in	O
asthma	O
,	O
but	O
little	O
is	O
known	O
about	O
downstream	O
effectors	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
population	O
genomics	O
and	O
signalling	O
effects	O
of	O
a	O
polymorphism	O
within	O
the	O
coding	O
region	O
of	O
the	O
AC9	B-DNAMutation
gene	O
that	O
results	O
in	O
an	O
Ile	B-DNAMutation
to	I-DNAMutation
Met	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
772	I-DNAMutation
within	O
the	O
C1b	O
region	O
of	O
the	O
enzyme	O
.	O

Allele	O
frequencies	O
were	O
0.300	O
and	O
0.375	O
in	O
Caucasians	O
and	O
Asians	O
but	O
were	O
lower	O
in	O
African-Americans	O
(0.163)	O
.	O

The	O
functional	O
effects	O
were	O
studied	O
in	O
stably	O
transfected	O
HEK293	O
cells	O
recombinantly	O
expressing	O
equivalent	O
levels	O
of	O
wild-type	B-DNAMutation
(Ile772)	I-DNAMutation
and	I-DNAMutation
polymorphic	I-DNAMutation
(Met772)	I-DNAMutation
AC9	B-DNAMutation
.	O

The	O
polymorphic	O
substitution	O
results	O
in	O
a	O
loss	O
of	O
function	O
compared	O
to	O
wild-type	O
AC9	B-DNAMutation
.	O

Met772	O
AC9	B-DNAMutation
has	O
lower	O
basal	O
and	O
beta2AR-mediated	B-DNAMutation
adenylyl	O
cyclase	O
activities	O
compared	O
to	O
Ile772	O
AC9	B-DNAMutation
,	O
as	O
well	O
as	O
reduced	O
activity	O
following	O
stimulation	O
of	O
G(alphas)	O
by	O
NaF	O
.	O

Direct	O
stimulation	O
of	O
AC9	B-DNAMutation
activity	O
by	O
Mn2+/-	O
was	O
also	O
depressed	O
in	O
Met772	O
membranes	O
,	O
indicating	O
decreased	O
catalytic	O
function	O
,	O
consistent	O
with	O
the	O
location	O
of	O
residue	O
772	O
.	O

AC9	B-DNAMutation
mRNA	O
and	O
protein	O
were	O
expressed	O
in	O
multiple	O
human	O
lung	O
cell-types	O
,	O
including	O
airway	O
smooth	O
muscle	O
and	O
airway	O
epithelium	O
.	O

In	O
the	O
treatment	O
of	O
asthma	O
,	O
there	O
is	O
marked	O
heterogeneity	O
in	O
the	O
response	O
to	O
inhaled	O
beta-agonists	O
which	O
is	O
associated	O
with	O
polymorphisms	O
of	O
the	O
beta2AR	B-DNAMutation
.	O

Identification	O
of	O
a	O
common	O
AC9	B-DNAMutation
variant	O
that	O
confers	O
reduced	O
enzyme	O
activity	O
reveals	O
an	O
additional	O
polymorphism	O
that	O
should	O
be	O
considered	O
in	O
pharmacogenetic	O
studies	O
of	O
beta-agonist	O
therapy	O
of	O
asthma	O
.	O

Functional	O
cloning	O
and	O
mutational	O
analysis	O
of	O
the	O
human	O
cDNA	O
for	O
phosphoacetylglucosamine	O
mutase	O
:	O
identification	O
of	O
the	O
amino	O
acid	O
residues	O
essential	O
for	O
the	O
catalysis	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
phosphoacetylglucosamine	O
mutase	O
is	O
encoded	O
by	O
an	O
essential	O
gene	O
called	O
AGM1	B-DNAMutation
.	O

The	O
human	O
AGM1	B-DNAMutation
cDNA	O
(HsAGM1)	O
and	O
the	O
Candida	O
albicans	O
AGM1	O
gene	O
(CaAGM1)	O
were	O
functionally	O
cloned	O
and	O
characterized	O
by	O
using	O
an	O
S	O
.	O

cerevisiae	O
strain	O
in	O
which	O
the	O
endogenous	O
phosphoacetylglucosamine	O
mutase	O
was	O
depleted	O
.	O

When	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
fusion	O
proteins	O
with	O
glutathione	O
S-transferase	O
,	O
both	O
HsAgm1	O
and	O
CaAgm1	O
proteins	O
displayed	O
phosphoacetylglucosamine	O
mutase	O
activities	O
,	O
demonstrating	O
that	O
they	O
indeed	O
specify	O
phosphoacetylglucosamine	O
mutase	O
.	O

Sequence	O
comparison	O
of	O
HsAgm1p	O
with	O
several	O
hexose-phosphate	O
mutases	O
yielded	O
three	O
domains	O
that	O
are	O
highly	O
conserved	O
among	O
phosphoacetylglucosamine	O
mutases	O
and	O
phosphoglucomutases	O
of	O
divergent	O
organisms	O
.	O

Mutations	O
of	O
the	O
conserved	O
amino	O
acids	O
found	O
in	O
these	O
domains	O
,	O
which	O
were	O
designated	O
region	O
I	O
,	O
II	O
,	O
and	O
III	O
,	O
respectively	O
,	O
demonstrated	O
that	O
alanine	B-DNAMutation
substitutions	I-DNAMutation
for	I-DNAMutation
Ser(64)	I-DNAMutation
and	I-DNAMutation
His(65)	I-DNAMutation
in	I-DNAMutation
region	I-DNAMutation
I	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
for	I-DNAMutation
Asp(276)	I-DNAMutation
,	I-DNAMutation
Asp(278)	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Arg(281)	I-DNAMutation
in	I-DNAMutation
region	I-DNAMutation
II	I-DNAMutation
of	O
HsAgm1p	O
severely	O
diminished	O
the	O
enzyme	O
activity	O
and	O
the	O
ability	O
to	O
rescue	O
the	O
S	O
.	O

cerevisiae	O
agm1Delta	B-DNAMutation
null	I-DNAMutation
mutant	O
.	O

Conservative	O
mutations	B-DNAMutation
of	I-DNAMutation
His(65)	I-DNAMutation
and	I-DNAMutation
Asp(276)	I-DNAMutation
restored	O
detectable	O
activities	O
,	O
whereas	O
those	B-DNAMutation
of	I-DNAMutation
Ser(64)	I-DNAMutation
,	I-DNAMutation
Asp(278)	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Arg(281)	I-DNAMutation
did	O
not	O
.	O

These	O
results	O
indicate	O
that	O
Ser(64)	O
,	O
Asp(278)	O
,	O
and	O
Arg(281)	O
of	O
HsAgm1p	O
are	O
residues	O
essential	O
for	O
the	O
catalysis	O
.	O

Because	O
Ser(64)	O
corresponds	O
to	O
the	O
phosphorylating	O
serine	O
in	O
the	O
E	O
.	O

coli	O
phosphoglucosamine	O
mutase	O
,	O
it	O
is	O
likely	O
that	O
the	O
activation	O
of	O
HsAgm1p	O
also	O
requires	O
phosphorylation	O
on	O
Ser(64)	O
.	O

Furthermore	O
,	O
alanine	B-DNAMutation
substitution	I-DNAMutation
for	I-DNAMutation
Arg(496)	I-DNAMutation
in	O
region	O
III	O
significantly	O
increased	O
the	O
K(m)	O
value	O
for	O
N-acetylglucosamine-6-phosphate	O
,	O
demonstrating	O
that	O
Arg(496)	O
serves	O
as	O
a	O
binding	O
site	O
for	O
N-acetylglucosamine-6-phosphate	O
.	O

Mint-3	O
regulates	O
the	O
retrieval	O
of	O
the	O
internalized	O
membrane-type	O
matrix	O
metalloproteinase	O
,	O
MT5-MMP	B-DNAMutation
,	O
to	O
the	O
plasma	O
membrane	O
by	O
binding	O
to	O
its	O
carboxyl	O
end	O
motif	O
EWV	O
.	O

Membrane	O
type	O
matrix	O
metalloproteinases	O
(MT-MMPs)	O
play	O
a	O
critical	O
role	O
in	O
promoting	O
cell	O
growth	O
and	O
migration	O
within	O
the	O
extracellular	O
matrix	O
by	O
trafficking	O
to	O
specialized	O
areas	O
.	O

Here	O
we	O
show	O
that	O
the	O
carboxyl	O
EWV	O
motif	O
of	O
MT5-MMP	B-DNAMutation
serves	O
as	O
a	O
retrieval	O
signal	O
for	O
internalized	O
MT5-MMP	B-DNAMutation
by	O
interacting	O
with	O
Mint-3	O
,	O
a	O
protein	O
with	O
two	O
type	O
III	O
PDZ	O
domains	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
EWV	I-DNAMutation
signal	I-DNAMutation
impairs	O
the	O
recycling	O
of	O
MT5-MMP	B-DNAMutation
without	O
affecting	O
its	O
internalization	O
,	O
leading	O
to	O
decreased	O
activity	O
on	O
the	O
cell	O
surface	O
.	O

A	O
yeast	O
two-hybrid	O
screening	O
identified	O
Mint-3	O
as	O
the	O
EWV-binding	O
protein	O
.	O

Mint-3	O
stimulates	O
MT5-MMP	B-DNAMutation
activity	O
when	O
expressed	O
at	O
low	O
levels	O
in	O
an	O
EWV-dependent	O
fashion	O
,	O
but	O
inhibits	O
its	O
activity	O
at	O
higher	O
levels	O
independent	O
of	O
the	O
EWV	O
motif	O
.	O

siRNA-mediated	O
knockdown	O
of	O
endogenous	O
Mint-3	O
decreased	O
MT5-MMP	B-DNAMutation
activity	O
.	O

Furthermore	O
,	O
Mint-3	O
significantly	O
increased	O
the	O
level	O
of	O
MT5-MMP	B-DNAMutation
on	O
the	O
cell	O
surface	O
without	O
affecting	O
its	O
synthesis	O
and	O
internalization	O
.	O

Therefore	O
,	O
Mints	O
may	O
be	O
the	O
adaptor	O
proteins	O
that	O
regulate	O
the	O
trafficking	O
of	O
MT-MMPs	O
.	O

CHMP4B	B-DNAMutation
,	O
a	O
novel	O
gene	O
for	O
autosomal	O
dominant	O
cataracts	O
linked	O
to	O
chromosome	O
20q	O
.	O

Cataracts	O
are	O
a	O
clinically	O
diverse	O
and	O
genetically	O
heterogeneous	O
disorder	O
of	O
the	O
crystalline	O
lens	O
and	O
a	O
leading	O
cause	O
of	O
visual	O
impairment	O
.	O

Here	O
we	O
report	O
linkage	O
of	O
autosomal	O
dominant	O
"progressive	O
childhood	O
posterior	O
subcapsular"	O
cataracts	O
segregating	O
in	O
a	O
white	O
family	O
to	O
short	O
tandem	O
repeat	O
(STR)	O
markers	O
D20S847	B-DNAMutation
(	O
LOD	O
score	O
[Z]	O
5.50	O
at	O
recombination	O
fraction	O
[theta]	O
0.0	O
)	O
and	O
D20S195	B-DNAMutation
(	O
Z=3.65	O
at	O
theta	O
=0.0	O
)	O
on	O
20q	O
,	O
and	O
identify	O
a	O
refined	O
disease	O
interval	O
(	O
rs2057262-(3.8	B-DNAMutation
Mb)-rs1291139	B-DNAMutation
)	O
by	O
use	O
of	O
single-nucleotide	O
polymorphism	O
(SNP)	O
markers	O
.	O

Mutation	O
profiling	O
of	O
positional-candidate	O
genes	O
detected	O
a	O
heterozygous	O
transversion	O
c.386A-->T	B-DNAMutation
in	O
exon	O
3	O
of	O
the	O
gene	O
for	O
chromatin	B-DNAMutation
modifying	I-DNAMutation
protein-4B	I-DNAMutation
CHMP4B	B-DNAMutation
that	O
was	O
predicted	O
to	O
result	O
in	O
the	O
nonconservative	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
valine	I-DNAMutation
residue	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
phylogenetically	I-DNAMutation
conserved	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
129	I-DNAMutation
p.D129V	B-DNAMutation
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
a	O
heterozygous	O
transition	O
c.481G-->A	B-DNAMutation
in	O
exon	O
3	O
of	O
CHMP4B	B-DNAMutation
cosegregating	O
with	O
autosomal	O
dominant	O
posterior	O
polar	O
cataracts	O
in	O
a	O
Japanese	O
family	O
that	O
was	O
predicted	O
to	O
result	O
in	O
the	O
missense	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
lysine	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
conserved	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
161	I-DNAMutation
p.E161K	B-DNAMutation
.	O

Transfection	O
studies	O
of	O
cultured	O
cells	O
revealed	O
that	O
a	O
truncated	O
form	O
of	O
recombinant	O
D129V-CHMP4B	B-DNAMutation
had	O
a	O
different	O
subcellular	O
distribution	O
than	O
wild	O
type	O
and	O
an	O
increased	O
capacity	O
to	O
inhibit	O
release	O
of	O
virus-like	O
particles	O
from	O
the	O
cell	O
surface	O
,	O
consistent	O
with	O
deleterious	O
gain-of-function	O
effects	O
.	O

These	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
CHMP4B	B-DNAMutation
,	O
which	O
encodes	O
a	O
key	O
component	O
of	O
the	O
endosome	O
sorting	O
complex	O
required	O
for	O
the	O
transport-III	O
(ESCRT-III)	O
system	O
of	O
mammalian	O
cells	O
,	O
plays	O
a	O
vital	O
role	O
in	O
the	O
maintenance	O
of	O
lens	O
transparency	O
.	O

Point	O
mutation	O
in	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	I-DNAMutation
of	O
atypical	O
Fabry	O
disease	O
with	O
only	O
nephropathy	O
.	O

A	O
point	O
mutation	O
in	O
exon	O
6	O
of	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	I-DNAMutation
(	O
alpha-GAL	B-DNAMutation
A	I-DNAMutation
)	O
was	O
found	O
in	O
a	O
Japanese	O
hemizygous	O
male	O
without	O
typical	O
manifestations	O
of	O
Fabry	O
disease	O
other	O
than	O
renal	O
involvement	O
.	O

This	O
45-year-old	O
man	O
developed	O
moderate	O
proteinuria	O
and	O
was	O
diagnosed	O
with	O
Fabry	O
disease	O
on	O
the	O
basis	O
of	O
renal	O
histologic	O
findings	O
and	O
prominent	O
decreases	O
in	O
alpha-GAL	B-DNAMutation
A	I-DNAMutation
activity	O
in	O
his	O
plasma	O
,	O
urine	O
,	O
leukocytes	O
,	O
and	O
skin	O
fibroblasts	O
.	O

Determination	O
of	O
the	O
cDNA	O
sequence	O
of	O
his	O
alpha-GAL	B-DNAMutation
A	I-DNAMutation
gene	O
revealed	O
substitution	O
of	O
a	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
301	I-DNAMutation
,	I-DNAMutation
resulting	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
glutamine	I-DNAMutation
rather	I-DNAMutation
than	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
residue	O
.	O

Our	O
case	O
is	O
unique	O
in	O
that	O
this	O
patient	O
only	O
demonstrated	O
renal	O
manifestations	O
while	O
all	O
other	O
reported	O
patients	O
with	O
atypical	O
Fabry	O
disease	O
,	O
including	O
a	O
case	O
with	O
the	O
identical	O
point	O
mutation	O
,	O
present	O
with	O
a	O
cardiomyopathy	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
exon	O
6	O
and	O
measurement	O
of	O
alpha-GAL	B-DNAMutation
A	I-DNAMutation
activity	O
among	O
the	O
patient's	O
family	O
confirmed	O
that	O
the	O
mutation	O
was	O
transmitted	O
from	O
his	O
mother	O
.	O

Molecular	O
basis	O
of	O
medium	B-DNAMutation
chain	I-DNAMutation
acyl-coenzyme	I-DNAMutation
A	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
.	O

An	O
A	B-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
985	I-DNAMutation
that	O
causes	O
a	O
lysine-304	B-DNAMutation
to	I-DNAMutation
glutamate	I-DNAMutation
substitution	I-DNAMutation
in	O
the	O
mature	O
protein	O
is	O
the	O
single	O
prevalent	O
mutation	O
.	O

We	O
sequenced	O
polymerase	O
chain	O
reaction	O
(PCR)-amplified	O
variant	O
medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
cDNAs	O
in	O
cultured	O
fibroblasts	O
from	O
three	O
MCAD-deficient	B-DNAMutation
patients	O
.	O

In	O
all	O
three	O
patients	O
,	O
an	O
A	B-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
transition	I-DNAMutation
was	I-DNAMutation
identified	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
985	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
coding	I-DNAMutation
region	I-DNAMutation
.	O

Since	O
no	O
appropriate	O
restriction	O
sites	O
for	O
detecting	O
this	O
point	O
mutation	O
were	O
found	O
,	O
we	O
devised	O
a	O
PCR	O
method	O
that	O
amplifies	O
an	O
87-bp	O
fragment	O
from	O
position	O
955	O
.	O

In	O
the	O
5'	O
primer	O
encompassing	O
positions	O
955	O
to	O
984	O
,	O
A-981	O
was	O
artificially	O
substituted	O
with	O
C	O
.	O

With	O
the	O
presence	O
of	O
C-981	O
and	O
G-985	O
,	O
an	O
Nco	O
I	O
restriction	O
site	O
is	O
introduced	O
in	O
the	O
mutant	O
copies	O
.	O

When	O
cDNA	O
or	O
genomic	O
DNA	O
from	O
fibroblasts	O
of	O
nine	O
MCAD-deficient	B-DNAMutation
patients	O
were	O
tested	O
with	O
this	O
method	O
,	O
the	O
copies	O
from	O
all	O
of	O
them	O
completely	O
cleaved	O
into	O
two	O
shorter	O
fragments	O
by	O
Nco	O
I	O
,	O
indicating	O
their	O
homozygosity	O
for	O
the	O
A----G-985	B-DNAMutation
transition	I-DNAMutation
.	O

In	O
contrast	O
,	O
the	O
copies	O
from	O
all	O
eight	O
controls	O
remained	O
intact	O
.	O

Thus	O
,	O
this	O
A----G-985	B-DNAMutation
transition	I-DNAMutation
is	O
the	O
single	O
prevalent	O
mutation	O
causing	O
MCAD	B-DNAMutation
deficiency	O
,	O
a	O
highly	O
unusual	O
feature	O
for	O
any	O
genetic	O
disorder	O
.	O

The	O
PCR/Nco	O
I	O
digestion	O
method	O
is	O
suitable	O
for	O
the	O
diagnosis	O
of	O
MCAD	B-DNAMutation
deficiency	O
.	O

APOBEC3A	O
,	O
APOBEC3B	O
,	O
and	O
APOBEC3H	O
haplotype	O
2	O
restrict	O
human	B-DNAMutation
T-lymphotropic	O
virus	O
type	O
1	O
.	O

The	O
human	B-DNAMutation
APOBEC3	O
family	O
consists	O
of	O
seven	O
cytidine	O
deaminases	O
(	O
A3A	O
to	O
A3H	O
)	O
,	O
some	O
of	O
which	O
display	O
potent	O
antiretroviral	O
activity	O
against	O
HIV-1	O
and	O
other	O
retroviruses	O
.	O

Studies	O
that	O
analyzed	O
the	O
effect	O
of	O
A3G	O
on	O
human	B-DNAMutation
T-lymphotropic	O
virus	O
type	O
1	O
(HTLV-1)	O
infectivity	O
resulted	O
in	O
conflicting	O
findings	O
,	O
and	O
our	O
knowledge	O
of	O
HTLV-1	O
restriction	O
by	O
other	O
A3	O
proteins	O
remains	O
limited	O
.	O

Since	O
HTLV-1	O
,	O
much	O
like	O
HIV	O
,	O
targets	O
CD4(+)	O
T	O
cells	O
,	O
we	O
hypothesized	O
that	O
A3	O
proteins	O
other	O
than	O
A3G	O
restrict	O
HTLV-1	O
.	O

All	O
seven	O
human	B-DNAMutation
A3	O
proteins	O
were	O
tested	O
in	O
HTLV-1	O
reporter	O
and	O
HIV-1	O
infectivity	O
assays	O
.	O

We	O
show	O
that	O
A3A	O
,	O
A3B	O
,	O
and	O
A3H	O
haplotype	O
2	O
(	O
A3H	O
hapII	O
)	O
acted	O
as	O
potent	O
inhibitors	O
of	O
HTLV-1	O
.	O

Wild-type	O
HIV-1	O
,	O
in	O
contrast	O
,	O
was	O
restricted	O
by	O
A3B	O
and	O
A3H	O
hapII	O
,	O
but	O
not	O
by	O
A3A	O
.	O

Catalytic	O
site	O
mutants	O
of	O
A3A	O
,	O
A3B	O
,	O
and	O
A3H	O
hapII	O
showed	O
that	O
A3A	O
and	O
A3B	O
restriction	O
of	O
HTLV-1	O
required	O
deaminase	O
activity	O
.	O

However	O
,	O
A3H	O
hapII	O
acted	O
in	O
a	O
deaminase-independent	O
manner	O
when	O
restricting	O
HTLV-1	O
,	O
while	O
requiring	O
deaminase	O
activity	O
for	O
HIV-1	O
restriction	O
.	O

We	O
also	O
analyzed	O
A3	O
editing	O
of	O
HTLV-1	O
in	O
five	O
T-cell	O
lines	O
obtained	O
from	O
HTLV-1-infected	O
patients	O
.	O

These	O
cell	O
lines	O
contained	O
extensively	O
edited	O
HTLV-1	O
sequences	O
with	O
G-to-A	O
mutations	O
in	O
dinucleotide	O
contexts	O
suggestive	O
of	O
APOBEC3	O
mutagenesis	O
.	O

Comparison	O
of	O
the	O
A3-induced	O
mutations	O
from	O
reporter	O
cells	O
and	O
the	O
patient-derived	O
cell	O
lines	O
indicate	O
that	O
A3G	O
but	O
also	O
other	O
A3	O
members	O
,	O
possibly	O
A3A	O
and	O
A3B	O
,	O
affect	O
HTLV-1	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
HTLV-1	O
is	O
a	O
likely	O
target	O
for	O
multiple	O
A3	O
proteins	O
.	O

Nonsense	O
and	O
missense	O
mutations	O
in	O
the	O
muscular	O
chloride	O
channel	O
gene	O
Clc-1	B-DNAMutation
of	O
myotonic	O
mice	O
.	O

In	O
mature	O
vertebrate	O
muscle	O
,	O
the	O
chloride	O
channel	O
Clc-1	B-DNAMutation
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
resting	O
potential	O
.	O

Its	O
functional	O
defect	O
leads	O
to	O
the	O
disease	O
myotonia	O
.	O

The	O
ADR	O
mouse	O
(	O
phenotype	O
ADR	O
,	O
genotype	O
adr/adr	O
)	O
is	O
an	O
animal	O
model	O
for	O
human	O
myotonias	O
.	O

The	O
adr	O
gene	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
non-complementing	O
recessive	O
autosomal	O
mutations	O
(	O
"alleles	O
"	O
of	O
adr	O
)	O
that	O
cause	O
myotonia	O
in	O
the	O
mouse	O
.	O

The	O
standard	O
allele	O
adr	O
has	O
arisen	O
by	O
the	O
insertion	O
of	O
a	O
retroposon	O
into	O
the	O
chloride	O
channel	O
gene	O
Clc-1	B-DNAMutation
(	O
Steinmeyer	O
,	O
K.	O
,	O
Klocke	O
,	O
R.	O
,	O
Ortland	O
,	O
C.	O
,	O
Gronemeier	O
,	O
M.	O
,	O
Jockusch	O
,	O
H.	O
,	O
GrÃ¼nder	O
,	O
S.	O
,	O
and	O
Jentsch	O
,	O
T	O
.	O

J	O
.	O

(1991)	O
Nature	O
354	O
,	O
304-308	O
)	O
.	O

In	O
order	O
to	O
study	O
the	O
nature	O
of	O
two	O
other	O
alleles	O
,	O
adrmto	O
and	O
adrK	O
,	O
we	O
have	O
analyzed	O
overlapping	B-DNAMutation
Clc-1	I-DNAMutation
cDNA	O
amplification	O
products	O
by	O
the	O
hydroxylamine	O
and	O
osmium	O
tetroxide	O
modification	O
technique	O
and	O
direct	O
sequencing	O
.	O

A	O
comparison	O
between	O
ADR*MTO	O
and	O
C57BL/6	O
wild	O
type	O
showed	B-DNAMutation
six	I-DNAMutation
base	I-DNAMutation
pair	I-DNAMutation
substitutions	I-DNAMutation
,	I-DNAMutation
one	I-DNAMutation
of	I-DNAMutation
which	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
in	I-DNAMutation
position	I-DNAMutation
47	O
,	O
whereas	O
the	O
five	O
others	O
are	O
either	O
silent	O
or	O
lead	O
to	O
amino	O
acid	O
substitutions	O
in	O
non-conserved	O
regions	O
of	O
the	B-DNAMutation
Clc-1	I-DNAMutation
sequence	O
and	O
were	O
already	O
present	O
in	O
the	O
wild	O
type	O
inbred	O
SWR/J	O
strain	O
from	O
which	O
adrmto	O
was	O
derived	O
.	O

The	O
detection	O
of	O
the	O
stop	O
codon	O
in	O
the	O
adrmto	O
allele	O
is	O
further	O
indication	O
of	O
the	O
identity	O
of	O
the	B-DNAMutation
Clc-1	I-DNAMutation
chloride	O
channel	O
with	O
the	O
adr	O
myotonia	O
gene	O
in	O
the	O
mouse	O
,	O
because	O
a	O
chain	O
termination	O
close	O
to	O
the	O
N	O
terminus	O
would	O
necessarily	O
destroy	O
gene	O
function	O
.	O

For	O
the	O
ethylnitrosourea-induced	O
mutation	O
adrK	O
,	O
an	B-DNAMutation
Ile-->Thr	I-DNAMutation
exchange	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
553	I-DNAMutation
was	O
identified	O
.	O

As	O
this	O
affects	O
a	O
conserved	O
residue	O
within	O
a	O
highly	O
conserved	O
region	O
of	O
the	B-DNAMutation
Clc-1	I-DNAMutation
gene	O
,	O
a	O
functional	O
significance	O
of	O
this	O
residue	O
is	O
suggested	O
.	O

Identification	O
and	O
molecular	O
characterization	O
of	O
the	O
new	O
alpha-1-antitrypsin	B-DNAMutation
deficient	O
allele	O
PI	O
Y	O
barcelona	O
(	O
Asp256-->Val	B-DNAMutation
and	O
Pro391-->His	B-DNAMutation
)	O
.	O

Mutations	O
in	O
brief	O
no	O
.	O

174	O
.	O

Online	O
.	O

To	O
characterize	O
the	O
molecular	O
basis	O
of	O
the	O
"new"	O
alpha1-antitrypsin	B-DNAMutation
alpha1AT	B-DNAMutation
deficient	O
variant	O
,	O
PI	O
Y	O
barcelona	O
,	O
DNA	O
sequence	O
analysis	O
of	O
the	O
coding	O
exons	O
of	O
the	O
alpha1AT	B-DNAMutation
gene	O
was	O
carried	O
out	O
using	O
an	O
amplification	O
DNA	O
technique	O
and	O
direct	O
sequencing	O
.	O

The	O
PI	O
Y	O
barcelona	O
allele	O
differs	O
from	O
the	O
normal	O
M1(Val213)	B-DNAMutation
allele	I-DNAMutation
sequence	I-DNAMutation
by	I-DNAMutation
two	I-DNAMutation
point	I-DNAMutation
substitutions	I-DNAMutation
:	I-DNAMutation
a	I-DNAMutation
transversion	I-DNAMutation
of	I-DNAMutation
GAT	I-DNAMutation
TO	I-DNAMutation
GTT	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
III	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
for	I-DNAMutation
residue	I-DNAMutation
256	I-DNAMutation
,	O
resulting	B-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
change	I-DNAMutation
of	I-DNAMutation
Asp256	I-DNAMutation
to	I-DNAMutation
Val256	I-DNAMutation
,	O
and	O
a	O
transversion	B-DNAMutation
of	I-DNAMutation
CCC	I-DNAMutation
to	I-DNAMutation
CAC	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
V	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
for	I-DNAMutation
residue	I-DNAMutation
391	I-DNAMutation
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
of	O
Pro391	B-DNAMutation
to	I-DNAMutation
His391	I-DNAMutation
.	O

On	O
isoelectric	O
focusing	O
analysis	O
these	O
substitutions	O
result	O
in	O
a	O
cathodal	O
migration	O
of	O
the	O
"new"	O
variant	O
close	O
to	O
the	O
PI	O
Z	O
.	O

The	O
index	O
case	O
,	O
diagnosed	O
with	O
severe	O
obstructive	O
pulmonary	O
disease	O
,	O
initially	O
phenotyped	O
a	O
PI	O
ZZ	O
,	O
was	O
homozygous	O
for	O
PI	O
Y	O
barcelona	O
.	O

The	O
patient's	O
serum	O
alpha1AT	B-DNAMutation
level	O
was	O
16	O
mg/dL	O
(	O
normal	O
values	O
115-220	O
mg/dL	O
)	O
.	O

Inheritance	O
of	O
the	O
PI	O
Y	O
barcelona	O
was	O
confirmed	O
by	O
family	O
study	O
.	O

Amino	B-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
postion	I-DNAMutation
391	I-DNAMutation
occurs	O
in	O
the	O
C-terminal	O
peptide	O
region	O
,	O
which	O
shows	O
a	O
high	O
degree	O
of	O
homology	O
with	O
the	O
family	O
of	O
serpins	O
.	O

Pro391	O
is	O
considered	O
to	O
have	O
special	O
relevance	O
in	O
the	O
secretion	O
of	O
alpha1AT	B-DNAMutation
.	O

Identification	O
of	O
point	O
mutations	O
in	O
the	O
alpha-galactosidase	O
A	O
gene	O
in	O
classical	O
and	O
atypical	O
hemizygotes	O
with	O
Fabry	O
disease	O
.	O

Efforts	O
were	O
directed	O
to	O
identify	O
the	O
specific	O
mutations	O
in	O
the	O
alpha-galactosidase	O
A	O
(	O
alpha-Gal	O
A	O
)	O
gene	O
which	O
cause	O
Fabry	O
disease	O
in	O
families	O
of	O
Japanese	O
origin	O
.	O

By	O
polymerase-chain-reaction-amplification	O
of	O
DNA	O
from	O
reverse-transcribed	O
mRNA	O
and	O
genomic	O
DNA	O
,	O
different	O
point	O
mutations	O
were	O
found	O
in	O
two	O
unrelated	O
Fabry	O
hemizygotes	O
.	O

A	O
hemizygote	O
with	O
classic	O
disease	O
manifestations	O
and	O
no	O
detectable	O
alpha-Gal	O
A	O
activity	O
had	O
a	O
G-to-A	B-DNAMutation
transition	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
1	I-DNAMutation
(	I-DNAMutation
codon	I-DNAMutation
44	I-DNAMutation
)	I-DNAMutation
which	I-DNAMutation
substituted	I-DNAMutation
a	I-DNAMutation
termination	I-DNAMutation
codon	I-DNAMutation
(TAG)	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
tryptophan	I-DNAMutation
codon	I-DNAMutation
(TGG)	I-DNAMutation
and	O
created	O
an	O
NheI	O
restriction	O
site	O
.	O

This	O
point	O
mutation	O
would	O
predict	O
a	O
truncated	O
alpha-Gal	O
A	O
polypeptide	O
,	O
consistent	O
with	O
the	O
observed	O
absence	O
of	O
enzymatic	O
activity	O
and	O
a	O
classic	O
Fabry	O
phenotype	O
.	O

In	O
an	O
unrelated	O
Japanese	O
hemizygote	O
who	O
had	O
an	O
atypical	O
clinical	O
course	O
characterized	O
by	O
late-onset	O
cardiac	O
involvement	O
and	O
significant	O
residual	O
alpha-Gal	O
activity	O
,	O
a	O
G-to-A	B-DNAMutation
transition	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
6	I-DNAMutation
(	I-DNAMutation
codon	I-DNAMutation
301	I-DNAMutation
)	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
replacement	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
glutamine	I-DNAMutation
for	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
residue	O
.	O

This	O
amino	O
acid	O
substitution	O
apparently	O
altered	O
the	O
properties	O
of	O
the	O
enzyme	O
such	O
that	O
sufficient	O
enzymatic	O
activity	O
was	O
retained	O
to	O
markedly	O
alter	O
the	O
disease	O
course	O
.	O

Identification	O
of	O
these	O
mutations	O
permitted	O
accurate	O
molecular	O
heterozygote	O
diagnosis	O
in	O
these	O
families	O
.	O

Cloning	O
,	O
expression	O
,	O
characterization	O
and	O
crystallization	O
of	O
BRP39	B-DNAMutation
,	O
a	O
signalling	O
glycoprotein	O
expressed	O
during	O
mammary	O
gland	O
apoptosis	O
.	O

Breast	O
regression	O
protein	O
BRP39	B-DNAMutation
is	O
a	O
glycoprotein	O
,	O
which	O
is	O
expressed	O
during	O
mammary	O
gland	O
involution	O
in	O
mouse	O
.	O

The	O
physiological	O
function	O
of	O
BRP39	B-DNAMutation
is	O
not	O
known	O
.	O

High	O
levels	O
of	O
expression	O
of	O
BRP39	B-DNAMutation
have	O
also	O
been	O
associated	O
with	O
breast	O
cancer	O
development	O
.	O

In	O
the	O
present	O
investigation	O
a	O
cDNA	O
encoding	O
rBRP39	O
(	O
recombinant	O
BRP39	B-DNAMutation
)	O
was	O
cloned	O
by	O
PCR	O
techniques	O
.	O

It	O
consists	O
of	O
1,143	O
nucleotides	O
and	O
encodes	O
an	O
open	O
reading	O
frame	O
of	O
381	O
amino	O
acid	O
residues	O
including	O
a	O
signal	O
sequence	O
of	O
21	O
amino	O
acids	O
.	O

Recombinant	O
BRP39	O
was	O
produced	O
in	O
E	O
.	O

coli	O
in	O
a	O
soluble	O
form	O
at	O
low	O
temperature	O
(	O
15	O
degrees	O
C	O
)	O
.	O

Expression	O
and	O
purification	O
of	O
rBRP39	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
.	O

Purified	O
rBRP39	O
showed	O
high	O
chitin-binding	O
activity	O
but	O
no	O
chitinase	O
activity	O
.	O

The	O
lack	O
of	O
chitinase	O
activity	O
may	O
be	O
attributed	O
to	O
the	O
mutation	O
of	O
critical	O
active	O
site	O
residue	O
Glu120	B-DNAMutation
to	I-DNAMutation
Leu120	I-DNAMutation
and	O
Asp118	B-DNAMutation
to	I-DNAMutation
Ala118	I-DNAMutation
in	O
BRP39	B-DNAMutation
.	O

However	O
,	O
a	O
mutant	O
in	O
which	O
the	O
residue	O
was	O
reverted	O
back	O
to	O
Glu	O
,	O
by	O
site	O
directed	O
mutagenesis	O
,	O
displayed	O
no	O
chitinase	O
activity	O
.	O

Purified	O
recombinant	O
BRP39	B-DNAMutation
was	O
crystallized	O
and	O
the	O
crystals	O
diffracted	O
X-rays	O
to	O
2.8A	O
resolution	O
.	O

The	O
crystals	O
belonged	O
to	O
the	O
space	O
group	O
C2	O
with	O
unit	O
cell	O
parameters	O
a=130.4A	O
,	O
b=81.3A	O
,	O
c=229.2A	O
,	O
beta=105.9	O
degrees	O
.	O

The	O
structure	O
refinement	O
is	O
in	O
progress	O
.	O

Identification	O
of	O
the	O
lesion	O
in	O
the	O
stimulatory	O
GTP-binding	O
protein	O
of	O
the	O
uncoupled	O
S49	O
lymphoma	O
.	O

The	O
stimulatory	O
GTP-binding	O
protein	O
(Gs)	O
of	O
the	O
uncoupled	O
mutant	O
of	O
S49	O
lymphoma	O
cells	O
is	O
deficient	O
in	O
its	O
ability	O
to	O
transduce	O
hormonal	O
signals	O
from	O
ligand-bound	O
beta-adrenergic	O
receptors	O
to	O
the	O
catalytic	O
component	O
of	O
adenylate	O
cyclase	O
.	O

In	O
order	O
to	O
define	O
the	O
genetic	O
defect	O
in	O
the	O
Gs	O
of	O
uncoupled	O
S49	O
cells	O
,	O
a	O
complementary	O
DNA	O
clone	O
encoding	O
the	O
alpha-subunit	O
of	O
Gs	O
was	O
analyzed	O
and	O
the	O
deduced	O
primary	O
structure	O
of	O
the	O
defective	O
subunit	O
compared	O
to	O
that	O
of	O
the	O
wild-type	O
subunit	O
.	O

A	O
single	B-DNAMutation
nucleotide	I-DNAMutation
transversion	I-DNAMutation
was	I-DNAMutation
found	I-DNAMutation
that	I-DNAMutation
coded	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
rather	I-DNAMutation
than	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
389	I-DNAMutation
.	O

The	O
results	O
indicate	O
a	O
domain	O
of	O
the	O
alpha-subunit	O
of	O
Gs	O
that	O
specifically	O
interacts	O
with	O
hormone	O
receptors	O
.	O

Alzheimer's	O
disease	O
amyloid	O
beta	O
peptide	O
25-35	O
inhibits	O
lipid	O
peroxidation	O
as	O
a	O
result	O
of	O
its	O
membrane	O
interactions	O
.	O

The	O
biological	O
activity	O
of	O
the	O
Alzheimer's	O
disease	O
amyloid	O
beta	O
protein	O
may	O
be	O
related	O
to	O
modulation	O
of	O
membrane	O
lipid	O
peroxidation	O
.	O

The	O
effect	O
of	O
amyloid	O
beta	O
protein	O
fragment	O
25-35	O
[	O
A	O
beta(25-35)	O
]	O
on	O
lipid	O
peroxidation	O
was	O
examined	O
in	O
liposomes	O
enriched	O
with	O
polyunsaturated	O
fatty	O
acids	O
.	O

The	O
activity	O
of	O
A	O
beta(25-35)	O
was	O
compared	O
to	O
that	O
of	O
A	O
beta(25-35)	O
with	O
either	O
a	O
scrambled	B-DNAMutation
sequence	I-DNAMutation
[	I-DNAMutation
A	I-DNAMutation
beta(25-35)scram	I-DNAMutation
]	O
or	O
a	O
peptide	B-DNAMutation
sequence	I-DNAMutation
in	I-DNAMutation
which	I-DNAMutation
methionine	I-DNAMutation
was	I-DNAMutation
replaced	I-DNAMutation
with	I-DNAMutation
leucine	I-DNAMutation
[	I-DNAMutation
A	I-DNAMutation
beta(25-35)	I-DNAMutation
met	I-DNAMutation
]	O
.	O

A	O
beta(25-35)	O
inhibited	O
lipid	O
peroxidation	O
in	O
a	O
dose-	O
and	O
time-dependent	O
manner	O
.	O

The	O
antioxidant	O
activity	O
of	O
A	O
beta(25-35)	O
was	O
observed	O
at	O
concentrations	O
as	O
low	O
as	O
10	O
nM	O
.	O

The	O
relative	O
antioxidant	O
activities	O
of	O
the	O
amyloid	O
beta	O
protein	O
fragments	O
were	O
as	O
follows	O
:	O
A	O
beta(25-35)	O
>	O
A	O
beta(25-35)	O
met	O
>	O
A	O
beta(25-35)scram	O
.	O

The	O
two	O
more	O
potent	O
peptides	O
intercalated	O
into	O
the	O
membrane	O
hydrocarbon	O
core	O
,	O
as	O
determined	O
by	O
small-angle	O
x-ray	O
diffraction	O
approaches	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
amphiphilic	O
A	O
beta(25-35)	O
peptide	O
inhibits	O
lipid	O
peroxidation	O
at	O
low	O
concentrations	O
as	O
a	O
result	O
of	O
physicochemical	O
interactions	O
with	O
the	O
membrane	O
lipid	O
bilayer	O
.	O

Signaling	O
kinase	O
AMPK	B-DNAMutation
activates	O
stress-promoted	O
transcription	O
via	O
histone	O
H2B	O
phosphorylation	O
.	O

The	O
mammalian	O
adenosine	B-DNAMutation
monophosphate-activated	I-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
AMPK	B-DNAMutation
is	O
a	O
serine-threonine	O
kinase	O
protein	O
complex	O
that	O
is	O
a	O
central	O
regulator	O
of	O
cellular	O
energy	O
homeostasis	O
.	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
AMPK	B-DNAMutation
mediates	O
cellular	O
responses	O
to	O
metabolic	O
stress	O
remain	O
unclear	O
.	O

We	O
found	O
that	O
AMPK	B-DNAMutation
activates	O
transcription	O
through	O
direct	O
association	O
with	O
chromatin	O
and	O
phosphorylation	O
of	O
histone	O
H2B	O
at	O
serine	O
36	O
.	O

AMPK	B-DNAMutation
recruitment	O
and	O
H2B	B-DNAMutation
Ser36	O
phosphorylation	O
colocalized	O
within	O
genes	O
activated	O
by	O
AMPK-dependent	B-DNAMutation
pathways	O
,	O
both	O
in	O
promoters	O
and	O
in	O
transcribed	O
regions	O
.	O

Ectopic	O
expression	O
of	O
H2B	B-DNAMutation
in	O
which	O
Ser36	B-DNAMutation
was	I-DNAMutation
substituted	I-DNAMutation
by	I-DNAMutation
alanine	I-DNAMutation
reduced	O
transcription	O
and	O
RNA	O
polymerase	O
II	O
association	O
to	O
AMPK-dependent	B-DNAMutation
genes	O
,	O
and	O
lowered	O
cell	O
survival	O
in	O
response	O
to	O
stress	O
.	O

Our	O
results	O
place	O
AMPK-dependent	B-DNAMutation
H2B	B-DNAMutation
Ser36	O
phosphorylation	O
in	O
a	O
direct	O
transcriptional	O
and	O
chromatin	O
regulatory	O
pathway	O
leading	O
to	O
cellular	O
adaptation	O
to	O
stress	O
.	O

A	O
cytoplasmic	O
region	O
determines	O
single-channel	O
conductance	O
in	O
5-HT3	B-DNAMutation
receptors	O
.	O

5-hydroxytryptamine	O
type	O
3	O
5-HT3	B-DNAMutation
receptors	O
are	O
cation-selective	O
transmitter-gated	O
ion	O
channels	O
of	O
the	O
Cys-loop	O
superfamily	O
.	O

The	O
single-channel	O
conductance	O
of	O
human	O
recombinant	O
5-HT3	B-DNAMutation
receptors	O
assembled	O
as	O
homomers	O
of	O
5-HT3A	B-DNAMutation
subunits	O
,	O
or	O
heteromers	O
of	O
5-HT3A	B-DNAMutation
and	O
5-HT3B	B-DNAMutation
subunits	O
,	O
are	O
markedly	O
different	O
,	O
being	O
0.4	O
pS	O
(	O
refs	O
6	O
,	O
9	O
)	O
and	O
16	O
pS	O
(	O
ref	O
.	O

7	O
)	O
,	O
respectively	O
.	O

Paradoxically	O
,	O
the	O
channel-lining	O
M2	O
domain	O
of	O
the	O
5-HT3A	B-DNAMutation
subunit	O
would	O
be	O
predicted	O
to	O
promote	O
cation	O
conduction	O
,	O
whereas	O
that	O
of	O
the	O
5-HT3B	B-DNAMutation
subunit	O
would	O
not	O
.	O

Here	O
we	O
describe	O
a	O
determinant	O
of	O
single-channel	O
conductance	O
that	O
can	O
explain	O
these	O
observations	O
.	O

By	O
constructing	O
chimaeric	O
5-HT3A	B-DNAMutation
and	O
5-HT3B	B-DNAMutation
subunits	O
we	O
identified	O
a	O
region	O
(	O
the	O
'HA-stretch'	O
)	O
within	O
the	O
large	O
cytoplasmic	O
loop	O
of	O
the	O
receptor	O
that	O
markedly	O
influences	O
channel	O
conductance	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
three	I-DNAMutation
arginine	I-DNAMutation
residues	I-DNAMutation
unique	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
HA-stretch	I-DNAMutation
of	O
the	O
5-HT3A	B-DNAMutation
subunit	O
by	O
their	O
5-HT3B	B-DNAMutation
subunit	O
counterparts	O
increased	O
single-channel	O
conductance	O
28-fold	O
.	O

Significantly	O
,	O
ultrastructural	O
studies	O
of	O
the	O
Torpedo	O
nicotinic	O
acetylcholine	O
receptor	O
indicate	O
that	O
the	O
key	O
residues	O
might	O
frame	O
narrow	O
openings	O
that	O
contribute	O
to	O
the	O
permeation	O
pathway	O
.	O

Our	O
findings	O
solve	O
the	O
conundrum	O
of	O
the	O
anomalously	O
low	O
conductance	O
of	O
homomeric	O
5-HT3A	B-DNAMutation
receptors	O
and	O
indicate	O
an	O
important	O
function	O
for	O
the	O
HA-stretch	O
in	O
Cys-loop	O
transmitter-gated	O
ion	O
channels	O
.	O

Catalytic	O
deficiency	O
of	O
human	O
aldolase	O
B	O
in	O
hereditary	O
fructose	O
intolerance	O
caused	O
by	O
a	O
common	O
missense	O
mutation	O
.	O

Hereditary	O
fructose	O
intolerance	O
(HFI)	O
is	O
a	O
human	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
a	O
deficiency	O
of	O
aldolase	O
B	O
that	O
results	O
in	O
an	O
inability	O
to	O
metabolize	O
fructose	O
and	O
related	O
sugars	O
.	O

We	O
report	O
here	O
the	O
first	O
identification	O
of	O
a	O
molecular	O
lesion	O
in	O
the	O
aldolase	O
B	O
gene	O
of	O
an	O
affected	O
individual	O
whose	O
defective	O
protein	O
has	O
previously	O
been	O
characterized	O
.	O

The	O
mutation	O
is	O
a	O
G----C	B-DNAMutation
transversion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
that	O
creates	O
a	O
new	O
recognition	O
site	O
for	O
the	O
restriction	O
enzyme	O
Ahall	O
and	O
results	O
in	O
an	O
amino	B-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
(Ala----Pro)	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
149	I-DNAMutation
of	O
the	O
protein	O
within	O
a	O
region	O
critical	O
for	O
substrate	O
binding	O
.	O

Utilizing	O
this	O
novel	O
restriction	O
site	O
and	O
the	O
polymerase	O
chain	O
reaction	O
,	O
the	O
patient	O
was	O
shown	O
to	O
be	O
homozygous	O
for	O
the	O
mutation	O
.	O

Three	O
other	O
HFI	O
patients	O
from	O
pedigrees	O
unrelated	O
to	O
this	O
individual	O
were	O
found	O
to	O
have	O
the	O
same	O
mutation	O
:	O
two	O
were	O
homozygous	O
and	O
one	O
was	O
heterozygous	O
.	O

We	O
suggest	O
that	O
this	O
genetic	O
lesion	O
is	O
a	O
prevailing	O
cause	O
of	O
hereditary	O
fructose	O
intolerance	O
.	O

Inactivation	O
of	O
erythropoietin	B-DNAMutation
receptor	I-DNAMutation
function	O
by	O
point	O
mutations	O
in	O
a	O
region	O
having	O
homology	O
with	O
other	O
cytokine	O
receptors	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
the	O
erythropoietin	B-DNAMutation
receptor	I-DNAMutation
EpoR	B-DNAMutation
contains	O
a	O
region	O
,	O
proximal	O
to	O
the	O
transmembrane	O
domain	O
,	O
that	O
is	O
essential	O
for	O
function	O
and	O
has	O
homology	O
with	O
other	O
members	O
of	O
the	O
cytokine	O
receptor	O
family	O
.	O

To	O
explore	O
the	O
functional	O
significance	O
of	O
this	O
region	O
and	O
to	O
identify	O
critical	O
residues	O
,	O
we	O
introduced	O
several	O
amino	O
acid	O
substitutions	O
and	O
examined	O
their	O
effects	O
on	O
erythropoietin-induced	B-DNAMutation
mitogenesis	O
,	O
tyrosine	O
phosphorylation	O
,	O
and	O
expression	O
of	O
immediate-early	O
(	O
c-fos	B-DNAMutation
,	O
c-myc	B-DNAMutation
,	O
and	O
egr-1	B-DNAMutation
)	O
and	O
early	O
(	O
ornithine	B-DNAMutation
decarboxylase	I-DNAMutation
and	I-DNAMutation
T-cell	I-DNAMutation
receptor	I-DNAMutation
gamma	I-DNAMutation
)	I-DNAMutation
genes	I-DNAMutation
in	I-DNAMutation
interleukin-3-dependent	I-DNAMutation
cell	O
lines	O
.	O

Amino	O
acid	O
substitution	B-DNAMutation
of	I-DNAMutation
W-282	I-DNAMutation
,	O
which	O
is	O
strictly	O
conserved	O
at	O
the	O
middle	O
portion	O
of	O
the	O
homology	O
region	O
,	O
completely	O
abolished	O
all	O
the	O
functions	O
of	O
the	O
EpoR	B-DNAMutation
.	O

Point	B-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
L-306	I-DNAMutation
or	I-DNAMutation
E-307	I-DNAMutation
,	O
both	O
of	O
which	O
are	O
in	O
a	O
conserved	O
LEVL	O
motif	O
,	O
drastically	O
impaired	O
the	O
function	O
of	O
the	O
receptor	O
in	O
all	O
assays	O
.	O

Other	O
point	O
mutations	O
,	O
introduced	O
into	O
less	O
conserved	O
amino	O
acid	O
residues	O
,	O
did	O
not	O
significantly	O
impair	O
the	O
function	O
of	O
the	O
receptor	O
.	O

These	O
results	O
demonstrate	O
that	O
conserved	O
amino	O
acid	O
residues	O
in	O
this	O
domain	O
of	O
the	O
EpoR	B-DNAMutation
are	O
required	O
for	O
mitogenesis	O
,	O
stimulation	O
of	O
tyrosine	O
phosphorylation	O
,	O
and	O
induction	O
of	O
immediate-early	O
and	O
early	O
genes	O
.	O

Site-directed	O
mutagenesis	O
of	O
mouse	O
steroid	O
7	O
alpha-hydroxylase	O
(	O
cytochrome	O
P-450(7)	O
alpha	O
)	O
:	O
role	O
of	O
residue-209	O
in	O
determining	O
steroid-cytochrome	O
P-450	O
interaction	O
.	O

We	O
have	O
cloned	O
a	O
cDNA	O
encoding	O
mouse	O
steroid	O
7	O
alpha-hydroxylase	O
P450(7)	O
alpha	O
(	O
cytochrome	O
P-450(7)	O
alpha	O
)	O
and	O
expressed	O
it	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Mouse	O
P450(7)	O
alpha	O
is	O
70%	O
identical	O
in	O
its	O
amino	O
acid	O
sequence	O
with	O
the	O
mouse	O
steroid	O
15	O
alpha-hydroxylase	O
P450(15)	O
alpha	O
(2A4)	O
.	O

The	O
Leu	O
at	O
position	O
209	O
of	O
P450(15)	O
alpha	O
is	O
the	O
most	O
important	O
residue	O
to	O
determine	O
the	O
steroid	O
hydroxylase	O
activity	O
of	O
the	O
P450	O
[	O
Lindberg	O
and	O
Negishi	O
(1989)	O
Nature	O
(London)	O
339	O
,	O
632-634	O
]	O
.	O

The	O
P450(7)	O
alpha	O
contains	O
Asn	O
at	O
the	O
position	O
corresponding	O
to	O
the	O
Leu-209	O
of	O
P450(15)	O
alpha	O
,	O
although	O
both	O
P450s	O
hydroxylate	O
testosterone	O
.	O

The	O
CO-reduced	O
P450(7)	O
alpha	O
complex	O
is	O
unstable	O
,	O
so	O
that	O
it	O
is	O
quickly	O
converted	O
into	O
the	O
inactive	O
P420	O
,	O
whereas	O
the	O
P450(15)	O
alpha	O
is	O
very	O
stable	O
.	O

The	O
P450(7)	O
alpha	O
,	O
however	O
,	O
is	O
stabilized	O
either	O
by	O
addition	O
of	O
testosterone	O
or	O
by	O
a	O
mutation	B-DNAMutation
of	I-DNAMutation
Asn-209	I-DNAMutation
to	I-DNAMutation
Leu	I-DNAMutation
.	O

The	O
mutant	O
P450(7)	O
alpha	O
displays	O
a	O
17-fold	O
lower	O
Vmax	O
.	O

value	O
than	O
the	O
wild-type	O
enzyme	O
.	O

Unexpectedly	O
,	O
it	O
also	O
has	O
3-fold	O
lower	O
Km	O
and	O
Kd	O
values	O
.	O

Residue	O
209	O
in	O
P450(7)	O
alpha	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
located	O
at	O
a	O
critical	O
site	O
of	O
the	O
haem-substrate-binding	O
pocket	O
.	O

Corticosterone	O
inhibits	O
the	O
testosterone	O
7	O
alpha-hydroxylase	O
activity	O
of	O
the	O
wild-type	O
P450(7)	O
alpha	O
,	O
whereas	O
it	O
does	O
not	O
inhibit	O
the	O
mutant	O
P450(7)	O
alpha	O
.	O

Conversely	O
,	O
the	O
P450(15)	O
alpha	O
activity	O
becomes	O
inhibited	O
by	O
corticosterone	O
upon	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
Leu-209	I-DNAMutation
by	I-DNAMutation
Asn	I-DNAMutation
.	O

In	O
addition	O
,	O
this	O
mutation	O
increases	O
the	O
corticosterone	O
15	O
alpha-hydroxylase	O
activity	O
of	O
P450(15)	O
alpha	O
at	O
least	O
20-fold	O
.	O

Whereas	O
the	O
inhibition	O
by	O
corticosterone	O
depends	O
on	O
the	O
presence	O
of	O
Asn	O
at	O
position	O
209	O
,	O
deoxycorticosterone	O
inhibits	O
the	O
activities	O
of	O
the	O
P450s	O
regardless	O
of	O
the	O
type	O
of	O
residue	O
at	O
209	O
.	O

The	O
results	O
indicate	O
,	O
therefore	O
,	O
that	O
the	O
identity	O
of	O
residue	O
209	O
determines	O
the	O
affinity	O
as	O
well	O
as	O
specificity	O
of	O
steroid	O
binding	O
to	O
both	O
P450(7)	O
alpha	O
and	O
P450(15)	O
alpha	O
.	O

The	O
structure	O
and	O
function	O
of	O
murine	O
factor	O
V	O
and	O
its	O
inactivation	O
by	O
protein	B-DNAMutation
C	I-DNAMutation
.	O

Factor	O
V	O
(FV)	O
is	O
a	O
central	O
regulator	O
of	O
hemostasis	O
,	O
serving	O
both	O
as	O
a	O
critical	O
cofactor	O
for	O
the	O
prothrombinase	O
activity	O
of	O
factor	O
Xa	O
and	O
the	O
target	O
for	O
proteolytic	O
inactivation	O
by	O
the	O
anticoagulant	O
,	O
activated	O
protein	B-DNAMutation
C	I-DNAMutation
(APC)	O
.	O

To	O
examine	O
the	O
evolutionary	O
conservation	O
of	O
FV	O
procoagulant	O
activity	O
and	O
functional	O
inactivation	O
by	O
APC	O
,	O
we	O
cloned	O
and	O
sequenced	O
the	O
coding	O
region	O
of	O
murine	O
FV	O
cDNA	O
and	O
generated	O
recombinant	O
wild-type	O
and	O
mutant	O
murine	O
FV	O
proteins	O
.	O

The	O
murine	O
FV	O
cDNA	O
encodes	O
a	O
2,183-amino	O
acid	O
protein	O
.	O

Sequence	O
comparison	O
shows	O
that	O
the	O
A1-A3	O
and	O
C1-C2	O
domains	O
of	O
FV	O
are	O
highly	O
conserved	O
,	O
demonstrating	O
greater	O
than	O
84%	O
sequence	O
identity	O
between	O
murine	O
and	O
human	O
,	O
and	O
60%	O
overall	O
amino	O
acid	O
identity	O
among	O
human	O
,	O
bovine	O
,	O
and	O
murine	O
FV	O
sequences	O
.	O

In	O
contrast	O
,	O
only	O
35%	O
identity	O
among	O
all	O
three	O
species	O
is	O
observed	O
for	O
the	O
poorly	O
conserved	O
B	O
domain	O
.	O

The	O
arginines	O
at	O
all	O
thrombin	O
cleavage	O
sites	O
and	O
the	O
R305	O
and	O
R504	O
APC	O
cleavage	O
sites	O
(	O
corresponding	O
to	O
amino	O
acid	O
residues	O
R306	O
and	O
R506	O
in	O
human	O
FV	O
)	O
are	O
invariant	O
in	O
all	O
three	O
species	O
.	O

Point	O
mutants	O
were	O
generated	O
to	O
substitute	B-DNAMutation
glutamine	I-DNAMutation
at	I-DNAMutation
R305	I-DNAMutation
,	I-DNAMutation
R504	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
both	I-DNAMutation
(R305/R504)	O
.	O

Wild-type	O
and	O
all	O
three	O
mutant	O
FV	O
recombinant	O
proteins	O
show	O
equivalent	O
FV	O
procoagulant	O
activity	O
.	O

Single	B-DNAMutation
mutations	I-DNAMutation
at	I-DNAMutation
R305	I-DNAMutation
or	I-DNAMutation
R504	I-DNAMutation
result	O
in	O
partial	O
resistance	O
of	O
FV	O
to	O
APC	O
inactivation	O
,	O
whereas	O
recombinant	O
murine	O
FV	O
carrying	O
both	O
mutations	O
R305Q/R504Q	B-DNAMutation
is	O
nearly	O
completely	O
APC	O
resistant	O
.	O

Thus	O
,	O
the	O
structure	O
and	O
function	O
of	O
FV	O
and	O
its	O
interaction	O
with	O
APC	O
are	O
highly	O
conserved	O
across	O
mammalian	O
species	O
.	O

Genetic	O
basis	O
of	O
hemolytic	O
anemia	O
caused	O
by	O
pyrimidine	O
5'	O
nucleotidase	O
deficiency	O
.	O

Pyrimidine	O
5'	O
nucleotidase	O
P5'N-1	B-DNAMutation
deficiency	O
is	O
an	O
autosomal	O
recessive	O
condition	O
causing	O
hemolytic	O
anemia	O
characterized	O
by	O
marked	O
basophilic	O
stippling	O
and	O
the	O
accumulation	O
of	O
high	O
concentrations	O
of	O
pyrimidine	O
nucleotides	O
within	O
the	O
erythrocyte	O
.	O

It	O
is	O
implicated	O
in	O
the	O
anemia	O
of	O
lead	O
poisoning	O
and	O
is	O
possibly	O
associated	O
with	O
learning	O
difficulties	O
.	O

Recently	O
,	O
a	O
protein	O
with	O
P5'N-1	B-DNAMutation
activity	O
was	O
analyzed	O
and	O
a	O
provisional	O
complementary	O
DNA	O
(cDNA)	O
sequence	O
published	O
.	O

This	O
sequence	O
was	O
used	O
to	O
study	O
3	O
families	O
with	O
P5'N-1	B-DNAMutation
deficiency	O
.	O

This	O
approach	O
generated	O
a	O
genomic	O
DNA	O
sequence	O
that	O
was	O
used	O
to	O
search	O
GenBank	O
and	O
identify	O
the	O
gene	O
for	O
P5'N-1	B-DNAMutation
.	O

It	O
is	O
found	O
on	O
chromosome	O
7	O
,	O
consists	O
of	O
10	O
exons	O
with	O
alternative	O
splicing	O
of	O
exon	O
2	O
,	O
and	O
produces	O
proteins	O
286	O
and	O
297	O
amino	O
acids	O
long	O
.	O

Three	O
homozygous	O
mutations	O
were	O
identified	O
in	O
this	O
gene	O
in	O
4	O
subjects	O
with	O
P5'N-1	B-DNAMutation
deficiency	O
:	O
codon	B-DNAMutation
98	I-DNAMutation
GAT-->GTT	I-DNAMutation
,	I-DNAMutation
Asp-->Val	I-DNAMutation
(	O
linked	O
to	O
a	O
silent	O
polymorphism	O
codon	B-DNAMutation
92	I-DNAMutation
,	I-DNAMutation
TAC-->TAT	I-DNAMutation
)	O
,	O
codon	B-DNAMutation
177	I-DNAMutation
,	I-DNAMutation
CAA-->TAA	I-DNAMutation
,	I-DNAMutation
Gln-->termination	I-DNAMutation
,	O
and	O
IVS9-1	B-DNAMutation
,	I-DNAMutation
G-->T	I-DNAMutation
.	O

The	O
latter	O
mutation	O
results	O
in	O
the	O
loss	B-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
9	I-DNAMutation
(	I-DNAMutation
201	I-DNAMutation
bp	I-DNAMutation
)	O
from	O
the	O
cDNA	O
.	O

None	O
of	O
these	O
mutations	O
was	O
found	O
in	O
100	O
normal	O
controls	O
.	O

The	O
DNA	O
analysis	O
was	O
complicated	O
by	O
P5'N-1	B-DNAMutation
pseudogenes	O
found	O
on	O
chromosomes	O
4	O
and	O
7	O
.	O

This	O
study	O
is	O
the	O
first	O
description	O
of	O
the	O
structure	O
and	O
location	O
of	O
the	O
P5'N-1	B-DNAMutation
gene	O
,	O
and	O
3	O
mutations	O
have	O
been	O
identified	O
in	O
affected	O
patients	O
from	O
separate	O
kindreds	O
.	O

(	O
Blood	O
.	O

2001;97:3327-3332	O
)	O
Ataxia	O
telangiectasia-mutated	O
phosphorylates	O
Chk2	B-DNAMutation
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
protein	O
kinase	O
Chk2	B-DNAMutation
,	O
the	O
mammalian	O
homolog	O
of	O
the	O
budding	O
yeast	O
Rad53	B-DNAMutation
and	O
fission	O
yeast	O
Cds1	O
checkpoint	O
kinases	O
,	O
is	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
DNA	O
damage	O
by	O
ionizing	O
radiation	O
(IR)	O
,	O
UV	O
irradiation	O
,	O
and	O
replication	O
blocks	O
by	O
hydroxyurea	O
(HU)	O
.	O

Phosphorylation	O
and	O
activation	O
of	O
Chk2	B-DNAMutation
are	O
ataxia	B-DNAMutation
telangiectasia-mutated	I-DNAMutation
ATM	B-DNAMutation
dependent	O
in	O
response	O
to	O
IR	O
,	O
whereas	O
Chk2	B-DNAMutation
phosphorylation	O
is	O
ATM-independent	B-DNAMutation
when	O
cells	O
are	O
exposed	O
to	O
UV	O
or	O
HU	O
.	O

Here	O
we	O
show	O
that	O
in	O
vitro	O
,	O
ATM	B-DNAMutation
phosphorylates	O
the	O
Ser-Gln/Thr-Gln	O
(SQ/TQ)	O
cluster	O
domain	O
(SCD)	O
on	O
Chk2	B-DNAMutation
,	O
which	O
contains	O
seven	O
SQ/TQ	O
motifs	O
,	O
and	O
Thr68	O
is	O
the	O
major	O
in	O
vitro	O
phosphorylation	O
site	O
by	O
ATM	B-DNAMutation
.	O

ATM-	B-DNAMutation
and	O
Rad3-related	B-DNAMutation
also	O
phosphorylates	O
Thr68	O
in	O
addition	O
to	O
Thr26	O
and	O
Ser50	O
,	O
which	O
are	O
not	O
phosphorylated	O
to	O
a	O
significant	O
extent	O
by	O
ATM	B-DNAMutation
in	O
vitro	O
.	O

In	O
vivo	O
,	O
Thr68	O
is	O
phosphorylated	O
in	O
an	O
ATM-dependent	B-DNAMutation
manner	O
in	O
response	O
to	O
IR	O
,	O
but	O
not	O
in	O
response	O
to	O
UV	O
or	O
HU	O
.	O

Substitution	O
of	O
Thr68	B-DNAMutation
with	I-DNAMutation
Ala	I-DNAMutation
reduced	O
the	O
extent	O
of	O
phosphorylation	O
and	O
activation	O
of	O
Chk2	B-DNAMutation
in	O
response	O
to	O
IR	O
,	O
and	O
mutation	O
of	O
all	O
seven	O
SQ/TQ	O
motifs	O
blocked	O
all	O
phosphorylation	O
and	O
activation	O
of	O
Chk2	B-DNAMutation
after	O
IR	O
.	O

These	O
results	O
suggest	O
that	O
in	O
vivo	O
,	O
Chk2	B-DNAMutation
is	O
directly	O
phosphorylated	O
by	O
ATM	B-DNAMutation
in	O
response	O
to	O
IR	O
and	O
that	O
Chk2	B-DNAMutation
is	O
regulated	O
by	O
phosphorylation	O
of	O
the	O
SCD	O
.	O

Phosphorylation	O
of	O
Activation	O
Transcription	O
Factor-2	O
at	O
Serine	O
121	O
by	O
Protein	B-DNAMutation
Kinase	I-DNAMutation
C	I-DNAMutation
Controls	O
c-Jun-mediated	O
Activation	O
of	O
Transcription	O
.	O

Activation	B-DNAMutation
transcription	I-DNAMutation
factor-2	I-DNAMutation
ATF-2	B-DNAMutation
is	O
phosphorylated	O
by	O
various	O
protein	O
kinases	O
,	O
such	O
as	O
JNK/p38/ERK	B-DNAMutation
,	O
calmodulin	O
kinase	I-DNAMutation
IV	I-DNAMutation
,	O
protein	B-DNAMutation
kinase	I-DNAMutation
A	I-DNAMutation
,	O
and	O
protein	B-DNAMutation
kinase	I-DNAMutation
C	I-DNAMutation
PKC	B-DNAMutation
,	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
phosphorylation	O
of	O
ATF-2	B-DNAMutation
by	O
PKC	B-DNAMutation
in	O
vivo	O
in	O
the	O
transcriptional	O
control	O
of	O
genes	O
that	O
include	O
the	O
activation	B-DNAMutation
protein-1	I-DNAMutation
(AP-1)/cyclic	B-DNAMutation
AMP-response	I-DNAMutation
element	I-DNAMutation
remains	O
to	O
be	O
defined	O
.	O

Using	O
antibodies	O
against	O
the	O
phosphorylated	O
serine	O
residue	O
(Ser(P))	O
at	O
position	O
121	O
of	O
ATF-2	B-DNAMutation
,	O
we	O
have	O
demonstrated	O
that	O
PKC	B-DNAMutation
phosphorylates	O
ATF-2	B-DNAMutation
at	O
Ser-121	O
and	O
that	O
phosphorylation	O
of	O
Ser-121	O
(	O
to	O
yield	O
ATF-2pS121	O
)	O
becomes	O
detectable	O
at	O
the	O
late	O
stage	O
of	O
the	O
response	O
of	O
HeLa	O
cells	O
to	O
12-O-tetradecanoylphorbol-13-acetate	B-DNAMutation
TPA	B-DNAMutation
and	O
is	O
maintained	O
for	O
more	O
than	O
2	O
h	O
.	O

By	O
contrast	O
,	O
phosphorylation	O
of	O
ATF-2	B-DNAMutation
at	O
threonine	O
residues	O
69	O
and	O
71	O
(	O
Thr-69/71	O
,	O
to	O
yield	O
ATF-2pT69/71	O
)	O
and	O
at	O
Ser-340	O
and	O
Ser-367	O
(	O
to	O
yield	O
ATF-2pS340	O
and	O
ATF-2pS367	O
)	O
is	O
detectable	O
as	O
an	O
immediate	O
early	O
response	O
.	O

Unlike	O
levels	O
of	O
ATF-2pT69/71	O
and	O
ATF-2pS340	O
,	O
the	O
level	O
of	O
ATF-2pS121	O
increases	O
in	O
the	O
nuclei	O
of	O
HeLa	O
cells	O
in	O
response	O
to	O
TPA	B-DNAMutation
.	O

A	O
serine-to-alanine	B-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
121	I-DNAMutation
of	O
ATF-2	B-DNAMutation
represses	O
the	O
c-Jun-dependent	O
transcription	O
of	O
AP-1/cyclic	B-DNAMutation
AMP-response	I-DNAMutation
element	I-DNAMutation
reporter	O
genes	O
and	O
also	O
the	O
p300-mediated	B-DNAMutation
activation	O
of	O
a	O
Gal4-reporter	O
gene	O
in	O
response	O
to	O
TPA	B-DNAMutation
.	O

Our	O
results	O
suggest	O
that	O
the	O
phosphorylation	O
of	O
ATF-2	B-DNAMutation
at	O
Ser-121	O
plays	O
a	O
key	O
role	O
in	O
the	O
c-Jun-mediated	O
activation	O
of	O
transcription	O
that	O
occurs	O
in	O
response	O
to	O
TPA	B-DNAMutation
.	O